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Abstract 
The chemical constraint of proteins has been demonstrated to improve the binding affinity of 
peptide ligands as well as improving properties such as cell penetrability and resistance to 
proteases. In this work two new chemical methodologies are presented for such constraint, 
widening the diversity of peptide structures available starting from a single linear peptide 
sequence. The combination of these chemical modifications with a library of peptide 
sequences access new classes of constrained peptides which bind protein surfaces. Such 
molecules could potentially be used in similar applications to antibodies: therapeutics, 
diagnostics, and molecular biology research tools. 
A two-step strategy to produce stereochemically diverse bicyclic peptides has been 
developed where the first step involves the conversion of multiple cysteine residues to 
dehydroalanines. The application of methyl 2,5-dibromovalerate proved superior for this 
transformation when compared to other chemical modification methodologies. The second 
step of the strategy involved cyclisation via nucleophilic attack at the dehydroalanine 
residues by a small molecule core bearing multiple thiol functional groups – generating an 
alkylated L- or D- cysteine in the peptide sequence. The effect of scrambling the 
stereochemistry at each of these positions is exemplified via the use of a human plasma 
kallikrein inhibitor PK15 as a model system. 
An alternative strategy to create diverse bicyclic peptides involved the synthesis of a new 
core molecule based upon Barbas reagent. The core molecule bearing three 
2-mesyl-1,3,4-oxadiazole moieties cyclised peptides containing three cysteines efficiently - 
constraining peptide loops in distinctly different structures from other established core 
molecules. Attempts were made to create a phagemid-encoded phage display library of 
peptides to subsequently modify with these chemical methodologies. 
A phage display library of Adhirons was screened for binders to the antifungal drug 
posaconazole. Adhirons are a non-antibody binding protein scaffold bearing variable peptide 
loops. The screening relied upon chemical derivatisation of the posaconazole structure to 
enable both screening and hit characterisation.  
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Chapter 1: An introduction to constrained peptides 
This chapter introduces the potential value of constrained peptides as therapeutics, 
diagnostics and molecular tools. Examples from both nature and chemical synthesis are used 
to demonstrate the wide range of potential applications of constrained peptides. Research 
into generating new classes of constrained peptide including chemical modification methods 
and peptide library display platforms are described. Of particular interest are the bicyclic 
peptide ligand classes which have recently been shown to be high affinity inhibitors of 
protein-protein interactions. The use of dehydroalanine as a reaction handle in peptides is 
briefly summarised before the aims of this project - incorporating dehydroalanine chemistry 
and bicyclic peptide formation - are outlined. 
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1.1 The rise of biologics 
1.1.1 Blockbuster biologics 
Biologically-derived molecules (biologics) such as peptides and proteins play an ever-more-
important role in healthcare - through both therapeutic and diagnostic applications. Of the 
top ten best-selling drugs of 2013, seven of these were biologics – in addition to insulin 
therapy there were five monoclonal antibodies and one TNF receptor-IgG Fc fragment 
fusion protein.
1
 
Table 1: The top ten selling prescription drugs worldwide in 2013, showing the increased importance 
and value of biologic therapies.
1
 
Rank Brand 2013 Sales ($US m) Type 
1 Humira 10,659 Monoclonal antibody 
2 Enbrel 8,776 Fusion protein 
3 Remicade 8,386 Monoclonal antibody 
4 Seretide/Advair 8,251 Small molecule 
5 Lantus 7,592 Protein (Insulin) 
6 Rituxan 7,503 Monoclonal antibody 
7 Avastin 6,751 Monoclonal antibody 
8 Herceptin 6,562 Monoclonal antibody 
9 Crestor 5,622 Small molecule 
10 Abilify 5,500 Small molecule 
 
While the top sellers are currently dominated by antibodies and insulin analogues, there are 
many other examples of peptide (e.g. cyclosporine, bivalirudin, liraglutide) and protein 
drugs (e.g. Pulmozyme, EPO).  Most drugs fit either into the small molecule (<500 Da) or 
large macromolecule (>5 kDa) categories; however the space between these has slowly been 
colonised as a result of the approval of peptide-based drugs.
2, 3
 
Antibodies are fundamental for biological research, for example as purification aids, 
imaging reagents and assay reporters. However antibodies can often be costly to develop or 
purchase, and batch production can be inconsistent.
4
 Molecules which can utilise the same 
recognition elements as antibodies, but can be produced more consistently, are more stable 
and are cheaper to use would be of great benefit to researchers. Such molecules would have 
a wide range of potential uses from diagnostics and therapeutics to lab reagents and 
purification aids.
5, 6
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There have been concerted research efforts into proteins which can present variable binding 
loops in a manner similar to antibodies but which are much smaller in size, leading to 
improved physical properties and simpler bacterial expression.
7
 Adhirons are one such 
molecular class based on a cystatin scaffold.
8
 The main advantage of using Adhirons over 
antibodies for diagnostic, therapeutic and research tool uses is their ease of production; 
Adhirons are easy to recombinantly express in Escherichia coli, require no post-translational 
modifications and their structure has a greater thermal stability compared to antibodies.
8
 
Developing antibodies is a more resource-intensive process – requiring more complicated 
expression and screening procedures and often the correct formation of disulfide bridges and 
post-translational modifications such as glycosylation.
9
 
 
Figure 1: Adhiron – a non-antibody binding protein based upon a cystatin fold. Variable loops are 
coloured in orange and blue – these are each four residues in the crystal structure but can contain 
larger loops of up to ten residues in library design. (PDB: 4N6T) 
Cystatins were used as the basis for the Adhiron scaffold because their favourable physical 
properties (in particular the high thermostability and low molecular weight) make them ideal 
for applications in which high-affinity binders are used, for example in biosensors or as lab 
reagents.
6
 The cystatin sequence used in this work is a consensus sequence of 57 plant 
cystatins. A consensus sequence should theoretically give the most stable scaffold as 
evolutionary mutations which have been preserved in multiple variants are conserved while 
negative mutations specific to one variant are removed. 
1.1.2 Peptides in therapeutics and diagnostics 
Peptides occupy an underdeveloped region of synthetic chemical space, intermediate 
between small molecules and proteins.
10
 However many peptidic structures of molecular 
weight 500-5000 Da are found throughout nature, playing a diverse array of roles including 
as toxins, neurotransmitters and defensive agents.  Peptides are natural ligands in many 
4 
 
interactions, or alternatively a peptide can mimic the binding interface of a protein ligand; 
taking advantage of this, peptides have great potential as therapeutics, diagnostics and 
research tools.
11
 Peptidic molecules are produced in nature via either ribosomal synthesis in 
the same manner as protein synthesis, or by non-ribosomal enzymatic methods. Both of 
these methods have been utilised in research in addition to the synthesis of peptides via 
solid-phase peptide synthesis (SPSS). The natural modularity of peptides lends itself to 
library screening - combined with the potential incorporation of non-canonical amino acids, 
peptides therefore provide an accessible and diverse source of potential for drug discovery.
12
 
 
Figure 2: Peptides occupy an intermediate region of chemical space between proteins and small 
molecules. They share properties but offer inherent advantages in discovery and application compared 
to these bordering classes. 
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1.2 Constraining Peptides 
While some peptides are active in their linear form, the constraint of these peptides into 
favourable binding conformations can improve their properties.
13
 This has been 
demonstrated for peptide sequences which were selected as a constrained form
14
, although 
the effect on proteins selected as linear binders is open to debate. It is proposed that 
constraint of the linear sequence reduces the entropic cost of binding to its target. In many 
cases constraint is essential for activity, while it also imparts increased resistance to 
proteases.
14-18
 Peptides can be constrained via native methods such as disulfide formation 
and enzymatic modifications, or alternatively chemical modification can be used; some of 
the methods used to constrain peptides are described below.  
1.2.1 Disulfide constraints 
The simplest form of peptide constraint, the oxidative cross-linking of two cysteine residues 
restricts the peptide’s movement. While this is a fundamental of protein structure it is also 
key to several smaller peptide structures. Conotoxins are potent neurotoxin peptides 
produced by venomous snails where a peptide is constrained by several disulfide linkages. 
Two classes exist: the ω- and α- families. ω-Conotoxins are 24-31 residue peptides with 
three disulfide bonds forming a four-looped structure. They have been shown to selectively 
block voltage gated calcium channels.
19, 20
 α-Conotoxins are related 12-16 residue structures 
containing two disulfide bonds and therefore two loops of sequence. The α-conotoxin family 
is known to hit a target other than calcium channels, but it is not clear what this target is.
19
 
Due to their venomous origins the conotoxins have potential as pain relief therapeutics. For 
this reason several structures have been developed as potential therapeutics and synthetic 
libraries based upon conotoxin structures have been produced and screened.
21-23
 In peptides 
containing multiple disulfide bonds there can be issues with switching of dynamic disulfides 
causing alternative structures to form. To alleviate this issue in their work with disulfide-rich 
peptide libraries, Heinis and co-workers synthesised an artificial amino acid 3, bearing two 
thiols in its side chain.
24
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Figure 3: Peptides constrained by disulfide bonds and backbone cyclisations. a) Conotoxins such as 
G1 1 are toxins found in venomous marine snails. They are short peptides constrained by disulfide 
bonds. Heinis and co-workers created synthetic peptides which were constrained by disulfide bonds in 
a similar manner – the incorporation of the artificial amino acid 3 avoided shuffling of disulfide bonds 
between cysteines at different positions – leading to a more consistent and stable structure of the 
urokinase plasminogen activator (uPA) inhibitor UK604 2.
24
 b) Potent cyclic peptides with 
continuous backbone include cyclosporin A 4, a non-ribosomal peptide, and the ATIC inhibitor 5 
identified from a SICLOPPS library of small peptides.
25
 
1.2.2 Head-to-tail backbone cyclisation 
Continuous peptide backbone macrocycles are common features of non-ribosomal peptides 
such as cyclosporin A 4.  It is a less-common feature of ribosomal peptides but there are 
select known examples. There may be many more undiscovered but it is an onerous effort to 
identify these and to confirm that the cyclisation is via the backbone rather than cross-
linkage involving a side-chain.
26
 ϴ-Defensins are of particular note – these peptides are 
formed from splicing of two ribosomally-expressed peptides. They are antimicrobials 
expressed in Old World monkeys and orangutans, their human homologues are not 
translated efficiently due to a premature stop codon mutation.
26
 However the putative 
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historical sequence was used to generate retrocyclin which is not only an antimicrobial but 
also blocks HIV-1 infection.
27
  
Cyclotides are a family of cyclic peptides produced in plants which contain a continuous 
backbone and are also further cross-linked by disulfide constraints, creating a knotted-like 
structure.
26, 28
 These constraints improve peptide stability, improving resistance to both 
enzymatic digestion and thermal degradation.
29
 They are probably the largest known family 
of constrained peptide, with an estimated 50000 members in plants.
30
 Their native function 
appears to be in the plant’s defences as they show insecticidal properties via inhibition of 
insect larvae development. However they have also been shown to have an array of other 
biological activities.
30
 This has led to interest in applying these structures in pharmaceuticals 
and agrochemicals. 
To generate cyclic peptide libraries in vivo, split-intein mediated cyclisation of peptides and 
proteins (SICLOPPS) was developed by Benkovic and co-workers.
25, 31
 A DnaE split-intein 
was modified to swap the domains either side of a variable peptide sequence, causing 
cyclisation of the peptide upon excision. The bacterial expression of cyclic peptide libraries 
was combined with a host-cell survival genetic screening approach to identify disruptors of 
protein-protein interactions. From a library of 10
7
 peptides an inhibitor of AICAR 
transformylase/IMP cyclohydrolase (ATIC) dimerisation was discovered (Ki = 17 ± 4 µM).
25
  
These initial efforts have now been adopted by several groups, with some significant 
evolutions including the adaptation to fluorescent-reporter phenotypic screens
32
, the 
incorporation of unnatural amino acids
33
, and the use of SICLOPPS in both yeast
34
 and 
human
35
 cell lines.   
 
1.2.3 Cross-linked side chains 
An incredibly diverse subset of constraints is the cross-linking of side chains. Again this is a 
common feature of NRPs – witness for example the tyrosine cross-linkage in vancomycin. 
Lantibiotics are a class of naturally occurring antibiotics produced by lactococcal bacteria 
which contain thioether linkages.
36
 A two-step enzymatic process creates the thioethers: first 
an enzyme dehydrates serine or threonine to give dehydroalanine and dehydrobutyrine 
respectively. This is accomplished either via a phosphorylation (Class II enzymes) or an 
unusual glutamylation which requires the formation of an activated ester between the serine 
or threonine and the glutamic acid tRNA synthetase complex, which then undergoes 
elimination (Class I enzymes).
37, 38
 A cyclase enzyme then catalyses the formation of 
thioether bonds in the structure with complete stereochemical control.
39-41
 The source of this 
control is debated since some members of the cyclase family are promiscuous and act on a 
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range of peptide substrates from other lanthipeptide pathways.
42
 The major products of these 
promiscuous cyclisations have the correct stereochemistry inserted, suggesting perhaps the 
peptide sequence is the defining factor in stereochemical control rather than the cyclase 
enzyme.
43
  
The enzymes involved in the lanthipeptide biosynthetic pathways are largely known, and 
some have been used in vivo on non-native sequences.
44
 The specificity of the enzymes is 
determined by a leader sequence on the peptide which is removed post-modification. The 
cleavage can be difficult to replicate in E. coli production of lanthipeptides from other 
organisms – often a specific enzyme is required to cleave in the correct position. van der 
Donk and coworkers have avoided this by genetically incorporating a hydroxy acid at the 
cleavage site, allowing facile ester cleavage to remove the leader peptide.
45
 It has been 
demonstrated that the leader sequence does not necessarily need to be attached to the 
substrate: a hybrid of the dehydratase LctM fused to the relevant leader sequence still 
dehydrated lacticin 481 analogues.
46
 An in vitro application has allowed the incorporation of 
nonproteinogenic amino acids into lantibiotic-type structures.
47
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Figure 4: Examples of cross-linked peptides. a) Vancomycin 6, a non-ribosomal peptide product, has 
an unusual tyrosine-tyrosine linkage and another unusual triaryl cross-bridge. b) Actagardine 7 is a 
member of the lanthipeptide family, where thioether cross-linking is achieved by enzymatic control of 
cysteine attack on dehydroalanine or dehydrobutyrine respectively. (Abu = 2-aminobutyric acid) 
These multiple cross-links hold the peptide loops in defined binding conformations as shown in the 
NMR structure. 
1.2.4 Synthetic cross-linking of side chains 
Moving further away from native structures, the combination of peptide structures with 
organic prosthesis is now a common approach to improve the properties of peptide ligands. 
10 
 
The most frequent variant is the stapling of linear peptides to stabilise α-helical 
conformations; the many stapling methodologies including triazole formation
48
, disulfide 
formation
49
 and alkene metathesis
50-52
 Metathesis of all-carbon side-chains has become the 
dominant methodology in the stapling field.
53-55
 Most methodologies require the input of a 
pair of artificial amino acids to provide biorthogonal functionality or to sufficiently span the 
helical length. There is ongoing debate as to whether stapling improves peptide binding – 
although there is a reduced entropic cost of binding, often this is cancelled out by enthalpic 
penalties. Stapling has been observed to increase protease resistance and in some cases also 
improve cell penetration (although the precise rationale for the latter is unknown).
16, 17
 
An alternative form of constraint is to cross-link across a cyclic peptide. Kritzer and co-
workers took this approach to improve the protease resistance of cyclic peptide G1, an 
inhibitor of the Grb2 SH2 domain.
56
 They replaced the disulfide bond in G1 with a covalent 
backbone and then stapled across two residues. These constraints are not dissimilar to the 
bicyclic peptides studied by Reymond and co-workers in their efforts to explore peptidic 
chemical space. Their structures were cross-linked by glutamic acid side chain amide 
coupling with amine side chains  – leading to structures consisting entirely of amino acid 
subunits which were shown by NMR to have globular structure with rigid backbones.
10
  
However these structures may not mimic discontinuous structures often found in protein 
binding interfaces – Liskamp and co-workers attempted to display 3 separate cyclic peptides 
on one central core via copper catalysed azide-alkyne cycloaddition.
57
 They mimicked the 
binding loops of HIV gp120 in the discontinuous CD4-binding epitopes – showing that even 
incorporating just two of the three loops onto their central scaffold was sufficient for CD4 
binding. The same group has also used the incorporation of artificial amino acids and 
subsequent intramolecular cycloadditions in attempts to mimic the peptidic CDE rings of 
vancomycin.
58
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Figure 5: Liskamp and coworkers synthesised 8 in an effort to mimic the HIV gp120 binding loops. 
The most potent mimic competed with gp120 to bind CD4 (IC50 16.9 µM).
57
 
1.2.5 Bicyclic peptides 
In a further extension of the cyclisations above, a new class of peptidic molecule is emerging 
consisting of two peptide loops constrained around a central core. These were pioneered as 
protein surface mimetics by Timmermann et al. with the development of CLIPS® 
technology – the reaction of cysteine residues with benzyl bromide linkers.59 This was then 
applied to a phage-displayed peptide library by Winter and co-workers to identify PK15, a 
bicyclic peptide inhibitor of human plasma kallikrein (Ki = 2 nM). The same screening 
platform has been used to identify inhibitors of several other protease targets. UK18, an 
inhibitor of urokinase-type plasminogen activator (uPA), was co-crystallised with uPA, 
showing both peptide loops bound to the uPA with an interaction surface area of 701 Å
2
 as 
shown in Figure 6a.
60
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Figure 6: Bicyclic peptides a) Bicyclic peptide inhibitor UK18: peptide sequence is constrained by a 
mesitylene core attached to three cysteine residues. The uPA inhibitor is shown bound to its target, 
with a large interaction area.
60
 b) Different organic cores that have been reacted with cysteine-
containing peptides by Heinis and co-workers. Different cores hold loops of the same peptide 
sequence in different orientation due to steric differences and in some cases hydrogen bonding 
between the core and the loops.
61
 c) A bicyclic peptide inhibitor of TNFα identified by Pei and co-
workers from a synthetic library containing both L- and D- amino acids including some non-canonical 
sidechains. A trimesic acid core (blue) is used to form loops via reaction with amine-containing side 
chains and the N-terminus.
62
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To demonstrate the diversity of structure available, Heinis and co-workers have shown that 
peptide loops of different sizes are tolerated and have produced phage-displayed libraries 
containing loops of varying size.
63
 They have also created several new core molecules which 
react with cysteine residues in the same manner as the CLIPS® technology (Figure 6b). It 
was shown that different cores constraining identical peptide sequences create bicyclic 
peptides with varied inhibitory strength.
61
 This suggests that not only does varying core size 
affect loop structure but that cores capable of hydrogen bonding to peptide backbones or 
side chains will further constrain the peptide into a unique binding conformation.
15
 A similar 
bicyclic structure Anticachexin C1 14, was generated by Pei and co-workers through the 
reaction of trimesic acid with terminal amino acids and an internal lysine residue.
62
 They 
screened a synthetic library for TNFα inhibitors – a target traditionally difficult for small 
molecule drug discovery – identifying a promising inhibitor (IC50 3.1 ±0.3 µM). Their 
library included several artificial amino acids and D-amino acids. 
An inherent problem with early iterations of these compounds was a low residency time in 
vivo. There are two contributing factors to this – firstly high clearance rates as the small 
structures are filtered from the blood via the kidneys. This particularly affects the bicyclic 
peptides which were extracellular protease inhibitors. Secondly the structures, although 
theoretically small enough to passively diffuse through a cell membrane, are not very cell 
permeable, thus they remain in circulation. To overcome the circulation issues, fusions of 
the linear peptide sequence were produced with either Fc antibody fragments
64
, or with a 
protein tag which binds to serum albumin.
65
 Cyclisation occurs as with the peptide alone to 
create a fusion of the inhibitor with a large protein partner. After linker optimisation a 
UK18-Fc fusion was shown to retain high potency (Ki = 76 nM), while terminal half-life 
had increased to 1.5 days in mice – a 100-fold improvement compared to similar non-
conjugated bicyclic peptides.
64
 When conjugated to the albumin-binding tag the bicyclic 
peptide is resistant to proteases and has 50-fold increase in terminal half-life.
65
 In an 
alternative approach to increasing protease resistance, whilst also increasing activity, a uPA 
inhibitor had a glycine residue replaced by D-Ser.
66
  This was guided by the crystal structure 
of the complex, showing the glycine residue had a large torsional twist, placing the side 
chain of the D-Ser mutant in a position where it would not sterically clash with the remainder 
of the peptide. 
Suga and co-workers developed a combination of flexizyme technology to incorporate 
non-canonical amino acids and mRNA display (Section 1.3) to create genetically encoded 
macrocylic peptides.
67, 68
 An N-chloroacetyl amino acid was incorporated via the flexizyme 
system, cyclisation then occurred spontaneously with an encoded C-terminal cysteine to 
form a  thioether cross-linkage. This linkage is non-reducible and so genetically encoded 
14 
 
libraries can be screened to identify hits where the molecule is definitely macrocyclic, in 
contrast to the disulfide-bridged macrocycles. The fact that screening is of a precyclised state 
implies that the hits will be superior binders to the related linear pepitdes as demonstrated by 
Heinis et al. Screening targets for the mRNA-displayed macrocycles included VEGFR2, 
where inhibitors were identified with nanomolar IC50 values
69
, and Hepatocyte growth 
receptor (also known as Met receptor) – in this case a binder was dimerised which in turn 
then brough two Met receptors together and initiated a signalling cascade.
70
 The 
methodology has been combined with reaction with TBMB to create genetically encoded 
tricyclic peptides.
71
 An investigation into the thioether cyclisation preferences when multiple 
cysteines are present in the encoded sequence showed that the first upstream cysteine is 
favoured unless it is in position two.
72
 Thus the tricyclic linkages can be assumed based 
upon the first cysteine reacting with the chloroacetyl functionality leaving the other three 
cysteines to react with TBMB. 
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1.3 Library Display Methods 
As mentioned in section 1.1.2 the modularity of peptides naturally lends itself to library 
screening. There are several methods of library display which have proved amenable to 
peptides, and in some cases to the chemical modification of displayed peptides. The key to 
successful display is the deconvolution of the original peptide sequence – usually this is 
through nucleic acid encoding of the peptide sequence. However in a synthetic peptide 
library the options are also extended to mass spectrometry-based deconvolution of 
fragmented peptide hits. 
1.3.1 Phage Display 
The use of phage to display a library of peptides or proteins is a well-established in vitro 
screening platform. Bacteriophage are viruses containing single stranded DNA which infect 
bacteria. Phage have two varieties depending on their effects on infected bacteria – lytic 
phage are released by cell lysis whereas other filamentous phage types are non-lytic as they 
are constantly secreted from infected cells. Typically non-lytic filamentous phage such as 
M13 or Fd are used to display a peptide, protein or antibody fragment library as a fusion 
with one of the phage coat proteins. The DNA within each phage encodes the library 
member displayed upon its surface. Binders to a target of interest are identified via an in 
vitro panning procedure, after several rounds of selection strong specific binders can be 
identified. Libraries can be generated displaying upwards of 10
9
 different variants. 
The most common phage proteins used to display peptides are the g3p and g8p proteins. As 
can be seen in Figure 7, g8p is the major coat protein, with each phage containing thousands 
of copies. g8p fusions therefore display many copies of a peptide per phage molecule, 
however there is a limit to the size of fusion which can be displayed – large fusions 
compromise the close packing of the phage coat. g3p is a tail protein with a role in phage 
infectivity and there are only five copies per phage molecule. Larger conjugates are tolerated 
however there can be issues with phage infectivity, particularly when polyvalent display is 
used. Both the packing and infectivity of g8p and g3p conjugates respectively can be 
overcome by the use of phagemid approaches described below. A further possibility is to use 
a truncated g3p variant containing the structural domain to allow association with the phage 
molecule but lacking the infective domain. This truncated variant requires wild type g3p to 
be provided in a helper phage vector to produce infective phage. 
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Figure 7: A) A schematic of M13 filamentous phage structure, with the most commonly used coat 
proteins g8p and g3p labelled. B)  The two genetic approaches to generate phage displaying pIII 
conjugates and the resultant level of display on the phage dependent on the vector approach utilised. 
 
There are two methods at the DNA level of displaying libraries on phage. The simplest 
approach is to edit the genome of the phage directly, thus all of the phage protein will carry a 
library conjugate. This gives high levels of display but may have negative effects on the 
phage structure or viability. To overcome this, a second approach has been developed 
termed the phagemid method. A phagemid vector is used which only encodes the fusion 
protein. To produce viable phage the E. coli need to be infected with a helper phage 
containing DNA encoding all of the M13 proteins, often including native forms of the 
protein used as a display fusion. The helper phage genome has a defunct Ff origin of 
replication, preventing it from being replicated and packaged in single stranded form. 
Therefore even though phage is produced from two distinct vectors, only the phagemid 
vector is packaged in the phage molecules produced. Due to the production of wild-type g3p 
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protein, the conjugate proteins are displayed effectively monovalently. In fact the majority 
of phage will only display wild-type coat protein, however these will not interfere with 
screening procedures. 
In a typical screening round, phage is prepanned against blank wells to remove binders to 
the plate, reducing the occurrence of false positive hits. Prepanned phage is then incubated 
with a target of interest which is adhered to the plate. Phage which do not bind are then 
removed by washing stringently. Phage bound to the target are then eluted via either pH 
change to disrupt the binding interface, or reduction of a disulfide bond in the linker holding 
the target to the plate. Eluted phage are then used to infect to an E. coli culture, this culture 
is incubated for a short time before being plated onto LB agar and incubated overnight. 
Colonies will grow where the phage has infected and provided antibiotic resistance. A 
comparison between infection of phage panned against the target vs phage panned against a 
blank negative control gives indication of the hit rate and library enrichment. Bacteria can 
then be scraped and cultured, infecting with helper phage if necessary, to produce new phage 
for a new screening round. Alternatively individual colonies can be picked and grown 
individually to be used in phage ELISA to identify particularly strong or specific binders. 
Phage-displayed libraries are usually composed of peptides or proteins composed of 
canonical amino acids. There are select examples of displayed libraries containing artificial 
amino acids using amber suppression
73-75
  and methionine biosynthesis inhibition
76
. However 
amber suppression approaches can be limited by the translation efficiency of the amber 
codon – depending upon the position and number of codons being replaced truncation 
mutants could prove problematic. Each artificial amino acid also requires the development 
of its own tRNA-synthetase. The Met replacement requires amino acids which can use the 
Met synthetase, and may cause problems with Met being replaced in all of the phage 
proteins. 
A more convenient approach to adding artificial functionality to phage-displayed peptide 
sequences is to use enzymatic or chemical modification to alter canonical amino acids. 
Enzymatic post translational modification (PTM) can take place in the host cell during phage 
production or in vitro after phage secretion. PTMs on phage-displayed sequences include 
biotinylation, glycosylation and ligation of molecules using Spf synthase or 
transglutamination. The main limitation of this approach with respect to library display is the 
requirement for recognition sites immediately around the site of modification. This limits the 
diversity available around the site, possibly reducing the value of the library approach. 
PTMs which have recognition signals distant from the modification sites may be of more 
interest. 
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Chemical modifications usually have less sequence-dependence, requiring only one or two 
specific residues. This makes them more appropriate for modification of a library of 
peptides. The toolkit of protein and peptide modification is ever-expanding as new methods 
are developed, however only a few have been used to modify phage-displayed libraries. 
While the incorporation of artificial amino acids extends this toolkit further it is possible to 
utilise the canonical amino acids to create diverse structures. 
One of the early modifications was the use of chemical ligation to append a synthetic peptide 
containing artificial amino acids. In an approach termed biosynthetic phage display, the 
protease c inhibitor eglin was split in two.
77
 Residues 8-40 were chemically synthesised 
including either kynurenine or norvaline at position 25. A library of residues 41-70 with 
randomisation at position 52 and 54 was created through either g3p or g8p fusions with an 
N-terminal cysteine. Native chemical ligation then fused the full-length sequence together 
which was subsequently tested for proper folding into the native eglin fold. 
A more common approach is to take advantage of the nucleophilicity of cysteine residues 
via alkylation. A number of functional groups will alkylate cysteine preferentially over other 
residues including haloacetamides
78
 and maleimides
79
. An interesting example is the creation 
of light-responsive ligands through the addition of haloacetamide derivatives of azobenzene, 
developed independently by both Heinis and Derda.
80, 81
 These cyclise peptide loops across 
two cysteine residues, with the ligand backbone changing from trans to cis under UV 
irradiation, altering the peptide loop structure.  Through selective screening procedures, UV 
light can be used to either activate or deactivate peptide ligand binding conformation. 
As mentioned in Section 1.2.5, Heinis and co-workers create bicyclic peptides through the 
reaction of tris(bromomethyl)benzene 10 (TBMB) and three displayed cysteine residues.
14
  
These reactions are not without pitfalls; M13 phage in particular has important cysteine 
residues in the g3p protein which when reacted with alkylating agents impair phage 
infectivity, for example Heinis and co-workers observed a 99% drop in infectivity after 
reaction with TBMB.
82
 This was predicted to be particularly drastic due to the tris-reactive 
functionality of the alkylating agent causing cross linking of g3p proteins. To overcome this 
a cysteine-free g3p variant has been utilised, containing fifteen stabilising mutations.
83
 Taki 
and co-workers found that the reaction of T7 phage gp10 protein did not cause the same 
problems when a displayed cysteine was reacted with 
tetramethylrhodamine-5-iodoacteamide.
78
 Derda and co-workers used a two-step process to 
glycosylate peptides at the N-terminus.
84
 An N-terminal serine or threonine was oxidised to 
the aldehyde and an oxime ligation attaches the mannose to the terminal residue specifically. 
Biotin was also attached in this manner and used to assess the yield of coupling.  
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One of the greatest challenges associated with chemical modification of phage is estimating 
the yield and rate of the reaction. Bacteriophage are too large to monitor reactions with 
traditional spectroscopic techniques such as NMR or mass spectrometry. In the case of g3p 
fusion modifications, each phage can carry five copies of the displayed peptide, and so 
estimating individual peptide conversion by phage-counting techniques assumes each 
peptide will have reacted identically. To overcome this problem Heinis and co-workers 
created a construct containing a trypsin digest site allowing release of displayed peptides and 
separation from phage by spin filtration and monitored by mass spectrometry.
85
 While this is 
not quantitative it is an improvement on previous approximations. 
 
1.3.2 mRNA and Ribosomal Display 
In vitro display technologies which do not require cellular production stages have an 
advantage in that library diversity is not limited by the cellular transformation step. Two 
such display methods are ribosomal and mRNA display. Ribosomal display involves the 
translation of RNA libraries with ribosomes, however due to the lack of any stop codon both 
the RNA and produced protein are not released from the ribosome complex. After the 
separation of active mutants, the RNA can be released from the complex, amplified in vitro 
and be used for further rounds of selection. 
mRNA display is similar in that mRNA is transcribed by ribosomes in vitro however in a 
preceeding step the RNA is ligated to a DNA section containing the ribosome inhibitor 
puromycin. The puromycin terminates the translation process and binds the synthesised 
protein to the RNA that encoded it. After removal of ribosomes the RNA-protein complexes 
can be purified and screened. RNA from hits can be amplified in vitro as before to generate 
an enriched library. 
In early iterations of this display platform synthetic mRNA libraries were combined with 
cellular translation machinery obtained from cellular extracts. It is now common for the 
components to be either purified extensively or produced recombinantly. In addition the 
system can be supplemented with artificial components and enzymes such as tRNA 
synthetases to incorporate unnatural amino acids in the displayed peptide. It is estimated that 
libraries can contain up to 10
13
 members, but this is only limited by DNA synthesis and the 
number of positions being varied.
86
 
Chemical modification of such libraries has fewer issues than with phage-displayed libraries. 
The use of artificial amino acids allows the application of biorthogonal chemistry, for 
example the installation of selenalysine allows the conversion to dehydroalanine with mild 
20 
 
oxidative conditions that do not affect the rest of the displayed peptide.
87
 This can then be 
used in conjunction with cysteines in the peptide to form lanthipeptide linkages.
88
 
 
1.3.3 Synthetic peptide libraries 
Both of the above screening classes link the protein to the DNA sequence that encodes it – 
linking phenotype to genotype. There is an alternative approach where a peptide library can 
be synthesised and the structure determined by mass spectrometry fragmentation of the 
peptide hits. When cross-linking across a peptide the mass spectrometry fragmentation can 
be incomplete as a single amide bond cleavage will not lead to the loss of any amino acid 
subunits. To get around this Pei and co-workers used a carefully-controlled protecting group 
strategy to create a two-tiered resin where the outer deprotected layer was cyclised while the 
inner layer remained protected and linear. This allowed deconvolution of the sequence of 
TNFα inhibitor hit 14 (Figure 6) by fragmentation of the linear peptide.62   
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1.4 Chemical Modification of Peptides 
1.4.1 Single-step modifications 
As described previously, the chemical modification of peptides can improve their properties 
and widen the diversity of structures accessible.
15, 61, 89
 The majority of chemical 
modifications of canonical amino acids in proteins and peptides rely on the nucleophilicity 
of side chains – predominantly cysteines and lysines. Labelling of lysine residues with 
molecules such as NHS esters is usually a high-yielding modification, however there can be 
drawbacks with undesired cross-reactivity leading to low selectivity and labelling of residues 
in binding interfaces leading to decreased efficacy of labelled molecules. Cysteines have 
been labelled by several classes of molecules including maleimides
90
, allenamides
91
 and 
iodoacetamides
92
. Since cysteines have a relatively low abundance in native peptide 
sequences these are often good choices for labelling – cysteine can often be introduced via 
mutation to then provide a single site for modification to occur. A caveat must be noted that 
introducing cysteine residues can disrupt the structure of proteins if disulfide bonds are 
formed or are shuffled by the introduction of a new cysteine.  
 
Figure 8: Common modifications to enable protein ligations a) Lysine labelling with NHS esters 
attaches cargoes via an amide linkage – this has low selectivity due to high lysine copy number. b) 
Cysteine labelling with bromomaleimide is reversible in the presence of high concentration of thiols 
or ethane dithiol. c) The two-step oxidation and ligation modification at protein N-terminus to 
selectively ligate a cargo to the protein. 
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Alternatively, the incorporation of non-canonical amino acids widens the scope of chemistry 
accessible. For example the incorporation of alkene-bearing alanine homologues has been 
used to create stapled peptides via metathesis as discussed in Section 1.2.3.
50, 52
 There are 
also a wide range of dienes and dienophiles which can be incorporated and allow 
cycloadditions including the ubiquitous copper-catalysed Click chemistry. This 
bio-orthogonal chemistry is now being used in a wide variety of chemical biology 
applications including super-resolution microscopy
93
, cell-surface glycan labelling
94
 and 
lysine side chain decaging.
95
 
1.4.2 Multi-step modifications 
Multi-step modification strategies involve an initial modification of an amino acid to 
modulate its reactivity and then a subsequent step to complete the reaction. An example of 
this is the NaIO4 oxidation of N-terminal serine and threonine residues to yield an aldehyde 
which can then react further with a wide range of nucleophiles – this oxidation step is often 
coupled with a reductive amination to label a protein at the N-terminus specifically (see 
Figure 8c).
84, 96
 A second example is the oxidation and elimination of alkylated 
selenocysteine residues giving access to dehydroalanine.
97
 
Both of the above strategies install electrophilic functionality into the protein at specific 
locations – electrophilic groups are rare in proteins, probably due to the likelihood of cross-
reactivity with nucleophilic side-chains and molecules such as glutathione. Dehydroalanine 
has recently been utilised as an electrophilic handle to either cyclise a protein (in a manner 
equivalent to lanthipeptide linkages)
87
 or to allow site-specific modification. These 
modifications have been to label with a dye
98
, to introduce novel functionality into a specific 
position in a histone
99
 or enzyme.
100, 101
 Alternatively the dehydroalanine has been used as a 
chemical handle, placed in the linker region between ubiquitin dimers to investigate 
deubiquitinase selectivity and activity.
102
 In many of these modifications, the addition of a 
nucleophile will give a mixture of isomers: for example the addition of a thiol will create a 
mixture of alkylated L- and D- cysteine derivatives. In many applications this is undesirable 
as the introduction of a D- amino acid can affect the structure and correct folding of a 
protein. 
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Figure 9: Dehydroalanine chemistry a) Cysteine can be converted into dehydroalanine which is 
subsequently reacted with thiols to generate alkylated cysteine variants with a mixture of L/D- 
stereochemistry. b) The double alkylation and elimination approach to convert cysteine to 
dehydroalanine using 2,5-dibromoadipamide pioneered by Davis and co-workers.
103
 The cyclic 
sulfonium ion is usually eliminated to form dehydroalanine however due to its stability, the 
interception of the sulfonium with another thiol has been observed giving an elongated thiol 
alkylation.
104
 
Dehydroalanine can be input by several chemical methods which were extensively reviewed 
by Chalker et al.
103
 and are discussed in Section 2.1. Methods include the aforementioned 
oxidative elimination of alkylated selenocysteines, and elimination of activated serines 
(either via enzymatic or chemical methods). However the most prominent method currently 
used is a double alkylation to activate a cysteine residue for elimination. This method has the 
advantage of the mildest conditions, with reagents which are easy to prepare and handle. The 
double alkylation generates a sulfonium ion which can then be eliminated to yield 
dehydroalanine. Davis and co-workers have exemplified this approach to generate 
dehydroalanine-containing peptides and proteins in good yields.
103
 A possible drawback of 
this method is the possibility of interception of the sulfonium ion by other thiol molecules – 
Nathani et al. took advantage of the long lifetime of the sulfonium to create extended thiol 
conjugates by adding a thiol to ring-open the sulfonium instead of eliminating.
104
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1.5 Research Outline 
The preceding sections demonstrate the value of the chemical constraint of peptides to 
deliver structures with interesting biological activity. This body of work aimed to 
demonstrate the effective constraint of peptides via the reaction between a peptide 
containing multiple dehydroalanine residues and a small molecule core bearing multiple 
thiol functionalities. It was envisaged that the stereochemical scrambling which occurs upon 
thiol addition would generate libraries similar to those discussed in Section 1.2.5 but with 
increased stereochemical diversity in peptide loop structure due to the effect of D-amino acid 
incorporation. The incorporation of D-amino acids would also likely improve protease 
resistance. 
To deliver this there was a requirement to investigate and optimise the following: 
1. The generation of multiple dehydroalanine residues in a peptide sequence via the 
conversion of cysteine residues 
2. The cyclisation of peptides bearing multiple dehydroalanine residues 
3. The synthetic accessibility and tractability of multithiol cores 
An ultimate aim of this project was to apply the two-step modification to phage-displayed 
peptide sequences. This would deliver access to a large library of peptides on a platform 
with easy amenability to screening against a diverse set of target molecules. The following 
aspects of this project are presented in this thesis: 
1. The generation of multiple dehydroalanine residues in a peptide sequence using a 
new reagent better-suited to this application than previous double-alkylation 
elimination reagents (Chapter 2) 
2. Exemplification of the effect of stereochemical scrambling on a bicyclic peptide 
structure using the model system PK15 kallikrein inhibitor (Chapter 2) 
3. The attempted synthesis of novel cores containing trithiol functionality in addition to 
the development of a core which reacts directly with cysteine residues (Chapter 3) 
4. An investigation into applying this two-step chemical modification to a peptide 
sequence displayed on phage (Chapter 4) 
In addition an investigation into the applicability of non-antibody binding proteins to bind 
small molecules was enabled by chemical modification of the antifungal drug posaconazole. 
Initial biotinylation allowed screening of an Adhiron library for binders and hits were 
characterised via a second derivative of posaconazole which allowed fluorescence 
anisotropy biophysical analysis (Chapter 5). 
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Chapter 2: The chemical modification of peptides to incorporate 
multiple dehydroalanines and subsequent cyclisation to form 
bicyclic structures
i
 
 
In this chapter the use of 2,5-dibromoadipamide to create multiple dehydroalanine residues 
is discussed. The associated problems then directed research into alternative reagents and the 
adoption of methyl 2,5-dibromovalerate as an improved reagent for the creation of multiple 
dehydroalanine residues. To exemplify this methodology a comparison with 
2,5-dibromoadipamide was undertaken and the new reagent utilised in the conversion of a 
model system kallikrein inhibitor sequence PK15. The second step of the constraint strategy 
involved the cyclisation of a peptide containing multiple Dha with a small molecule core 
bearing multiple thiol functionality. This was exemplified through the synthesis of 
1,3,5-tris(mercaptopmethyl)benzene and the subsequent cyclisation of the PK15-derived 
sequence to yield stereoisomers of the original PK15 bicyclic peptide which is formed 
through alkylation of the cysteine-containing peptide with 1,3,5-tris(bromomethyl)benzene. 
The mixture of stereoisomers was then tested in a human plasma kallikrein inhibition assay. 
Individual stereoisomers were resynthesised by solid phase peptide synthesis
ii
 and cyclised 
with tris(bromomethyl)benzene to investigate the effect of stereochemical scrambling on 
inhibitor structure. 
 
  
                                                     
i
 The work presented in this chapter formed the basis of the publication “Chemical generation and 
modification of peptides containing multiple dehydroalanines”, Morrison et al., Chem. Commun., 
2015, 51, 13470-13473 
ii
 Individual stereoisomers were synthesised and cyclised by Patrick J. Foley (MChem student) and 
tested in a kallikrein inhibition assay by both PJF and PMM 
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2.1 Reported methods to generate dehydroalanine 
As set out in Section 1.5, it was aimed to utilise a two-step chemical strategy to constrain 
peptides in which the first step involved the incorporation of multiple dehydroalanine (Dha) 
residues (Figure 10). In a second step a polythiol core was to be added to cyclise the peptide, 
scrambling the stereochemistry at the alpha carbons of the newly-formed cysteine 
derivatives.   
 
Figure 10: The two-step chemical strategy to constrain peptides. After generating a peptide containing 
three dehydroalanine versions it was aimed to cyclise the peptide via addition of a core bearing three 
thiol moieties (green). This would constrain the two linear sequences (blue and red) into constrained 
binding loops. The stereochemistry at the cysteine residues will be scrambled by the thiol addition – 
leading to a diverse subset of bicyclic peptides being generated from a single linear peptide. 
Due to the highly reactive nature of dehydroalanine, the residue is best incorporated in a 
masked residue and subsequently converted to form Dha. Methods to generate Dha have 
been reported starting from serine, cysteine and selenocysteine derivatives. Synthetic 
methods which mimic the lantibiotic enzymatic dehydration of serine residues involve 
activation of the serine toward a subsequent elimination to form dehydroalanine. This 
activation typically involves tosylation
105, 106
, or dichloroacetyl chloride ester formation.
107
 
These esters eliminate in the presence of sodium hydroxide, triethylamine or DBU bases, 
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often requiring elevated temperature to ensure complete reaction. In a similar vein, 
carbodiimide reagents such as EDC can be used to activate the serine and in the presence of 
catalytic copper this will eliminate
108
, but it has also been shown that base elimination can be 
required to ensure complete reaction.
109
 Lanthipeptide enzymatic elimination of serine 
residues (Section 1.2.3) has also been replicated in vitro by Van der Donk and co-workers.
110
 
 
Figure 11: Methods of converting serine to dehydroalanine. Activation by a) tosylation and b) 
dichloroacetate ester formation both require base elimination. c) Carbodiimide activation with copper 
catalysed elimination first demonstrated by Miller with diisopropylcarbodiimide (DiPCD). d) 
Biosynthetic transformation using LctM, requiring adherence to a leader sequence peptide. 
The elimination of the sulfur of cysteine residues has also been achieved via double 
S-alkylations
111
 and also by the oxidation and elimination of S-methyl cysteine using 
periodate with subsequent elimination of the sulfinic acid.
112, 113
 The oxidative elimination 
methodology has also been applied successfully to Se-alkylated selenocysteine amino acids. 
Selenoxide elimination can be achieved without the need for elevated temperatures.
87, 97, 114, 
115
 This method does however require the incorporation of artificial amino acids – methods 
such as amber suppression are efficient enough for high yielding incorporation at a single 
position, but incorporation at multiple positions is less efficient. mRNA display replacing 
lysine with selenalysine has been used to generate lantipeptide-like cyclic peptides (Figure 
12b) however to date these examples contain only one Dha residue. Synthetic methods have 
produced multiple dehydroalanines but these are through purely synthetic efforts rather than 
methods which could be applied to peptides or proteins expressed using biosynthetic 
apparatus.
109, 113, 116
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Figure 12: Alternative routes to dehydroalanine. a)  The incorporation of S-methyl cysteine into a 
SPPS-built peptide allowed oxidation and subsequent elimination. b) mRNA display of a peptide 
containing selenalysine was followed by hydrogen peroxide oxidation to yield dehydroalanine. c) The 
genetic incorporation of phenylselenocysteine enabled dehydroalanine formation via Se oxidation. d) 
Cysteine can be converted to dehydroalanine by double-alkylation elimination with 
2,5-dibromoadipamide. 
The most accessible chemical approach to install dehydroalanine functionality is the double-
alkylation and elimination methodology established by Davis and co-workers which 
converts cysteine residues to dehydroalanine via a cyclic sulfonium intermediate.
103
 The 
reagent they developed for this transformation, 2,5-dibromoadipamide 27, has since been 
used by many researchers to perform this transformation.
98, 100, 101
 The methodology benefits 
from mild reaction conditions and the low occurrence of free cysteines in protein sequences. 
The double alkylation-elimination mechanism involves an initial alkylation at cysteine by 27 
followed by a second alkylation to form a positively charged sulfonium species 29 which 
undergoes elimination to form dehydroalanine 24. When using dibromoadipamide the cyclic 
sulfonium intermediate is long-lived and often requires heating at 37 °C to eliminate. This 
has been utilised by Nathani et al. to form elongated alkylated cysteines via the interception 
of the sulfonium with another thiol.
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Figure 13: The double-alkylation elimination mechanism, utilising 2,5-dibromoadipamide 27 to 
convert cysteine to dehydroalanine. 
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2.2 Chemical generation of multiple dehydroalanine residues 
2.2.1 Aims 
An outline of the research objectives are summarised in Figure 14. It was aimed to generate 
multiple dehydroalanine residues in a peptide via the conversion of cysteine to 
dehydroalanine. Due to the literature precedent of 2,5-dibromoadipamide use this was the 
intended method. It was then aimed to synthesise the trithiol tris(mercaptomethyl)benzene 
TMMB 39 to create analogous structures to the bicyclic peptides formed by the cyclisation 
with TBMB 10. 
 
Figure 14: The proposed work undertaken in this project. A two-step strategy in which a peptide 
containing multiple dehydroalanines is initially formed and then reacted with a trithiol core to create 
peptide stereoisomers of the bicyclic peptides formed from direct reaction of cysteine-containing 
peptide with TBMB. PK15 sequence is used as an exemplar. 
 
2.2.2 Application of dibromoadipamide for multiple dehydroalanine formation 
The initial objective was to demonstrate the conversion of multiple cysteine residues to 
dehydroalanine using the double-alkylation elimination mechanism with 
2,5-dibromoadipamide 27. 27 was synthesised from adipic acid following literature 
procedure in 46% yield.
103
 The product was isolated as a mixture of the meso and d/l 
diastereomers. Initial investigations confirmed the conversion of peptide H-Ala-Tyr-Cys-
Asp-Gly-OH to H-Ala-Tyr-Dha-Asp-Gly-OH. Addition of alkyl thiols then created alkylated 
cysteine derivatives as expected. In contrast to literature reports
101
 it was observed by LCMS 
that the addition of thiophenol to dehydroalanine was reversible. 
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Figure 15: The conversion of cysteine to dehydroalanine using 27 and the results of subsequent thiol 
attack to form the mixture of alkylated cysteine derivatives 43. Addition of thiophenol gave a small 
level of product 44 however this reaction appeared to be reversible. 
The application of 27 to convert multiple cysteine residues to dehydroalanine residues 
proved more problematic – although the desired product was produced, there was parallel 
production of a cyclised by-product in which two cysteine residues had reacted with one 
equivalent of 27. This problem was exacerbated with increasing numbers of cysteines in the 
peptide sequence. For example treatment of the peptide GCSDYVCGTHACA 45 with 30 
equivalents of dibromoadipamide led to a 2 to 1 ratio of product 46:stapled by-products 47 
(Figure 16). This was assessed by extraction of the relevant ions for both the 1
+
 and 2
+
 
charge states of the relevant molecules from the LCMS trace. Integration of the extracted ion 
chromatographs gave an approximation of the concentration of product and by-products. 
This assumes that the ionisations of the related peptide species are approximately 
comparable. 
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Figure 16: LCMS observation of the stapling issues observed when peptide 45 is reacted with 27. 
Extracted ion chromatograms are depicted for ions corresponding to product 46 and by-products 47. 
Despite use of excess 27 there was 32% formation of stapled by-products 47a/b/c containing one 
dehydroalanine and two stapled cysteines. 
 
The most likely mechanism of this by-product formation is the second bromide displacement 
being hijacked by the second cysteine (Figure 17). An alternative possible mechanism is that 
a neighbouring cysteine could intercept the sulfonium intermediate, especially given the 
long lifetime of this intermediate when using 27. This would be similar to the thiol 
elongation observed by Nathani et al.
104
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Figure 17: The two possible mechanisms of undesired cyclised peptide formation when using a 
double-alkylation elimination reagent (exemplified with 2,5-dibromoadipamide) to create multiple 
dehydroalanine residues. 
2.2.3 Development of alternative reagents for dehydroalanine conversion 
Due to the inconsistent and unfavourable stapled by-product formation it was decided to 
investigate alternative reagents for dehydroalanine production. The rationale was to decrease 
the likelihood of a second alkylation by a neighbouring cysteine and this was approached 
from two angles – the first of these was the use of steric restriction to prevent the 
intramolecular stapling.  
The use of increased steric control with a symmetrical reagent was investigated through the 
synthesis of benzyl bromide derivatives. It was thought that the flexiblility of the adipamide 
may be allowing the second bromide to come into close proximity with the second cysteine 
residue. It was reasoned that the introduction of a rigid backbone may keep the second 
bromide in closer proximity to the initially alkylated cysteine. Chalker et al. showed the 
reagent 1,2-bis(bromomethyl)benzene was able to convert cysteine to dehydroalanine,
103
 
albeit in poor yield, thus this was used as a starting point. A combination of α-bromo-α-acyl 
benzylic positions would increase reactivity of the bromides and reduce the backbone 
conformational freedom. The amide and ester variants shown in Figure 18 were the initial 
targets to be synthesised. 
 
Figure 18: Targets of synthetic efforts to make double-alkylation elimination reagents selective for a 
single cysteine via steric constraint of the second bromide.  
The synthetic route to these compounds were similar to the synthesis of 27 (Figure 19). The 
formation of the α,α’-dibromo-1,2-phenylenediacetoyl chloride intermediate 56 proceeded as 
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expected, however the reaction of this with amines proved more problematic. Reaction with 
ammonia and diethyl amine created multiple by-products, most likely due to attack on the 
very reactive bromides thus no single products were isolated. When piperidine was used the 
product 52 was initially formed and purified by column chromatography, however after 
being left under vacuum for 72 hours the product had degraded, possible degradation 
products are shown with the LCMS trace in Figure 20. In a final attempt amide derivatives 
were abandoned and the methyl ester 53 synthesised. Although it was possible to isolate and 
characterise 53; upon addition to basic aqueous media, the solution immediately turned 
bright red and LCMS showed that 53 had degraded. Given this instability, it is probable that 
the benzylic positions are simply too reactive and will not be selective for cysteine residues 
thus this series of compounds was abandoned. 
 
Figure 19: The one-pot synthetic route to the sterically hindered targets 50 to 53. 
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Figure 20: The breakdown of compound 52. After initially appearing pure after column 
chromatography (A) after leaving under vacuum at room temperature for 64 hours the compound 
degraded to several by-products (B). The mass spec of these peaks gives indication of possible 
degradation products b-e which are shown beside the relevant MS peaks. The MS of c and d are very 
similar – suggesting possible diastereomers (MS signals labelled are different due to Br isotope 
pattern observed in both compounds). Br isotope patterns are in accordance with that expected for 
each compound. 
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2.2.4 The development of methyl 2,5-dibromovalerate for dehydroalanine generation 
In an alternative approach, the reactivity of the second alkylation step could be fine-tuned to 
favour intermolecular alkylation with a second equivalent of reagent over intramolecular 
cyclisation with a single equivalent. The use of an unsymmetrical reagent containing one 
α-bromo carbonyl and a less reactive alkyl bromide was investigated through the synthesis 
of methyl 2,5-dibromovalerate 63. It was predicted that due to the lower reactivity at the 
5-position, neighbouring cysteine residues would favour alkylation with a further equivalent 
of reagent rather than form the cyclised by-product. Figure 21 demonstrates this strategy 
wherein we aimed to slow steps A and B1 in order to favour step C. 
 
Figure 21: The rationale for the synthesis of methyl 2,5-dibromovalerate 63. To prevent cyclisation of 
the peptide via routes A or B, it is necessary to slow these steps such that route C becomes favoured 
and the peptide reacts with a second equivalent of 63 rather than undergoing intramolecular 
cyclisation. The reduction of reactivity in the change from α-bromo carbonyl in 
2,5-dibromoadipamide  27 to a simple alkyl bromide in 63 was designed to effect this bias. 
Methyl 2,5-dibromovalerate 63 was deemed an appropriate target to validate the hypothesis 
that reducing reactivity at the second bromide position would moderate stapled peptide 
formation. An ester was chosen over the primary amide to avoid any possible lactam 
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formation through cyclisation at the 5 position. 63 was synthesised in good 77% yield from 
δ-valerolactone 69 adapting a literature preparation.117 The bromination utilised 
substoichiometric PBr3 although elementary red phosphorus has been utilised previously as 
this forms PBr3 via reaction with Br2.
118
  This PBr3 mediated reaction is similar to the Hell 
Volhard Zelinski bromination of carboxylic acids, forming a bromoacyl bromide which was 
then reacted with methanol to form methyl 2,5-dibromovalerate 63. 63 proved to be very 
stable, even at room temperature and open to the air. 
 
Figure 22: The synthesis of methyl 2,5-dibromovalerate 63 from δ-valerolactone 69 via 
PBr3-mediated bromination.  
Initial tests with peptide 70 proved that 63 was adept at converting cysteine to 
dehydroalanine through the same double alkylation-elimination mechanism as 27. 
Interestingly the major intermediate observed was that of the monoalkylated cysteine 72; in 
contrast to the use of 27 there was only extremely low observation of the sulfonium 
intermediate. 
 
Figure 23: Conversion of peptide 70 to dehydroalanine-containing peptide 71 proved 63 was an 
alternative double-alkylation elimination reagent. 
38 
 
 
Figure 24: LCMS extracted ion chromatograms in the reaction of 70 with 63 to form 71. Starting 
peptide 70 (green) is completely consumed and converted to the dehydroalanine-containing analogue 
71 (blue) via the singly-alkylated cysteine intermediate 72 (pink). There is little evidence of any stable 
sulfonium intermediate 73 in contrast to the equivalent sulfonium when 27 is used to perform the 
transformation. 
It was then verified that 63 was superior to 27 in the conversion of multiple cysteine residues 
to dehydroalanine. To compare the two reagents in more detail a number of solvent and base 
mixtures were examined utilising an LCMS assay (Figure 25 and Figure 26). The peptide 74 
was converted to its dehydroalanine-containing analogue 75 using varying equivalents of 
either reagent 27 or 63. The intensities of ions corresponding to cyclised by-products 76/77 
and desired product 75 were extracted and the peak integrals compared to give an estimate 
of the product:by-product ratio. 
 
Figure 25: The reaction used to compare reagents dibromoadipamide 27 and methyl 
2,5-dibromovalerate 63 in the conversion of multiple cysteine residues to dehydroalanine. 
39 
 
Conditions were selected based upon previous dehydroalanine forming conditions (K2CO3 
and DMF), or upon conditions thought to be applicable to modification of residues displayed 
on phage (NH4HCO3 and acetonitrile – used by Heinis et al. in reaction with TBMB
14
). 
DMSO was also tested as it was thought the percentage of DMSO could be reduced to levels 
suitable for phage modification. 63 proved superior to 27 in all conditions tested. Although 
at low equivalents of 63 there was observation of the cyclised by-product in many solvent 
conditions, this was much lower than when using 27. Of particular interest was that in 1:1 
H2O:DMSO there was no cyclisation observed using 63, a feature not shared by 27. Under 
all reaction conditions using 27 there remained a cyclised fraction of around 10% despite 
using large excess of dibromo reagent 27. The equivalent residual by-product was not 
observed using 63. A serendipitous advantage was also discovered in that at the 
concentrations used 63 proved much more soluble than 27. In particular the solubility in 
acetonitrile proved promising as this solvent was used in the chemical modification of phage 
by Heinis et al.
14
 The use of ammonium bicarbonate as the base appeared to produce less 
stapled product when 63 or 27 was used in DMF, however this trend was reversed when 27 
was used in DMSO. Since the use of DMSO and K2CO3 with 63 led to extremely low levels 
of stapled by-product these conditions were used in subsequent experiments. 
 
Figure 26: LCMS optimisation of dehydroalanine conversion in peptide 74 using 27 and 63. 63 
proved to be superior to 27 in all comparable conditions and was additionally soluble in acetonitrile, 
allowing examination of the reaction by LCMS without filtration. Solvents were 1:1 mixture of H2O 
and the organic solvent stated in the key. For each reaction condition, the ratio of stapled to 
dehydroalanine-containing peptide was determined after reaction for 3 hours at 37 °C; this 
corresponds to complete reaction of the peptide for all except the lowest ratios of 27 and 63 to peptide 
74 in which small quantities of residual unmodified peptide were present. 
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2.3 Exemplification of the use of methyl 2,5-dibromovalerate to 
incorporate multiple Dha residues using the PK15 bicyclic peptide as a 
model system 
2.3.1 One-pot synthesis of stereochemically-scrambled PK15 structures 
In order to exemplify the use of 63 to incorporate multiple dehydroalanine residues in a 
peptide the human plasma kallikrein (HPK) inhibitor PK15 37 developed by Heinis et al. 
was used as a model system.
14
 HPK is a serine protease which forms part of the clotting 
cascade. HPK makes a good model system as there is a straight-forward in vitro assay and 
since it is found in the blood any in vivo assays are not complicated by cell penetration 
properties of the inhibitors being tested. The bicyclic peptide inhibitor PK15 was identified 
from a phage display library which had been cyclised using TBMB 10. Incorporating the 
dehydroalanine formation strategy it was envisaged that eight stereoisomers of PK15 could 
be synthesised in one pot in two-steps. The first step would convert cysteine residues to 
dehydroalanine and subsequently a polythiol would cyclise the peptide via reaction with 
these dehydroalanine residues, scrambling the stereochemistry at these positions to create 
mixture 40. 
Starting from peptide 36, 63 was used to convert the three cysteine residues to 
dehydroalanine forming the peptide 38 in 35% yield which was deemed good given the low 
purity of starting material (approx. 65%) and HPLC purification. 
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Figure 27: The PK15 kallikrein inhibitor model system used in this work. PK15 is synthesised by 
alkylation of three cysteine residues with TBMB 10. The two step strategy would convert the 
cysteines to dehydroalanines and subsequent cyclisation with trithiol TMMB 39 would not only 
reproduce the original PK15 structure 37 but additionally form seven stereoisomers 40 with the 
stereochemistry at the cysteine residues being a mixture of L/D. 
Cyclisation of peptide 38 was achieved using 1,3,5-tris(mercaptomethyl)benzene 39 to 
replicate the mesitylene core of PK15 37. 39 was synthesised from TBMB 10 via thiourea 
alkylation and hydrolysis (Figure 28). 
 
Figure 28: The synthesis of tris(mercaptomethyl)benzene from tris(bromomethyl)benzene via thiourea 
alkylation and hydrolysis. 
The reaction of 39 with dehydroalanine-containing peptide 38 to form mixture 40 proved 
straight-forward. A caveat of the addition of a polythiol to dehydroalanine is that the product 
of single addition has the same mass as that of the products of multiple additions of the same 
core. Therefore although the initial addition of thiol was complete within 5 minutes, the 
reaction time was extended to ensure full cyclisation occurred. Purification of the bicyclic 
peptide ligands by mass-directed HPLC observed several closely-spaced peaks of mass 
corresponding to the desired peptides 40, these were collected together.  
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Figure 29: HPLC purification trace of PK15 stereoisomer mix 40. The top trace shows the UV 
absorption trace at 254 nm while the bottom trace is an extracted ion trace for the mass corresponding 
to PK15 peptides 37/40. Multiple peaks indicate the presence of multiple stereoisomers. 
To probe for full cyclisation the purified product was tested with excesses of both N-methyl 
maleimide and β-mercaptoethanol as detailed in Table 2. Although an observed single 
addition of N-methyl maleimide was initially concerning, repeating this test using a sample 
of PK15 37 independently synthesised through cyclisation of peptide 36 with TBMB 10 the 
bicyclic peptide 37 showed identical behaviour when reacted with N-methyl maleimide. 
Thus it can be assumed that the maleimide is reacting with the free N-terminal amino group 
rather than with any free cysteine. No addition of BME was observed, indicating full 
addition to the dehydroalanine residues. 
 
Table 2: Chemical diagnostic tests to confirm full cyclisation of peptide 38 with 39 
Reactant 
Observed additions to 
Conclusion 
PK15 mix 40 PK15 37 
N-methylmaleimide 1 1 N-terminal addition, no free thiol 
β-mercaptoethanol 0 n/a No free Dha 
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2.3.2 Testing of stereoisomers in kallikrein inhibition assay 
The mixture of stereoisomers 40 was tested in a human plasma kallikrein inhibition assay 
(Figure 30). The bicyclic peptides were incubated with human plasma kallikrein for 30 
minutes before addition of the substrate Z-Phe-Arg-AMC 78. The release of fluorescent 
aminomethylcoumarin 80 was observed to estimate inhibition levels. The mixture of 
stereoisomers was tested as both crude reaction mixture (estimating the concentration of 
ligand by the initial starting material concentration) and as an HPLC-purified mixture. 
 
 
Figure 30: The inhibition of human plasma kallikrein. HPK cleaves substrate 78 to release free 
aminomethylcoumarin 80 (AMC) which can be observed by fluorescence (excitation 360 nm, 
emission 440 nm). The mixture of stereoisomers 40 (both as reaction crude and HPLC purified) was 
compared to that of the literature (all L-Cys) PK15 37. 
The observed IC50 values for both crude (238 ± 21 nM) and purified (144 ± 31 nM) were 
encouraging although intriguing. The scrambling of the stereochemistry has clearly altered 
the bicyclic peptide loop structure leading to reduced inhibition of the HPK. However if a 
stoichiometric mixture of stereoisomers was produced it may be expected that the 2 nM 
activity of the LLL PK15 ligand
iii
 should dominate and the IC50 of the mixture would be one 
eighth of this, i.e. 16 nM. Therefore the lower inhibition value suggests that a scalemic 
mixture was produced. 
                                                     
iii The nomenclature of the PK15 stereoisomers used in this work denotes the stereochemistry at each 
of the cysteine residues at positions 2, 9 and 16 in turn. 
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The nature of D- or L- cysteine formation upon addition of the thiol to dehydroalanine is 
determined by the reprotonation of the enolate intermediate 25 (Figure 31). It is not 
surprising that this reprotonation can be biased thus producing non-stoichiometric mixtures 
of enantiomers. The local peptide sequence probably influences which products are more 
energetically favoured. To support this, it has been suggested that lanthipeptide 
stereochemistry is also encoded by sequence rather than by the cyclase enzyme.
43
 This 
phenomenon is observed in lanthipeptide formation where cyclase substrates maintain their 
stereochemical bias of cysteine cross-linking when alternative cyclase enzymes are used.
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The cyclisation with a trithiol may create bias in that there will likely be subtle differences in 
reactivity between the three dehydroalanine residues. The conformation of one thiol addition 
is then likely to affect the stereochemistry of subsequent additions – not through control of 
the thiol attack but via backbone strain and possibly steric hindrance of the reprotonation 
event.  
 
Figure 31: The attack on dehydroalanine by a thiol and subsequent reprotonation of the enolate 
intermediate. It is the second step which determines the stereochemistry at the alkylated cysteine 
derivative. 
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2.4 Further investigations into the effects of stereochemical scrambling on 
PK15 
2.4.1 Synthesis and testing of individual PK15 stereoisomers 
To further investigate the effect of stereochemical scrambling the eight individual 
stereoisomers were synthesised by solid phase peptide synthesis (SPPS).
iv
 After the peptides 
were cleaved from the resin they were cyclised with TBMB using an established literature 
protocol.
14
 The stereoisomers were then purified by HPLC and tested in the same HPK 
inhibition assay as the mixture (Section 2.3.2). 
 
Figure 32: HPK inhibition by the 8 individual stereoisomers of PK15 where the stereochemistry at 
each of Cys2, Cys9 and Cys16 are either L or D. 
 
Table 3: IC50 values of PK15 stereoisomers in kallikrein inhibition assay 
 Isomer IC50 /nM  Isomer IC50 /nM 
37 LLL
a
 2.7 ± 0.10 84 DDD > 1 × 10
7
 
81 LDD 3740 ± 480 85 DDL > 1 × 10
7
 
82 LDL 240 ± 14 86 DLD 1700 ± 50 
83 LLD > 1 × 10
7
 87 DLL 311 ± 15 
[a] Naming refers to stereochemical configuration at Cys2, Cys9 and Cys16 in sequence 
 
                                                     
iv
 Synthesis and cyclisation carried out by P.J. Foley. Assay carried out by PMM with PJF’s 
assistance. 
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This data validated the hypothesis that inverting the stereochemistry of the cysteine residues 
would significantly alter the structure of the peptide loops. The library of eight stereoisomers 
have inhibitory values spanning at least four orders of magnitude. Both LDL and DLL ligands 
remain potent inhibitors while LLD and the inhibitors with multiple stereochemical 
inversions had considerably reduced activity. It is not surprising that none of the 
stereoisomers are more active than the LLL PK15 standard – the mixture results suggested 
this, and the LLL ligand was already an extremely potent ligand identified through an 
extensive phage display screening process. 
The stereochemical inversions give an insight into interesting structural-activity features of 
the PK15 molecule. It can be observed that single stereochemical inversions at the Cys2 and 
Cys9 positions, while reducing activity relative to the LLL ligand, still produce potent 
molecules. Of the three single inversion stereoisomers it was anticipated that the Cys9 
inversion would have the largest effect due to being central in the peptide chain. However it 
was inversion of stereochemistry at Cys16 that almost destroyed the inhibition. To further 
compound this, a second stereochemical inversion to create DLD or LDD ligands rescues the 
activity relative to the LLD ligand. This suggests that the two loops may be interacting with 
each other as well as to the target kallikrein, or alternatively that the stereochemical 
inversions significantly alter loop structure throughout the molecule rather than just in the 
immediate surrounding area. Heinis et al. previously studied PK15 by NMR and found no 
interloop NOE signals indicating an absence of interaction between the loops.
14
 However 
their data was for unbound ligand free in solution, there could be significant differences to 
the bound ligand conformation. 
2.4.2 Modelling the PK15 stereoisomers 
Further to the NMR work mentioned above, Heinis et al. attempted to model the structure of 
PK15 using the NOE constraints. This produced a model with two independent loops in an 
extended conformation. Recently the MacroModel (Schrodinger Inc.) suite has been shown 
to model macrocycles well, although large macrocycles are still a challenge for the 
program.
119
 In the absence of NMR data for each isomer it was decided to use the 
MacroModel suite to investigate the effect of stereochemical inversion in the backbone. 
Given the large effects stereochemical inversions have on loop structure as observed via 
kallikrein inhibition above it was rationalised that modelling of the macrocyclic 
conformation may be insightful. 
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A 2D representation of each ligand was produced in ChemDraw and then converted to a 
random 3D structure using Pipeline Pilot.
v
 This was used to seed the MacroModel suite’s 
macrocycle sampling script, wherein five thousand rounds of simulated annealing were 
followed by five thousand rounds of energy minimisation with structures within 0.75 Å 
r.m.s.d.h. being discarded. The lowest twenty conformations were exported and visualised 
using Pymol. The results for the LLL and LLD ligands are displayed in Figure 33. 
 
Figure 33: Comparison of LLL-PK15with LLD-PK15 molecular modelling results using the 
macrocycle sampling tools in Macromodel® The peptides are displayed as backbone ribbons with the 
mesitylene core and side chains omitted for clarity. 
While it was encouraging that the modelling protocol was generating distinctly different 
peptide backbone structures it was of concern that the LLL structure would violate the NOE 
signals observed by Heinis et al.
14
 They identified only one weak NOE signal across atoms 
more than two residues apart - HB Arg5: HN Cys2. Because of the lack of long- and 
medium-range NOE signals no single distinct structure could be proposed however the 
ensemble of structures which all fit with the gathered data all had an extended conformation 
with the loops not interacting with each other. The positions of the sidechains in the LLL 
ligand results are shown in Figure 34 – the close interactions between the loops would 
presumably have led to the observation of NOE signals. 
                                                     
v
 3D structure generated by George Burslem 
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Figure 34: The lowest energy conformation of LLL-PK15 modelling results – the proximity of the 
sidechains is in clear violation of the NMR data obtained by Heinis and coworkers which showed 
only one weak NOE signal (HB Arg5: HN Cys2) between residues more than 2 positions apart. Loop 
1 (blue) and 2 (orange) are clearly held closely together by the mesitylene core (green) in the 
modelling results which contrasts the NOE data. 
To further investigate whether this modelling protocol is producing relevant structures an 
alternative bicyclic peptide ligand was used. UK18 is an inhibitor of urokinase plasminogen 
activator (uPA) which has been co-crystallised bound to its target (PDB 3QN7). The ligand 
was extracted from the pdb file to use as the starting point of the modelling protocol in 
parallel with a 3D structure generated at random from a 2D structure as above. The results of 
this control are shown in Figure 35 and 36. Using the pdb structure as the seed for the 
modelling procedure results in convergence towards a structure with similar structure in loop 
1 but different loop 2 structure compared to the pdb structure (Table 4). However starting 
from the random 3D structure, the modelling converged on a different structure entirely. 
When aligned with the pdb structure the core is in an alternative conformation and there is 
very poor overlap with the loop structures. 
37 
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Figure 35: The lowest energy conformation of the UK18 structure determined in the macrocycle 
sampling protocol using both the PDB crystal structure and a random 3D structure generated from a 
2D drawing as the initial seed. Not only are these different in both loops but it can be seen that when 
overlayed with the bound PDB ligand structure (sky/magenta) there is slight overlay in loop 1 (blues) 
but loop 2 overlays very poorly in both cases (reds/magenta). In the PDB seeded results the core 
aligns relatively well, however in the 2D seeded result the core is in an entirely different position. 
Table 4: Calculated energies and r.m.s.d.h. values of modelling results vs the bound-ligand structure 
from the crystal structure 
Structure Potential Energy 
(kJ/mol)
[1]
 
r.m.s.d.h. from bound structure (Å) 
Total Loop 1 
(res. 1-8) 
Loop 2 
(res. 10-16) 
PDB UK18 Structure 7a -2259.955 N/A N/A N/A 
Model from PDB Seed 7b -3759.138 4.56 3.23 5.20 
Model from 2D Seed 7c -3163.600 5.72 4.69 4.55 
[1] Calculated using OPLS-2005 force field   
 
These results with the UK18 peptide indicate that the modelling protocol is not converging 
on a global minimum. The calculated energies of the three compared structures are shown in 
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Table 4. This may suggest that the structure has a large degree of conformational flexibility 
and may reflect that the solution structure may be an ensemble of structures, and binding to a 
protein can stabilise one conformation in an induced fit manner. There is a large difference 
in energy between the bound structure and the modelling results – this is presumably offset 
by the binding interactions with the uPA target. Although the protocol discards conformers 
within 2 kcal/mol of existing hits, the backbone structure was conserved amongst the low 
energy hits. This suggests the sidechains have too much flexibility for this modelling 
protocol to work efficiently under the current restraints and a larger r.m.s.d. cut-off would 
need to be applied to identify alternative backbone constraints. 
 
Figure 36 Overlay of the PDB bound UK18 structure (sky/magenta), the modelling result from the 
PDB UK18 seed (blue/red) and the modelling result from the 2D UK18 sequence seed (dark 
blue/brick red). Loop 1 (blues) tracks well for the PDB seed but due to the different position of the 
core in the 2D seed this loop does not overlay well. Loop 2 overlays poorly between all 3 structures. 
2.5 Conclusions 
The key step in this work involved the application of a new reagent 
methyl 2,5-dibromovalerate 63 to dehydroalanine conversion. This proved adept in the 
conversion of multiple cysteine residues to form multiple dehydroalanine residues. While 
this conversion was successfully incorporated into a two-step strategy to create diverse 
bicyclic peptides there are other applications where this conversion could prove useful. 
Of primary interest is the application of this reagent to replace 2,5-dibromoadipamide in the 
formation of single dehydroalanine residues. 63 is more soluble than 27 and so has potential 
to be used in a wide range of protein modifications, using only low equivalent numbers of 
reagent. The reagent is stable at room temperature, although it was observed that a DMSO 
stock solution turned yellow over the course of about one month at 4 °C. Potential 
applications of dehydroalanine-containing peptides were covered in section 2.1. Preliminary 
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attempts at protein modification have successfully converted cysteine to dehydroalanine 
using 63.
vi
 
Applications requiring multiple dehydroalanine residues may be less frequent, however 
herein was presented an interesting use of the dehydroalanines to generate constrained 
peptides with diverse stereochemistry via reaction with a polythiol core. In the same manner 
that Heinis and co-workers have shown that different cores can then cyclise the same peptide 
sequence, different thiols may cyclise the dehydroalanine-containing peptides. The nature of 
the thiol may be vital to cyclisation though – attempts with alkyl thiols (dithiothreitol and 
trimethylolpropane tris(3-mercaptopropionate)) were inconclusive and the addition of 
thiophenol to dehydroalanine was observed to be reversible. It is interesting to hypothesise 
what might happen upon addition of 3,5-disulfhydrylthiophenol – in solution the ensemble 
of stereoisomers may equilibrate to form the most thermodynamically stable isomer. 
Alternatively temporary protection or labelling of a dehydroalanine residue with a 
thiophenol derivative could be achieved which is then removed by addition of a second thiol. 
In the case of the stereochemically scrambled bicyclic peptides presented in this work, the 
deconvolution strategy which was applied to identify the individual activities of each 
stereoisomer could feasibly be applied to hit sequences from a library screen. The method of 
display, although intended as via phage display (see Chapter 4), could be through any of the 
peptide display platforms discussed in Chapter 1. Given that the crude reaction mixture gave 
good agreement with the purified mixture of stereoisomers this is also promising as cyclised 
products can immediately be used in assays without extensive purification to identify 
mixtures containing potent stereoisomers. This of course may be an assay-dependent feature 
and adequate controls would have to be established. 
Perhaps the most valuable application of the new reagent would be in the production of 
lanthipeptides, both the final products and also intermediates to study the cyclase enzymes in 
detail. While preliminary attempts were made to carry out the transformation on solid-phase 
support (Section 6.2), these were complicated by inefficient deprotection of cysteine 
residues. This work merits further interest as the production of lantibiotic analogues by 
SPPS would allow the incorporation of non-canonical amino acids, or a focussed library 
approach.
120
 
To further expand the applicability to lantibiotic synthesis, it would be of value to synthesise 
β-methylcysteine (See Section 6.2.2), a threonine mimic. This could in theory undergo 
double-alkylation elimination in the same manner as the cysteine residues to form 
                                                     
vi
 Work carried out by Rob Smith, Berry group, FBS Leeds 
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dehydrobutyrine. The stereoselective synthesis of this amino acid has been demonstrated 
starting from threonine.
121
 Previous attempts to install Dhb have used solution phase 
chemistry to create peptide fragments containing Dhb which are then coupled by SPPS, or 
have created methyllanthionine building blocks.
122
 The use of a chemical modification to 
insert Dhb would allow control over when a cyclisation reaction can occur. 
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Chapter 3: The synthesis of alternative cores for bicyclic peptide 
formation 
In this chapter, investigations into the synthesis and use of alternative classes of small 
molecule core for bicyclic peptide formation are presented; efforts toward both polythiol and 
alkylating agent cores are discussed. Of particular interest is the synthesis of a core based on 
the selective cysteine-labelling Barbas reagent - this new core forms different peptide 
structures from established cores. 
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3.1 Introduction 
Bicyclic peptides consisting of a peptide attached around a small molecule core are potential 
modulators of protein-protein interactions (Section 1.2.5). Previous work by Heinis and co-
workers has demonstrated that switching the small molecule core causes the same peptide 
sequence to adopt different loop structures (Figure 37a/b).
15, 61
 This was first demonstrated 
using the kallikrein inhibitor PK15 sequence – switching the core used in the cyclisation of 
PK15 sequence 36 from 10 to 1,3,5-tris(bromoacetamido)benzene 13 (TBAB)  altered its 
kallikrein inhibition.
61
 They then observed that selecting against uPA from a phage library 
gave different results dependent upon which core was used for cyclisation.
15
 Crystal 
structures of inhibitors demonstrated that the cyclisation with 13 creates a core wherein the 
amides are able to form intramolecular hydrogen bonds with the peptide, thus influencing 
the loop structure (Figure 37c). 
The small molecule cores which have previously been used in the generation of bicyclic 
peptides are approximately similar in reactivity, size and topography (Figure 37a/b). In these 
cases the use of symmetrical cores avoids the production of constitutional isomers which 
simplifies any screening process and hit deconvolution. It was predicted that the use of a 
core based around a tetrahedral centre would generate an added layer of diversity through 
the production of enantiomeric structures where the fourth substituent of the tetrahedral 
centre is held on either face of the bicyclic peptide (Figure 38). This fourth substituent 
would also allow functionalisation of the bicyclic peptide structure without direct 
modification of the peptide, thus avoiding disruption of any binding interface as the fourth 
substituent should, in theory, be held away from the peptide structure. To combine these 
advantages it was aimed to either synthesise cores based upon pentaerythritol such as 89 
(Figure 38b) or alternatively to investigate the use of cores based on the related 
tris(hydroxymethyl)methylamine base such as 90. Both of these structures would allow 
further derivatisation to, for example, attach imaging reagents, adhere to surfaces or attach to 
another ligand.  
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Figure 37: Alternative cores for bicyclic peptide formation. a) Cores used by Heinis and coworkers 
which imparted different loop structures when used to cyclise identical linear peptides. b) The 
trimesic acid core used by Pei and coworkers to identify 14. c) The crystal structure of UK903 
extracted from the bound crystal structure to target uPA (PDB: 4MNY). Three hydrogen bonds 
formed between the core and the peptide backbone are marked by black dashed lines between the 
heavy atoms involved. 
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Figure 38: Tetrahedral core molecules a) The constraint of a peptide sequence by a tetrahedral core 
bearing three identical thiol arms generates two stereoisomers – here the residue number to prioritise 
the substituents and define the pseudo-stereochemistry at the tetrahedral centre. b) Two example 
target cores: alkyl trithiol core 89 bearing a tetrahedral centre derived from pentaerythritol 94 and a 
PEG chain to allow further conjugation and trithiol 90 derived from Tris base. 
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3.2 Synthesis of alkyl trithiol cores 
Due to the success of cyclisation of dehydroalanine-containing peptides with TMMB 39 it 
was aimed to develop alternative thiol-based cores which could be used in the same role and 
test their cyclisation efficiency. Due to the observed reversible nature of thiophenol addition 
to Dha it was decided to focus synthetic efforts on alkyl thiols. It was aimed to incorporate a 
tetrahedral centre and a fourth substituent bearing a functionalised PEG tail for further 
conjugation. 
3.2.1 Synthesis of the functionalised PEG tail 
The initial objective was to synthesise the functionalised hexa-PEG 93 to be used to attach a 
fourth substituent to a tetrahedral core. A terminal alkyne was chosen to allow further 
derivatisation via copper-catalysed cycloaddition with an azide. The initial aim for the 
opposite terminus was to synthesise the alkyl bromide 93 for further alkylation of a 
tetrahedral core. 
 
Figure 39: The synthesis of 93 from hexa-PEG 91 and attempted reaction to form 95. An initial 
alkylation to add a propargyl group was followed by an Appel reaction to synthesise the alkyl 
bromide. The alkylation of pentaerythritol to deliver 95 proved problematic. 
The synthesis of 93 was carried out in two steps from 91. The initial alkylation produced a 
stoichiometric mixture of 1:2:1 double:single:zero alkylation products with the single 
alkylation product 92 being isolated in 47% yield. An Appel reaction
123
 was then used to 
convert the alcohol 92 to the primary bromide 93 in 53% yield. With 93 in hand it was then 
aimed to insert a tetrahedral core bearing hydroxyl groups which could subsequently be 
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converted to thiols. Pentaerythritol 94 was chosen, although there were concerns about its 
low reactivity. Alkylation using pentaerythritol 94 was attempted but under conditions tested 
the bromide favoured elimination to form the alkene 96 (Figure 40). Pentaerythritol was a 
poor nucleophile – no reaction was observed when using mild bases triethylamine and 
imidazole, necessitating the use of the relatively strong bases. Some of the desired ether 
product 95 was observed by LCMS but upon addition of further base to drive reaction to 
completion the product also eliminated to form 96. 
 
Figure 40: Elimination was observed in attempts to use 93 to alkylate pentaerythritol 94. No reaction 
was observed using weaker bases. 
It was therefore decided to replace the ether linkage with a more stable amide linkage 
(Figure 41). Jones oxidation of 92 delivered the carboxylic acid 97. An EDC-activated 
amide coupling was carried out with tris(hydroxymethyl)methylamine (Tris) to provide the 
trishydroxy compound 98 (Figure 41). EDC-activated amide formation was initially 
attempted in aqueous conditions to solubilise the Tris. However the amide bond formation 
was low yielding due to competing hydrolysis of the EDC-activated acid. The polar product 
required continuous extraction to purify. Addition of DMAP to the reaction failed to 
improve the conversion and additionally DMAP was co-purified in the continuous extraction 
process. An attempt was made to replace the EDC coupling with a two-step conversion via 
acid chloride synthesis with thionyl chloride followed by reaction with Tris in DMF. 
Although the first step proceeded quantitatively by NMR, the second step proved more 
problematic and only a 19% yield was achieved following continuous extraction.   
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Figure 41: The synthesis of 98 from alcohol 92. Jones oxidation of 92 provided acid 97 which was 
either directly coupled with Tris via an EDC-activated amide formation, or was converted to the acid 
chloride before direct reaction with Tris. 
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3.2.2 Synthesis of trithiol subunits 
With 98 in hand the next step in the proposed synthesis was the conversion of hydroxyl 
groups to thiols. An alternative route to the pentaerythritol-derived core 89 was targeted via 
the route shown in Figure 42. Tribromide 99 was synthesised via bromination of 
pentaerythritol in 31% yield. The tribromide 99 was shown to be unreactive toward the 
PK15 peptide sequence 36 under the cyclisation conditions used for the reaction of PK15 36 
with TBMB 10.
vii
 It was aimed to convert 99 to trithiol core 100 via thiourea alkylation and 
hydrolysis. Although an initial addition of thiourea was observed by MS, subsequent 
additions were not observed and intermediates or product 100 could not be detected by 
NMR. 
 
Figure 42: Attempted synthesis of 100 via bromination and thiourea alkylation. The bromide 99 was 
inert to peptide cyclisation, and alkylation with thiourea also proved problematic.  
It was decided to attempt a Mitsunobu reaction with thioacetic acid to install the thiol 
functionality (Figure 43). 102 was used as a model system to develop conditions for this 
conversion. The alkylation of pentaerythritol was again hampered by its poor solubility and 
nucleophilicity. Reaction with one equivalent of benzyl bromide led to multiple additions 
due to enhanced solubility of the alkylated products compared to pentaerythritol. The 
polyalkylated by-products were removed by ether extraction and a subsequent extraction of 
the aqueous layers with dichloromethane then gave straight-forward purification of 101. 
Though low-yielding this reaction gave sufficient material to proceed in preference to 
investigating protecting group strategies. 
                                                     
vii
 Attempted cyclisation with 36 carried out by Patrick Foley 
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Figure 43: The attempted synthesis of 103 via monobenzylation of pentaerythritol followed by a 
Mitsunobu reaction to convert the hydroxyls of 101 to thioacetates. Deacetylation of 102 was thought 
to be achievable via either hydrolysis or reduction however attempts were unsuccessful. 
A Mitsunobu reaction with thioacetic acid was used to install the masked thiol functionality, 
there remained trace triphenylphosphineoxide (TPPO) impurity present.
124
 In contrast to the 
literature reports,
124
 deprotection of the acetate groups of 102 was not without complication. 
Lithium aluminium hydride did not appear to deprotect the thioacetates as intended. Due to 
further problems with thioacetate deprotection, as discussed below, this route was 
abandoned and an alternative thiol synthesis sought. 
Synthetic efforts also focussed on Tris-based cores and attentions returned to the use of 
thioacetate to install thiol functionality. The Mitsunobu reaction with thioacetic acid was 
attempted using 98 as a substrate however this failed – the amide appeared to intercept the 
activated alcohol, forming the oxazoline structure 105.  
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Figure 44: The unsuccessful attempted Mitsunobu reaction to install thioacetate functionalities and 
form 104 starting from 98 was disrupted by formation of the oxazoline 105. 
An alternative strategy would be to generate a protected tris(mercaptomethyl)methylamine 
prior to amide coupling to the PEG tail. It was rationalised that using Tris directly as a 
substrate in the Mitsunobu reaction with thioacetic acid would be unwise due to acetyl 
transfer from thioesters to the free amine. This would obstruct attempts at further 
functionalization at this position. It was thought that the use of 
tris(hydroxymethyl)nitromethane may circumvent this if the thiols could be deprotected 
prior to nitro reduction. The Mitsunobu reaction proceeded in 54% yield however the 
removal of the acetate groups again proved problematic – a white polymeric substance 
formed which solubilised upon treatment with DTT. Presumably a disulfide polymer was 
formed which still formed oligomeric species upon reduction. Due to the difficulties in 
obtaining the tris(mercaptomethyl)methane-based cores 104 and 108 work on this motif was 
abandoned.  
 
Figure 45: The synthesis of 107 via a Mitsunobu reaction with thioacetic acid. Deprotection attempts 
were unsuccessful – leading to suspected polymerisation. 
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3.3 Synthesis of alternative alkylating core molecules 
It was also aimed to test the effects of varying the core topography on peptide structure via 
the synthesis of cores 109 and 110 (Figure 46). Both cores were intended to react directly 
with cysteines in peptides. 109 was previously shown to react with nucleophiles to form 
trisubstituted tertiary amines.
125
 The 1,3,4-oxadiazole core was inspired by work by Barbas 
and co-workers. They demonstrated that 2-mesyl-5-phenyl-1,3,4-oxadiazole selectively 
labels cysteine residues as an alternative to maleimide chemistry.
126
 The extended aromatic 
ring structure should provide a more rigid and planar core than the previously-used cores. 
Heinis and co-workers have made cores slightly larger than TBMB 10 (Figure 37) but these 
have flexible arms and so the distance between cysteine residues can vary for example in a 
range of 3.5 to 13.1 Å using TBAB 13.
15
  
 
Figure 46: Target core molecules to investigate the effect of small and large steric constraints on 
peptide structure 
 
3.3.1 Tris(chloromethyl)amine-derived cores 
The synthesis of tris(chloromethyl)amine 109 was first reported in 1967 via the reaction of 
trisodium 1,1′,1″-nitrilotrismethylsulfonate and PCl5.
127
 This was improved upon by Fluck 
and Meiser with the reaction of hexamethylenetetramine 111 with PCl5 (Figure 47).
128
 They 
then demonstrated the reaction of 109 with a range of nucleophiles, including alkoxides, 
amines and Grignard reagents. All classes of nucleophile tested underwent triple addition to 
the trimethylamine core with the exception of the addition of β-mercaptoethanol which was 
observed to undergo only two additions, with the product appearing to have molecular 
formula N(CH2SCH2CH3)2CH2Cl.
125
 109 has subsequently been shown to react with sodium 
azide and ammonium 5-nitrotetrazolate to form explosive materials by Klapötke and co-
workers.
129
 It was decided to use the small trimethylamine core as the basis of potential new 
cores for bicyclic peptides. The close resemblance of 109 to carcinogenic nitrogen mustard 
gases was noted – tris(chloroethyl)amine is the only nitrogen mustard still used in chemical 
warfare. However due to the inability of 109 to form a reactive aziridinium intermediate it 
was hoped that this structure would be less hazardous. 
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Figure 47: The synthesis of 109 from 111 following literature procedure
128
 
Tris(chloromethyl)amine 109 was synthesised following the literature procedure from 
hexamethylenetetramine 111 (Figure 47).
128
 Due to technical difficulties with sublimation 
apparatus product 109 was instead purified by recrystallization from dichloromethane in 
43% yield. An initial reaction of 109 with peptide ACAHTGCVYDSCG did not lead to any 
observed cyclisation in either water or acetonitrile. This was not unexpected as 109 appears 
extremely reactive with water – when exposed to air an acute smell of HCl was observed. 
Using 109 as a starting point, it was targeted to synthesise the trithiol 113. It was aimed to 
synthesise this via the displacement of the chlorides with a protected thiol and subsequent 
deprotection. In contradiction to Fluck and Meiser’s observation of βME addition noted 
above, the addition of tert-butyl thiol gave the product of triple-addition 112 in 56% yield 
(Figure 48). Attempts to deprotect the tBu groups were unsuccessful. It may be possible to 
synthesise 113 directly from 109 with sodium sulfide, however this was not attempted. 
 
Figure 48: The synthesis of 112 was achieved from 109 however deprotection attempts were 
unsuccessful. 
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3.3.2 Cores based on Barbas reagent - synthesis of oxadiazole core 110 
As described in Section 3.3 it was aimed to synthesise the core 110, containing multiple 
2-mesyl-1,3,4-oxadiazole moieties. It was thought this extended aromatic system would 
have a rigid extended structure when compared to the cores in Figure 37. 
 
 
Figure 49: The synthesis of 2-mesyl-5-phenyl-1,3,4-oxadizole 116 by Toda et al.
126
 
The synthesis of 2-mesyl-5-phenyl-1,3,4-oxadiazole 116 by Barbas and co-workers
126
 is 
shown in Figure 49 (molecules derived from this have since been classified as Barbas 
reagents). These conditions were adapted to the proposed synthesis of core 110 displayed in 
Figure 50.  
This synthetic route adapted to the synthesis of multifunctional core 110 (Figure 50) proved 
inefficient. While the initial hydrazide formation proved straight-forward, the cyclisation 
reaction with carbondisulfide proved low-yielding. The methylation was also 
disappointingly low-yielding – it was observed that hydrazide by-products were formed.  
The final oxidation step also proved to be problematic – it was observed that over-oxidation 
of the mesylate species 120 to form oxadiazal-2-one by-products occurred. This was 
presumably not a major problem for the synthesis of 116, where the lower levels of oxidant 
required would lead to less by-product formation. However when six oxidations were 
attempted simultaneously, the reaction profile was more complicated – the over-oxidation to 
form a 1,3,4-oxadiazol-2-one appears to be at least as favoured as the sulfur oxidations. The 
extended conjugation in 120 relative to 115 could also mean the carbon is even more 
electropositive. 
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Figure 50: Initial synthetic efforts to core 110 replicating methods used in the synthesis of 116. 
The yield of the methylation step to form 120 was improved by a switch of solvent to 
DMSO. The starting material 119 proved more soluble in DMSO than THF, and fortuitously 
the product 120 precipitated from the reaction mixture. This serendipitous development 
avoided the need for further work-up or purification steps. This change improved the yield, 
however for a simple alkylation it was still below expectations. 
Several attempts were made to improve the oxidation step (Table 5) using either 120 or 
5-phenyl-2-thiomethyl-1,3,4-oxadiazole 115 as substrates. Only minimal improvements 
were achieved via the use of peroxide based approaches. The greatest improvement was 
achieved using a biphasic reaction involving ruthenium catalysis and sodium periodate. This 
forms ruthenium tetroxide in situ, which although usually unstable, is stable in carbon 
tetrachloride. This oxidant proved superior as, similar to oxidation with chromium trioxide 
(Section 3.2.1), the target of oxidation must interact with the metal centre. The lone pairs of 
the sulfide are capable of this co-ordination whereas the carbon is unable to co-ordinate. The 
reaction proceeded quickly and cleanly and after HPLC purification a greatly improved 65% 
yield was obtained. It should be noted that purification by silica chromatography led to the 
degradation of 110. 
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Table 5: Synthetic methods attempted in the optimisation of the oxidation of 120 to 110 
Entry Conditions Observations Yield of 
 Substrate 115  116 
1 Oxone, 2:1 MeOH:H2O, rt Over-oxidation observed 69% 
2 MMPP.6H2O, MeCN, rt Complete over-oxidation - 
3 
NaIO4, RuCl3, 1:1:2 
CCl4:MeCN:H2O, rt 
Quantitative conversion 100% 
 Substrate 120  120 
4 
(NH4)6Mo7O24.4H2O, 30% H2O2, 
EtOH, 60 °C 
Over-oxidation - 
5 5% KMnO4 (aq), AcOH, 10 °C No reaction (insoluble) - 
6 
(NH4)6Mo7O24.4H2O, 30% H2O2, 
[bmim]PF6, 60 °C 
Poor solubility, Over-
oxidation of soluble material 
- 
7 mCPBA, 3:4 DMF:CH2Cl2, 40 °C Over-oxidation observed 8%
a 
8 
NaIO4, RuCl3, 1:1:2 
CCl4:MeCN:H2O, rt 
No over-oxidation observed. 65%
a
 
[a] NB do not column on silica – product degrades 
 
The optimisation of the alkylation and oxidation steps greatly improved the synthesis of 110 
(Figure 50). Combining the original synthetic route to 119 with the use of DMSO as solvent 
in the methylation reaction and the use of the ruthenium catalyst in the oxidation (Table 5 
entry 8) gives an 11% yield over the four steps to synthesise 110. While there is still room 
for further optimisation of these conditions this route delivered  81 mg of final product – 
more than sufficient to investigate bicyclic peptide formation with 110. 
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Figure 51: Optimised synthesis of 110 from intermediate 119 and subsequent use in the cyclisation of 
PK15 sequence peptide 36 to generate bicyclic peptide 121. 
 
3.4.3 Testing and modelling bicyclic peptide PK15-oxa 121 
To demonstrate the potential of the core 110 to cyclise cysteine-containing peptides it was 
reacted with the PK15 kallikrein inhibitor sequence 36 (Figure 51). The reaction appeared 
complete within five minutes by LCMS and after HPLC purification 121 was obtained in 
65% yield. This compound was tested in the same kallikrein inhibition assay used in Section 
2.3.2 and shown to be inactive within the concentration range tested (Figure 52); as an 
approximation a logistic fit with the baseline activity set at 0% and the power set as 1 gives 
an approximate IC50 of 360 ± 62 µM. This is 10
5
 times lower than the PK15 sequence when 
cyclised with the mesitylene core and 100-fold worse than the TBAB core Heinis and co-
workers tested. This suggests that the peptide structure is very different between the two 
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cores; in this case the loops presumably have less backbone flexibility due to the rigid core. 
It would be of interest to obtain an NMR or crystal structure of 121 and compare it to the 
modelled structure shown in Figure 53. A single linear peptide library would give rise to 
very different bicyclic peptide libraries if cyclised in parallel with TBMB 10 and the Barbas-
based core 121. 
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Figure 52: The results of testing compound 121 for inhibition of HPK via the cleavage of Z-Phe-Arg-
AMC 78. 121 proved almost totally inactive in the concentration range tested – at least 5 orders of 
magnitude worse than the same peptide sequence cyclised by TBMB 10 (PK15 37), and 2 orders of 
magnitude worse than the same sequence cyclised by TBAB 13. 
The lack of activity indicates the peptide is adopting a significantly different structure and is 
held unable to form the correct binding pose. The same macrocyclic modelling protocol was 
followed as for the stereoisomers in Section 2.4.2 (Figure 53). The results for the PK15 
sequence attached around the oxadiazole core determined a relatively rigid core with the 
sulfur atoms of the cysteine residues spaced between 9.6 and 11.7 Å apart – with the 
variance due to slight twisting of the aryl rings and the relative orientation of the oxadiazole 
rings (Figure 53). This result supports our hypothesis that the core forms a less flexible 
scaffold than the molecules used previously (Figure 1) and leads to a peptide of significantly 
different structure. 
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Figure 53: The structure of the PK15 sequence attached around a 1,3,5-tri-1,3,4-oxadiazolylbenzene 
core modelled using the same macrocyclic sampling protocol as in section 2.4.2. The core is relatively 
rigid which holds the sulfur atoms of three cysteines approximately planar with the core. 
3.4.4 A bis-Barbas stapling reagent 
In preliminary efforts to synthesise 110, the hydrazide formation step to form 118 produced 
a high yield of bis-hydrazide material 123 rather than tris-hydrazide 118 or even a 
stoichiometric mixture of hydrazides despite the use of ten equivalents of hydrazine hydrate. 
In contrast the use of fifteen equivalents gave clean production of 118. This is difficult to 
rationalise other than to assume that the concentration of hydrazine was below that stated. 
This material was used to test the subsequent reaction steps in the synthetic route to 110 and 
often the products were taken on directly as this was only intended as preliminary method 
development. The product of the oxadiazole formation step 124 was taken on into the 
methylation step without further purification. Post-cyclisation the methylation step was 
straight-forward, in contrast to the problems with the synthesis of 120. The oxidation step to 
form 126 was also more straight-forward than in the synthesis of 110 – the use of the 
molybdenum catalyst and hydrogen peroxide gave 126 in 23% yield. Although 126 was 
further reacted with a peptide (see below), it degraded prior to complete characterisation. 
121 
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Figure 54: The synthesis of bis-Barbas reagent 126 
It was subsequently realised that 126 may make a useful reagent for the cyclisation or 
stapling of peptides. As well as incorporating the 2-mesyl-1,3,4-oxadiazole moieties the 
third substituent acts as a point for further functionalization. To prove the appropriate 
reactivity of 126, it was reacted with peptide LTFCEYWAQLCSAA 74 wherein the 
cysteines have been introduced as potential cyclisation handles at positions 4 and 11. This 
peptide sequence was chosen as it closely resembles that of an MDM2 inhibitor 127 
developed by Aileron Therapeutics (Figure 55).
130
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Figure 55: Application of the bis-Barbas reagent 126 as a staple. a) the MDM2 inhibitor ATSP-7041 
developed by Aileron Therapeutics contains a hydrocarbon staple which presents the three residues in 
a position to mimic the P53 helix which binds to MDM2.
130
 b) Cyclisation of the similar peptide 74 
with reagent 126 in an effort to stabilise a helical conformation. 
The synthesis of 128 proceeded cleanly with the 20% yield attributable to losses on the 
HPLC purification system. 128 was compared to the parent peptide 74 by circular dichroism 
(CD) in 1:1 water:acetonitrile for evidence of alpha helicity. Unfortunately 128 appears to 
have even less helical character than the parent peptide 74. The stapling has instead induced 
an alternative cyclised form. There are two likely causes of this – firstly the stereochemistry 
of the cysteine at position 4 is the opposite of the amino acid used in the MDM2 inhibitor. 
Secondly the choice of solvent used in the CD was not optimised – the peptide is likely to 
adopt different conformations dependent upon the solvent used. It is likely that a switch to a 
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mixture of water:trifluoroethanol might enhance helix formation. Spring and co-workers 
have previously used a similar class of i, i+7  staple formed via an azide-alkyne 
cycloaddition as demonstrated in stapled peptide  129.
131
 The stapling using 126 would 
create a constraint of similar size and geometry if homocysteine was used in place of 
cysteine in the peptide sequence. 
 
Figure 56: The CD spectra of the peptide 74 (black) and its cyclised variant 128 (red) in 1:1 
water:acetonitrile. 74 has minor alpha helical character which is not observable in cyclised peptide 
128. 
In summary the 2-mesyl-5-phenyl-1,3,4-oxadiazole is a synthetically tractable alternative to 
halides for the selective alkylation of cysteine residues to create constrained peptides. The 
rigid cores have potential to restrain peptides in bioactive structures which may be useful as 
modulators of PPIs. 
 
Figure 57: A similar triaryl staple developed by Spring and co-workers.
131
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Chapter 4: Phage display of bicyclic peptides via g3p phagemid 
vector 
In this chapter, work toward the development of a phage display construct for the display of 
a peptide containing multiple cysteine residues is presented. Two approaches are presented – 
display of a fusion with either cysteine-free g3p protein or a g3p truncation mutant. The 
challenges of efficient display and chemical modification of phage are discussed. 
  
75 
 
4.1 Introduction 
Following the development of both the dehydroalanine chemistry (Chapter 2) and the 
oxadiazole-based core (Section 3.3.2) it was aimed to test these methods on peptides 
displayed using a library display platform. Previous work with bicyclic peptide structures 
has used either phage display
14, 82
 or solid-phase resin approaches.
62
 Phage display 
methodology was selected due to existing expertise and facilities in the McPherson and 
Tomlinson groups. Phage display of the linear peptides and subsequent cyclisation has 
previously been achieved by Heinis and co-workers using a single phage vector approach 
(Section 1.2.5) to display a peptide sequence containing three cysteine residues as a g3p 
conjugate. g3p is the ‘tail’ protein of a phage, present in five copies per phage unit, with an 
important role in binding to E. coli pili to initiate infection of the bacterium. g3p consists of 
three domains – two N-terminal domains with similar beta barrel structure and a C-terminal 
domain which attaches to the rest of the phage. Heinis and co-workers reported treatment 
with TBMB caused problems with phage infectivity – proposed to be due to cross-linking of 
WT g3p proteins via native cysteines. These problems were alleviated by use of a cysteine-
free g3p mutant. This cysteine-free g3p (Figure 58) was developed by Kather et al. in a 
protein folding mutagenesis study;
83
 six native cysteines in the N1 and N2 domains have 
been removed and the protein structure stabilised by a further nine mutations.  The mutated 
g3p has reduced infectivity compared to the wild-type g3p, however this was still greater 
than the infectivity observed when WT g3p had been reacted with TBMB.
82
 
 
Figure 58: The mutations introduced into g3p by Kather, Bippes and Schmid to replace three disulfide 
bonds in the N1 and N2 domains of g3p. 
In contrast to the single vector approach employed by Heinis, the Adhiron library developed 
at Leeds (Section 1.1 and Chapter 5) is displayed using a phagemid approach. In this 
approach one vector – pBSTG1 – encodes the Adhiron as a fusion with a truncated g3p 
76 
 
variant consisting of only the C-terminal domain. A second vector encodes the remainder of 
the phage proteins including a WT g3p to ensure infectivity. This second phage vector is 
delivered to the E. coli via use of a secondary helper phage. This approach avoids the use of 
a whole-phage vector which could cause contamination issue for other researchers. In 
addition the in-house standard phagemid protocols are well optimised and have been used 
for a variety of displayed libraries. It was aimed to adapt this approach to display a peptide 
containing two variable loops spaced by three cysteine residues which can be modified 
chemically.  
4.2 First iteration phage studies 
The target pBSTG1 vector is depicted in Figure 59. The leader sequence is responsible for 
export of the fusion protein to the periplasm where it can fold correctly. Several leader 
sequences were tested as different sequences have been shown to be better for different 
fusion protein exports.  
The mutated cysteine-free g3p, hereafter termed g3p*, was used as although we did not 
anticipate the same problems with cross-linking when using methyl 2,5-dibromovalerate 63 
to install dehydroalanine residues, it is possible that the oxadiazole reagent would cross-link 
the g3p proteins. The PK15 sequence 36 was used as the model system peptide to test 
display and the success of chemical modifications as it had previously been reacted 
successfully with both methyl 2,5-dibromovalerate 63 and the oxadiazole-based core 110. In 
addition it was aimed to use the TBMB 10 cyclisation chemistry to verify the level of 
display and infectivity. 
With respect to the secondary phage used to supply the second vector, two options were 
considered. The standard helper phage was the first option – there were concerns that the 
WT g3p would be cross-linked and impair infection but this might be overcome by 
combination with the use of the g3p* fusion. Additionally the WT g3p might be 
incorporated into phage in preference to the g3p* fusion leading to low display levels of the 
conjugate. A second option was the use of commercially available Hyperphage® - a helper 
phage system which lacks a g3p variant in the genome it delivers. This hyperphage system 
would be compatible with all the regular helper phage protocols but should produce phage 
which display multiple copies of the g3p* fusion. The major drawback of Hyperphage is it is 
an expensive commercial option (approximately £360 per litre of culture). 
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Figure 59: The target vector to express a conjugate between the PK15 peptide sequence and g3p* . 
Important features include the ribosome binding sequence, a leader sequence for periplasmic export 
containing a restriction site which along with the NheI site in the g3p* sequence could be used to 
create a library of peptide sequences in place of the PK15 sequence. 
The g3p* gene was supplied in the pUC57 vector (Genscript), codon optimised for E. coli 
with the dsba leader sequence and HindIII/EcoRI restriction sites. A two-step PCR 
procedure was undertaken to change the leader sequences to yield a library of six leader 
sequences detailed in Table 6. Silent mutations were introduced into the leader sequence 
DNA to input a restriction site which could be used in any future library generation. A 
second glycine was inserted at the N-terminus of the PK15 sequence to ensure appropriate 
peptide cleavage as guided by the SignalP prediction algorithms. 
Table 6: The periplasmic export leader sequences used in this work 
Leader sequence Amino acid sequence 
dsba MKKIWLALAGLVLAFSASA 
OmpA MKKTAIAIAVALAGFATVAQA 
MalE MKIKTGARILALSALTTMMFSASALA 
STII MKKNIAFLLASMFVFSIATNAYA 
PhoA MKQSTIALALLPLLFTPVTKA 
M13KE MKKLLFAIPLVVPFYSHS 
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Figure 60: The PCR and cloning strategy to create the library of BSTG1 vectors containing the PK15-
g3p* fusion protein and a range of leader sequences. Starting from a gene in pUC57 (A), a two-step 
PCR process installed the leader sequences (B) and reinstalled the ribosome binding site and HindIII 
restriction site (C). The original gene was subcloned into BSTG1 plasmid (D) and the resultant 
plasmid used as the recipient plasmid for the PCR products (E). This gave a set of four leader 
sequences to test. 
 
An intial PCR step inserted the leader sequences ahead of the PK15 sequence (Figure 60B). 
The reverse primer used covered the NheI site which was incorporated in the g3p* sequence 
to allow cloning of an intermediate fragment – this site could then be used in any future 
library generation. A second PCR step then extended each gene to reinsert the ribosome 
binding site and the HindIII restriction site (Figure 60C). Optimisation of annealing 
temperature led to successful first steps for all five sequences. The original dsba construct 
was cloned into the pBSTG1 vector using HindIII and EcoRI (Figure 60D). The resultant 
pBSTG1-g3p* vector was then used to clone in the three new leader sequence fragments 
produced from the PCR strategy using HindIII and NheI (Figure 60E). Results of the PCR 
reactions are shown in Figure 61. The first PCR step was successful for all five leader 
sequences however the second PCR step was only successful for MalE, PhoA and M13KE. 
Attempts were made to resolve the problematic second PCR step for OmpA and STII leader 
sequences. This included using a wide range of annealing temperatures, supplementing the 
reaction with 1% glycerol in an attempt to disrupt any secondary structure of the long 
primers used, and lowering the magnesium concentration. However none of these attempts 
were successful. It was decided to press on with the set of four leader sequences to test 
including the original dsba vector. 
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Figure 61: The results of the two-step PCR process to vary the leader sequence on the PK15-g3p*. 
The first step used primers which coded for the new leader sequences (MalE, PhoA, M13KE, OmpA 
and STII) and overlapped with the PK15 sequence, giving fragments around 350 base pairs in length. 
These were then extended in a second step with primers encoding the ribosome binding site and 
HindIII restriction site. 
 
The four PK15-g3p* genes were cloned into the pBSTG1 vector using HindIII and NheI-
HF. Sequences were confirmed by Sanger sequencing before the vectors were transformed 
into E. coli ER2738 cells. Cultures of each leader sequence variant were grown with IPTG 
induction and infected with either helper phage or hyperphage to produce phage overnight. 
Upon centrifugation to isolate phage it was observed that some of the hyperphage cultures 
had white cell debris in the pellet. After precipitation, centrifugation, resuspension and 
filtering, phage concentration was measured using UV absorption at 269 and 320 nm (Table 
7). It appeared that the total phage produced by each combination of leader sequence and 
secondary phage method was approximately the same. The infectivity of the phage batches 
was tested via trial infections of ER cell cultures. 10
10
 phage produced only around 1 to 3 
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million infected bacteria when using the phage produced using helper phage. The phage 
derived from hyperphage had 100-fold less infectivity. 
Table 7: Phage titres of different phage cultures 
Secondary Phage Leader Sequence Phage Titre (25 mL culture) 
Helper Dsba 1.92 ×10
13
 
 MalE 4.62 ×10
13
 
 PhoA 3.20 ×10
13
 
 M13KE 8.60 ×10
13
 
Hyper Dsba 2.61 ×10
13
 
 MalE 2.18 ×10
13
 
 PhoA 7.36 ×10
13
 
 M13KE 4.70 ×10
13
 
 
To test whether the peptide was indeed being displayed, it was necessary to cyclise the 
displayed peptide using TBMB to create the functional PK15 kallikrein inhibitor. To ensure 
sufficient levels of functional phage, one litre cultures of the dsba and PhoA variants were 
grown, with addition of helper phage (hyper phage was not an economically viable long-
term option for litre-scale production). These cultures gave phage titres of an estimated 10
15
 
phage per mL. 
The litre cultures were modified with TBMB 10 following literature protocol.
82
 Following 
precipitation, centrifugation and resuspension the phage titre was measured as around 10
15
 
phage per mL. However in an ELISA assay to test binding of the phage to human plasma 
kallikrein there appeared to be no binding (Figure 62). Given that there was enough phage 
present to bind to the background of the plate with a strong signal, it was disappointing that 
the phage did not appear to bind to kallikrein at all. There were two possible reasons for this 
– either the peptide was not displayed at all, or the chemical modification failed. Attempts to 
examine the phage by SDS-PAGE were dominated by the g8p protein. The g8p protein is 
present in around 10
3
-fold excess relative to the g3p.  Due to difficulties in observing or 
isolating the other phage proteins from the SDS-PAGE gel this was abandoned. 
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Figure 62: Phage ELISA results for binding of phage which should display the PK15 peptide 
modified by TBMB show no binding to the kallikrein target of PK15 with any signal being equal to 
that of the phage binding to the background. 
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4.3 Second Iteration Phage Studies 
The failure of the first generation construct could not be attributed directly to either poor 
expression or failure of the chemical modification, therefore both of these factors were taken 
into account in designing a new construct. The new construct contained both an internal 
myc-tag for use in immunohistochemistry and a tobacco etch virus (TEV) cleavage site to 
allow release of any expressed peptide from the g3p conjugate. This TEV site was included 
with the aim of observing chemical modifications by mass spectrometry which is not 
possible on intact phage due to their large size. The peptide was to be displayed as a 
conjugate with a truncated variant of g3p consisting only of the C-terminal domain which is 
used in the Adhiron library in the McPherson and Tomlinson groups; helper phage would 
then supply infective WT g3p as before. Given the lack of difference in expression levels 
observed with different leader sequences in the first iteration, the dsba leader sequence was 
retained. 
 
Figure 63: The second targeted vector containing the same PK15 sequence as previously but with 
additions of a myc-sequence for antibody detection, a TEV site for cleavage and MS studies and a 
truncated WT g3p variant consisting of the C-terminal domain. 
The second generation construct (Figure 63) was supplied in puc57 (Genscript) and cloned 
into a pBSTG1 plasmid containing truncated g3p using NheI and NdeI. Successful ligation 
was confirmed by Sanger sequencing. Phage were produced using the standard BSTG 
protocol from ER cells which had been transformed with the second generation pBSTG1 
construct. Helper phage were used to provide the remainder of the phage genome. Phage 
were precipitated, centrifuged and resuspended – it was found that the phage concentration 
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was low – in the order of 1011 phage per 8 mL culture. This is 102-104 times lower than 
Adhiron-displaying phage using the same protocol. 
The low levels of phage produced led to difficulty with detection of the displayed peptide by 
mass spec. The phage were concentrated in a centrifugal spin concentrator and incubated 
with TEV protease. Any cleavage products were then isolated via centrifugal concentration 
and a sample examined using high resolution ES-MS. However no signal corresponding to 
PK15 peptide was observed.  
The phage was tested for presence of the myc epitope via an ELISA with anti-myc antibody 
as the target. No binding to the target was observed – suggesting either the peptide is not 
being expressed, or the truncated g3p is not being incorporated into the phage secreted from 
the E. coli cells. No binding to the background was observed either – not surprising due to 
the low phage titre used. It is possible that a Western blot with the anti-myc antibody would 
confirm the presence of the myc tag. However it was thought that due to inexperience with 
the technique a negative result would not be reliable, and if sufficient display was achieved 
the anti-myc phage ELISA should have given signal. Due to these disappointing results and 
impending time constraints further work on the phage display of the PK15 sequence was 
halted. 
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4.4 Discussion 
It was clearly disappointing that attempts to display the PK15 peptide using phagemid 
display approaches failed. With the first generation construct it was difficult to assess 
whether the phage produced were displaying the PK15-g3p* fusion protein. Although phage 
appeared to be produced using all leader sequences, there was low infectivity with helper 
phage as well as with hyper phage. The method of assessing phage concentration was based 
only upon UV absorption of both protein and DNA – there is no indication whether phage is 
fully constructed or viable. 
Chemical modification with TBMB was carried out following literature procedure but the 
phage did not appear to bind to the kallikrein target – with the first generation construct it 
was impossible to determine whether this was due to the lack of displayed peptide or due to 
failure of the chemical modification. The second generation construct also expressed poorly 
with low levels of phage produced. However the failure to bind to the anti-myc antibody 
suggests the level of displayed conjugate is either extremely low or non-existent. When 
using helper phage, phage will be produced which do not contain the display conjugate but 
which will be included in any concentrations assessed via UV absorbance – again this 
measure of phage concentration is at best a rough estimate.  
The poor or non-existent expression was unexpected due to the successful expression of 
PK15-g3p* by Heinis and co-workers. They used a leader sequence very similar to M13KE, 
only differing in the last 3 amino acids. This leader sequence should have been included in 
the set of sequences chosen. It was considered that the expression may be failing due to 
inadvertent disulfide formation. There is a pair of cysteine residues in the C-terminal domain 
which may be disrupted by the PK15’s free cysteines, this may particularly be of concern 
with the second construct used. It may be of use to express the PK15 sequence with the 
cysteines mutated to alanine, to test this hypothesis. The cell strain used for phage display 
was not the same in both pieces of work; in this work ER2738 cells were used whereas 
Heinis and co-workers use TG1. Therefore it is possible but unlikely that a lack of 
chaperones or transport machinery was responsible for the poor expression. 
It is possible that the peptide is being successfully displayed but the myc binding was 
inhibited by the construct. The myc tag was an internal sequence however this should still be 
identified by the anti-myc antibody. It may be possible that a Western blot would identify 
the presence of the myc tag and have a lower detection limit, however if the peptide was 
expressing to sufficient levels for display purposes it would be expected that the ELISA 
protocol would be sufficient to detect the myc sequence. The TEV cleavage site was 
intended to be used to act as a secondary check, however the TEV-cleaved peptide could not 
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be detected by MS. Due to the low concentration of phage produced this is not unexpected; 
the concentration of peptide assuming full expression and cleavage was low nanomolar - 
below the recommended detection limit of the mass spectrometry setup although other 
researchers have reported signals at this concentration. Previous work by Chen et al. used a 
MALDI mass spectrometry approach
85
 whereas here it was attempted to use an ES-MS setup 
including a column separation step. 
It is difficult within the context of these results to assess whether the conjugate was being 
expressed at all. If a phagemid vector approach is retained there are a few potential options 
to further investigate this. First there may be an issue with the leader sequence used, 
although this has been used for the truncated g3p previously. Similar to the work with the 
first construct, the leader sequence could be varied to investigate phage production. 
Alternatively a reporter system other than the myc tag could be used. For example the 
display of fluorescent proteins including mCherry and green fluorescent protein has 
previously been achieved using filamentous phage
132
 – the expression of a variable peptide 
conjugated to these could be assessed via phage solution fluorescence. 
A whole-phage vector could be used as an alternative phage production system, as 
demonstrated by Winter, Heinis and co-workers. However if aiming to use the 
dehydroalanine chemistry then it is likely that a return to WT g3p or the truncated g3p 
should be feasible. It would be of interest to treat phage displaying these g3p variants with 
methyl 2,5-dibromovalerate and examine the effect on infectivity. 
In conclusion the standard protocols for the BSTG1 plasmid phage production were co-
opted from the expression of Adhiron-displaying phage to the display of a peptide and 
ultimately this may not have been the most appropriate approach. A great deal more work 
needs to be undertaken to investigate and optimise expression of the PK15 peptide using a 
phagemid approach.  
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Chapter 5: Screening of a non-antibody binding protein library 
against a small molecule target 
In this chapter the synthesis of a posaconazole biotin conjugate is presented alongside efforts 
to incorporate a disulfide linker. Biophysical analysis of the interaction between 
posaconazole and Adhirons identified in a screening process
viii
 is presented. This involved 
creating further conjugates of posaconazole with both a PEG tail in attempts to increase 
solubility and then fluorescein to enable a fluorescence anisotropy assay to accurately 
characterise the interaction. 
  
                                                     
viii
 Screening carried out by Anna Tang and Darren Tomlinson, BSTG (FBS, University of Leeds) 
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5.1 Introduction to Adhiron diagnostics for small molecule detection 
Antibodies most commonly bind to protein or peptide surfaces and can be tailored to have 
extremely high selectivity for small differences in molecular structure such as 
phosphorylation of individual amino acids.
133, 134
 Binding of antibodies to small molecules is 
also feasible and can be used in diagnostics and perhaps even in therapeutic roles binding to 
signalling molecules or cofactors for example. Antibody screening is not without practical 
and ethical hurdles – often either requiring animal hosts to challenge with an antigen or in 
vitro display of antibody fragments via phage or yeast display.
133
 In addition the detection of 
small molecules using an animal challenge requires the use of haptens – conjugates between 
the molecule and an inert protein such as albumin. Non-antibody binding proteins which are 
cheaper and more reliable to produce could potentially replace antibodies in many roles. 
Adhirons (Section 1.1) - a non-antibody protein binder family which contain two variable 
nine-residue loops - could be used in exactly the same manner and may be more suited to 
incorporation into diagnostics due to their increased stability.  
It was aimed to screen the Adhiron library for binders to the small molecule antifungal drug 
posaconazole 130 (Figure 64). Posaconazole is variably absorbed by patients depending on 
many factors including diet, dosage routine and gut pH.
135
  It is therefore an important 
diagnostics target, especially in the accurate and selective measurement of drug levels in 
infants. The viability of therapies has been shown to be reliant on the serum drug levels. 
Current testing regimes involve either microbiological assays or HPLC analysis. However 
the microbiological assays are often unsuitable in examining drugs used in a combination 
therapy – as is often the case for antifungal therapies. HPLC analysis requires specialised 
equipment and knowledge – leading to wait times for results if the equipment is available at 
all. A biosensor device which is specific for posaconazole would allow bedside monitoring 
specific for posaconazole, overcoming these associated problems. It was therefore aimed to 
screen the Adhiron library for binders to the small molecule antifungal drug posaconazole 
130 (Figure 64). Posaconazole contains a secondary alcohol at one end of the molecule 
which was also a convenient synthetic handle for modification. 
 
 
Figure 64: Posaconazole, the antifungal drug used as a target for Adhiron binders in this work 
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5.2 Synthesis of a posaconazole-biotin conjugate 
To fix the target to the plate surface in an in vitro screening process biotinylation is often the 
method of choice. In order to screen for Adhiron binders to posaconazole it was necessary to 
create a posaconazole-biotin conjugate – due to the lack of amine or thiol groups in 129 
common biotinylation reagents were not appropriate. These reagents are designed for protein 
biotinylation via NHS ester reaction with lysine residues or maleimide conjugation to thiols. 
A desirable feature of the linker between posaconazole and biotin would be a cleavable 
moiety such as a disulfide. This would allow elution of bound phage from the screening 
platform via disulfide reduction. Direct labelling of a small molecule with biotin may leave 
the molecule too close to the surface of the plate for the protein of the phage display library 
to bind efficiently. An extra linker is incorporated between the biotin and the small molecule 
to prevent this. It was also of interest to incorporate a linker containing a disulfide bond as 
this aids with the elution of the phage from the plate using a reducing agent such as DTT. 
It was therefore aimed to synthesise the biotin linker 131 (Figure 65), containing a disulfide 
bond for cleavage and an acid functionality to react with the hydroxyl of posaconazole. The 
commercially-available linker 132 was purchased as a contingency. This can still be used in 
phage display screening assays using either pH change elution or a competition elution 
method rather than a disulfide reduction. 
 
Figure 65: The two biotin linkers discussed in this section. Linker 45 is a novel target which would 
allow cleavage from a streptavidin plate using DTT. Linker 46 is commercially available but is reliant 
upon competition elution in the screening process. 
The synthesis of 131 is shown in Figure 66. The first amide coupling had literature 
precedent but was found to be low yielding.
136
 A switch to DMF as a solvent rather than the 
reported methanol/acetonitrile mixture improved the isolated yields, and heating the reaction 
increased this further, far beyond that achieved following the method reported in the 
literature. After Boc group deprotection using TFA, a second amide coupling was attempted. 
This appeared to give a small level of product by LCMS which also appeared to run on a tlc 
plate. However upon attempting to purify by silica column chromatography the product 
could not be isolated. When the column was washed with methanol/CH2Cl2/acetic acid 
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(10:88:2) 3,3′-dithiodipropionic acid was eluted. This suggests that the biotin conjugate is 
sticking to the column and the use of acetic acid initiated disulfide exchange but the biotin 
remained on the column.  Since the previously synthesised Boc-protected biotin derivative 
135 had been successfully purified by silica column chromatography it was suspected that 
the incorporation of the thiopropionic acid 137 was responsible for the retention on the 
column. Due to this it was anticipated that the biotinylated drugs with this linker may also be 
irreversibly retained on silica.  Therefore focus switched to the simpler, commercially 
available biotin derivative 132. 
 
Figure 66: The attempted synthesis of biotin linker 138. An amide coupling between biotin 133 and 
Boc protected ethylenediamine 134 yielded 135 which was then deprotected to yield 136. However 
attempts to purify 138 failed and led to disulfide exchange regenerating 3,3’-dithiodipropionic acid 
137. 
Posaconazole was extracted from the pharmaceutical Noxafil oral suspension, with all other 
suspension components remaining in the aqueous phase. 130 was successfully coupled to the 
biotin linker 132 using EDC-activated ester formation (Figure 67). The conjugate 139 was 
obtained in 18% yield (limiting reagent being the biotin derivative). This biotinylated 
molecule was purified by silica column chromatography unlike the previously discussed 
biotin linker 138. 
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Figure 67: The biotinylation of posaconazole. EDC ester coupling was used to generate drug-biotin 
conjugate 139 in 18% yield. 
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5.3 Screening results from the Adhiron screen against posaconazole 
 
The biotinylated posaconazole 139 was used in a phage display screen in the BioScreening 
Technology Group (BSTG) at the University of Leeds.
ix
 Binders to biotinylated 
posaconazole 139 were selected from a phage-displayed library, using three iterative 
selection rounds to enrich the best binders. This process identified several binders from the 
Adhiron library of non-antibody binding proteins.  
48 colonies expressing individual phage conjugates were cultured and phage isolated from 
the media. A binding ELISA of this phage expressing the Adhiron-g3p conjugates bound to 
biotinylated posaconazole is shown in Figure 68 which demonstrated that the binders were 
binding to the posaconazole rather than the plate background.  Phage were incubated with 
the target before washing off unbound phage and treatment with an anti-phage antibody 
conjugated to horseradish peroxidase. HRP oxidation of 3,3′,5,5′-tetramethylbenzidine is 
then quantified to estimate the levels of bound phage. 16 of the hits were sent for 
sequencing. 
  
                                                     
ix
 Screening carried out by Darren Tomlinson and Anna Tang 
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Figure 68: The results of a phage ELISA binding test against biotinylated posaconazole. Wells on the 
left half have been precoated with biotinylated posaconazole, the right half are blank negative 
controls. Phage displaying the same protein sequence are added to the same relative well in left and 
right halves. An anti-phage antibody and secondary antibody conjugated with horseradish peroxidase 
gives readout of the binding affinity of the phage-displayed protein. The more intense the blue colour, 
the stronger the binding event between protein and posaconazole is. Several different strength binders 
have been identified which were to be further investigated for binding affinity quantification and 
physical properties. Quantification of the ELISA signal is shown in the bar chart (blue bars represent 
hits which were sent for sequencing) 
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The sequencing results are shown in Table 8.  A4 was the predominant hit – the same 
sequence was returned from 8 other clones out of the 16 tested. F5 also shares a large 
sequence similarity with A4 in both loops – suggesting they would bind in very similar 
orientations. Outside of these two sequences, no further consensus sequence can be seen but 
it is evident that both loops contain a high proportion of aromatic and hydrophobic residues. 
This is not surprising as the posaconazole has several aromatic rings and very few groups 
capable of hydrogen bonding. It was interesting that two of the hits have truncated second 
loops – this is not uncommon in Adhiron screens and is an artefact of library production. It 
does suggest that in some cases the Adhiron may rely on only one loop to bind the 
posaconazole. Loop two in particular is very proline rich – perhaps these influence the loop 
structure in an important manner. 
Table 8: The variable loop sequences of the three possible posaconazole binders identified from a 
phage-displayed Adhiron library. 
Well N Loop 1  Loop 2 
A4 9 Y W V V Q W G M D  W A R E W P S F H 
B1 1 M A Q W M Q Y Y S  Truncated (TNRG ΔKE) 
E1 1 H R W D P Y N W W  Y E W L G G P I M 
F1 1 H T L V L E D R W  W P P F S F G Y L 
F5 1 V R V V Q W T M D  S W R E W P S F M 
G1 1 Q M Q Y Q S Y L S  Truncated (QHQT ΔKE) 
H4 2 W Q Q H N F F I Y  W Y Q V T P P Y W 
N = Occurrences in sequencing results (Total N=16) 
 
In most screening procedures successful binders typically have their interactions 
characterised biophysically by techniques including ITC, SPR and bio-layer interferometry. 
Therefore it was aimed to characterise the posaconazole binders’ interactions. Three of the 
Adhiron sequences were subcloned (A4/E1/H4) and expressed by the BSTG. Initial 
characterisation of the Adhirons’ interactions with posaconazole was not possible due to the 
drug’s poor solubility. While use of DMSO increases posaconazole solubility, the Adhirons 
do not tolerate large percentages of DMSO – typically 5 to 10% maximum. In addition the 
small size of posaconazole precludes its use in SPR or biolayer inferometry without further 
derivatisation to facilitate adhesion to the chip surface. Therefore it was decided to 
investigate the synthesis of further posaconazole conjugates which would enable biophysical 
characterisation via either improvement in solubility or production of a fluorescent reporter 
molecule.  
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5.4 Synthesis of further posaconazole conjugates for biophysical 
characterisation of the interaction between Adhiron hits and 
posaconazole 
5.4.1 Synthesis of a posaconazole-PEG conjugate for ITC studies 
Given that it was likely the Adhirons were binding at the opposite end of the posaconazole 
from the site of biotinylation, it was decided to use the same point for further derivatisation.  
It was first aimed to create a conjugate with the addition of a PEG chain to increase aqueous 
solubility and facilitate ITC characterisation of the interaction with the Adhiron. The PEG 
acid 140 was used as the azide functionality would serve as a convenient handle for any 
further modification. This subunit was attached to posaconazole via the same EDC ester 
formation as in synthesis of 139 above. 
 
Figure 69: The synthesis of PEGylated posaconazole 141 via EDC ester formation between 
posaconazole 130 and the azido-PEG derivative 140. 
The posaconazole-PEG conjugate 141 was still not entirely soluble at high µM concentration 
in 5% DMSO. This prevented ITC analysis due to domination of the signal in the instrument 
by the solvation energy upon dilution, although as will become apparent in section 5.4.2 it is 
also possible that the ITC was carried out at concentrations too low to detect the interaction. 
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5.4.2 Synthesis of a posaconazole-fluorescein conjugate for fluorescence anisotropy 
studies 
Due to the failure of ITC experiments it was decided to use fluorescence anisotropy (FA) as 
an alternative assay. It was aimed to synthesise a conjugate of posaconazole attached to a 
fluorophore to allow analysis of the binding via FA. FA was deemed an appropriate reporter 
for this interaction as the fluorescently labelled posaconazole probe could be used at low 
concentration (100 nM), thus avoiding the solubility problems. The difference in size 
between drug and Adhiron should facilitate an observable change in the anisotropy upon 
binding. 
The inclusion of the azide moiety on the PEG chain proved advantageous as it allowed 
further derivatisation. In order to attach fluorescein to the posaconazole it was aimed to use a 
copper catalysed azide-alkyne cyclisation. This necessitated the synthesis of 143 via reaction 
of fluorescein isothiocyanate (FITC) 142 with propargyl amine. Initially this was attempted 
in the presence of triethylamine and although some product was formed it appeared that the 
thiourea may be cleaving to release fluorescein. Repeating the reaction in DMSO and 
without any additional base, the reaction proceeded in just 5 minutes. Purification by HPLC 
gave 143 in a 30% yield giving enough material to perform the cycloaddition reaction. 
The copper-catalysed reaction between 143 and 141 formed a triazole as expected, 
presumably in the 1,4-substitution common to the Cu(I) catalysed Huisgen cycloaddition. In 
an unexpected development the thiourea was also converted to a urea, presumably due to the 
presence of ascorbic acid – this conversion is well precedented in acidic conditions,137 
although not with ascorbic acid. 
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Figure 70: The synthesis of a posaconazole-fluorescein conjugate 144 via a copper-catalysed 
cycloaddition reaction between 141 and the fluorescein-derived alkyne 143. 
144 was used in a fluorescence anisotropy assay with the three subcloned Adhiron binders. 
Binder A4C gave the highest quality data (Figure 71), and binds to 144 with a Kd of 
158 ± 44 µM. Binders E1C and H4C proved weaker binders and were not observed to bind 
within the concentration range tested. Binder E1C appeared to precipitate under 
concentration in a centrifugal spin concentrator – the addition of BME to the buffer did not 
seem to alleviate this. Although the concentration of the soluble fraction was measured and 
used in the assay it is likely this was not a homogenous protein sample. The binding of A4C 
was weaker than the typical affinities of Adhiron binders for protein targets which have been 
measured as low nanomolar affinity. 
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Figure 71: Binding of Adhiron A4C to posaconazole derivative 144 – as observed by fluorescence 
anisotropy measurements. 
5.5 Discussion 
The direct labelling of posaconazole via ester formation enabled screening to identify a 
binder from a non-antibody binding library of Adhirons. This direct labelling avoided the 
need to display the molecule on the surface of a protein, as is often required for antibody 
screening.  The use of 132 should be transferable to the labelling of other small molecules 
bearing either amine or hydroxyl functionality. 
Further synthetic derivitisation of posaconazole 130 then allowed characterisation of the 
binding between posaconazole and the Adhiron binder A4C. The labelling with a 
fluorophore and subsequent use of fluorescence anisotropy avoided allowed confirmation 
that the Adhiron was binding posaconazole regardless of which linker was attached to the 
alcohol. It is possible that the biotinylated posaconazole 139 could have enabled this 
characterisation via SPR – the addition of 139 to a streptavidin-coated surface would then 
allow observation of the binding of the adhiron to the chip. The observed anisotropy was 
relatively small ranging from 0.05 to 0.08 compared to the maximum obtainable with bound 
fluorescein (0.37).
138
 The small change in anisotropy observed is probably due to the 
flexibility of the PEG linker and the large distance between where the Adhiron is assumed to 
bind and where the fluorescein is attached. 
It was encouraging that A4C was the hit most-enriched in the phage library and also the best 
binder of those tested – in both the phage ELISA and the FA assay. The binding affinity was 
disappointingly low – Adhirons have previously been found to bind to protein targets with 
nanomolar affinity.
8
 Closer examination of the posaconazole structure shows it has no 
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hydrogen bond donors and only a few acceptors. The majority of interactions will be 
hydrophobic, including interactions with the many aromatic rings. It is therefore no surprise 
that Adhiron A4C has hydrophobic loops. The hydropathicity of the loop regions as 
determined using protparam are shown in Table 9. Loop 1 of Adhiron A4C is particularly 
hydrophobic which may explain the better binding affinity to posaconazole. 
Table 9: Hydropathicity scores as calculated using ProtParam.
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Adhiron Loop 1  Score Loop 2  Score 
A4C YWVVQWGMD -0.022 WAREWPSFH -1.2 
E1C HRWDPYNWW -2.25 YEWLGGPIM 0.23 
H4C WQQHNFFIY -0.64 WYQVTPPYW -0.844 
 
Whether this binding affinity is sufficient for biosensor use would require further 
investigation. An Adhiron which binds to an anti-myc antibody with nanomolar affinity 
(Kd = 360 ± 10 nM) was incorporated into an electrochemical biosensor and measured levels 
of target in the pM range, saturating above 330 pM.
140
 The recommended treatment levels of 
posaconazole in adults is 1 µM serum concentration. Therefore for a similar set-up to the 
proof-of-principle electrochemical biosensor above, the weaker binding of A4C may be 
advantageous, although the proof-of-principle device did not measure serum samples. If a 
higher affinity Adhiron is required a focussed library could be produced based on the loop 
regions in A4C. Due to the low affinity of hits, it is probable that a focussed approach may 
yield better results than repeating the phage display process from the completely randomised 
library. 
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Chapter 6: Conclusions and Future Work 
 
6.1 Conclusions 
The synthetic methods developed in this body of work broaden the diversity of accessible 
bicyclic peptide structures. Starting from one linear amino acid sequence, two chemical 
methodologies were developed which lead to bicyclic peptides with significantly different 
structures.  
It was first demonstrated that methyl 2,5-dibromovalerate 63 can cleanly convert multiple 
cysteine residues to dehydroalanine (Chapter 2). This avoids the formation of cyclic 
by products present when other double-alkylation elimination reagents are used and also 
requires only native amino acids and mild reaction conditions to perform the transformation. 
The dehydroalanine-forming step was incorporated into a two-step strategy to access a 
diverse subset of bicyclic peptide structures, exemplified via the one-pot synthesis of a 
library of stereoisomers 40 of kallikrein inhibitor PK15. Although none of the individual 
stereoisomers were more potent than the LLL-PK15 37, the spread of IC50 values over at least 
four orders of magnitude was validation that altering the stereochemistry of these peptides 
had a significant effect on their structure. 
The development of a new core based on Barbas reagent (Chapter 3) should give access to 
bicyclic peptides which are distinct in structure when compared to the same sequence 
cyclised with established cores. It was aimed to widen the range of bicyclic peptide scaffolds 
which can be accessed by dehydroalanine cyclisation with a polythiol. The synthesis of 
polythiols proved problematic but the intermediates 102, 107 and 112 produced require only 
deprotection. Further work into the development of these deprotection steps and preventing 
polymerisation of cores could provide alkyl polythiols which cyclise the 
dehydroalanine-containing peptides. 
The power of phage display libraries was demonstrated via the Adhiron screening for 
binders to posaconazole (Chapter 5). Synthetic modification of posaconazole enabled both 
its use in in vitro screening and the biophysical characterisation of the interaction between 
posaconazole and the best binder Adhiron A4C. Attempts to set up a phage display platform 
for library display were ultimately unsuccessful (Chapter 4) however if these library display 
problems can be overcome then bicyclic peptides could be used in a variety of potential 
applications. The following sections present suggested future directions for both the 
chemical methods developed and the use of bicyclic peptides in general. 
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6.2 Expanding the scope of dehydroalanine formation with methyl 
2,5-dibromovalerate 
6.2.1 Modifying expressed peptides and proteins 
In Chapter 2 an example use of peptides containing multiple dehydroalanines was presented 
in which a trithiol core cyclised the three dehydroalanine positions, scrambling the 
stereochemistry at each alpha carbon and creating a diverse library of peptide structures. The 
same cyclisation chemistry could be used on a library scale, with hits from a screening 
procedure being deconvoluted by individual synthesis of peptides containing D- or L- 
cysteine and cyclisation with TBMB as was carried out in Section 2.4.1. It has been 
demonstrated that combining a binding loop with a poly-arginine loop can improve cell 
penetration.
141
 It is possible that combining a known binding epitope with a polyarginine 
loop could create potent and cell penetrant compounds. However since the introduction of 
the polyarginine loop may lead to altered structure in the epitope and lower affinity it might 
be of use to generate the D- and L- stereosiomers of the peptide structure to identify an 
improved inhibitor. The dehydroalanine chemistry could be used on a small focussed library 
using the epitope as a starting point. Hits can then be deconvoluted by individual SPPS and 
retesting. 
One area where the use of methyl 2,5-dibromovalerate 63 can be applied is in the chemical 
modification of proteins. Dibromoadipamide 27 has become the standard for dehydroalanine 
conversion from cysteine but 63 is perhaps more suitable to this transformation due to its 
increased solubility. Preliminary work into using 63 to perform this transformation is taking 
place in the Berry research group at Leeds with positive results so far. The valerate 
compound produces a cleaner reaction profile than the adipamide compound, is more soluble 
and requires fewer equivalents of reagent to perform the transformation.
x
 
6.2.2 Using methyl 2,5-dibromovalerate to create Dha and Dbu in lanthipeptides 
However perhaps the most interesting and useful area where 63 could be applied to insert 
multiple dehydroalanine residues is in lanthipeptide research (Section 1.2.3). The solid-
phase synthesis of entire peptides or distinct rings of the lanthipeptides allows understanding 
of their properties and investigation of their structure and binding to targets. The substrates 
of known cyclases could be synthesised and then cyclised in vitro, this would be particularly 
useful for the study of such cyclases when the dehydratase is unknown or not available for in 
vitro studies. For example a photocaged cysteine could be combined with the free cysteine 
                                                     
x
 Robert Smith, personal communication 
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which is converted to Dha. Uncaging would then allow temporal control of the lanthionine 
formation. 
Preliminary attempts to synthesise Dha on resin via the double alkylation-elimination of 
cysteine are described below. In addition it would be of interest to synthesise the thiol amino 
acid 149 – a threonine analogue. This should in theory undergo the same double-alkylation 
elimination upon reaction with 63 to give access to dehydrobutyrine. This can then be 
crosslinked with cysteine to form methyllanthionine.
121
 The amino acid 149 was synthesised 
by Gellman and co-workers
142
 via the aziridine 148 which had been synthesised previously 
by Vederas and co-workers.
143
 Allyl deprotection of 149 to form 150 would access a subunit 
which could be directly used in an Fmoc synthesis strategy, alternatively experiments on the 
amino acid conversion could first be facilitated by deprotection of the trityl protecting group 
of 149. 
 
Figure 72: The synthesis of protected thiol amino acid 150 could be achieved via allyl deprotection of 
149 which has previously been synthesised via ring opening of the aziridine 148.
142, 143
 
6.2.3 Preliminary attempts to synthesise Dha on resin 
With a new reagent for dehydroalanine in hand it was decided to test the scope of the reagent 
through the conversion of a cysteine in a peptide attached to solid phase resin. A preliminary 
investigation was undertaken with the solid phase synthesis of the peptide 151 on 
chlorotrityl resin. The use of differential protecting groups was designed to allow selective 
deprotection of the tBS protecting group from one cysteine while leaving the other protected 
to give 152. Samples of the resin were isolated and cleaved with either TFA or 
hexafluoroisopropanol to monitor the progress of reactions by LCMS. 
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Figure 73: The attempted synthesis of cyclic peptide 155 via lanthionine formation on-resin. Attempts 
were hindered by inefficient deprotection of the tBS protecting group. 
Synthesis of the peptide 151 proceeded successfully, although the coupling of the Cys(tBuS) 
amino acid proved less efficient than the other Fmoc amino acids as the peptide 
Ac-AGAWAGASG-OH was observed as a major by-product. Deprotection of the tBS 
protecting group was attempted with a variety of reagents with limited success (Table 10) 
and full deprotection to yield 152 could not be achieved. As a proof of principle 63 was 
applied to the resin and conversion to dehydroalanine in 153 was observed by MS. It was 
difficult to estimate the success of conversion due to both the presence of the truncated 
peptide impurity and the extensive attempts at deprotection leading to several by-products 
and traces of reagents being present. 
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Table 10: Conditions which were used in the attempted deprotection of the tBS group on peptide 151. 
Reagents Conditions Observations 
βME (100 eq), DMF rt, 18 h  Low levels of deprotection 
PBu3 (1.1 eq), DMF:H2O 99:1 rt, 1 h No further deprotection 
PBu3 (10 eq), DMF:H2O:DCM 2:1:2 rt, 18 h No further deprotection 
DTT (10 eq), NEt3, DMF:H2O 3:1 rt, 16 h Low levels of deprotection 
DTT, K2CO3, DMF:H2O 1:1 37 °C, 2 h Overswollen resin/insoluble K2CO3 
 
Due to time constraints this work was not repeated. In a future iteration it would be 
interesting to replace the tBS protecting group with a methoxytrityl group which should 
selectively deprotect using hexafluoroisopropanol. Resynthesis of the peptide on a non-trityl 
resin such as Rink amide would then allow reaction monitoring with TFA cleavage. 
 
 
  
104 
 
6.3 Further research with the core molecules 
6.3.1 Utilising the Barbas-type cores 
The trifunctional core 110 based on Barbas reagent has been demonstrated to cyclise a 
cysteine-containing peptide efficiently. This core could be applied directly to the phage 
display approach developed by Heinis and co-workers and would produce peptides of 
different backbone structure to those currently accessible. The problems with oxidation of 
this core may actually prove useful – it may be possible that a peptide wherein cysteines are 
attached to the 1,3,4-oxadiazole could be treated with oxidant, oxidising cysteines and 
eliminating them to form the oxadiazolone and free sulfinic acids. The core could also be 
used as a peptide stapling reagent – the third 2-mesyl-1,3,4-oxadiazole can be used as a 
functional handle for dyes or conjugation to other molecules. 
6.3.2 Alternative thiol-based cores 
There are other cores which could potentially be synthesised which could cyclise the 
dehydroalanine-containing peptides appropriately. For example although the aim of the 
tetrahedral cores was to attach a cargo, cores such as 156 and 157 might also be of interest. 
Recently the groups of Derda and Heinis independently developed light-responsive peptide 
ligands wherein an azobenzene derivative was used to cyclise a peptide.
80, 81
 This allowed 
photoswitching to moderate the binding of the peptide. Similar cores could be created with 
more than two attachment points such as 158. 
 
Figure 74: Potential cores based on TMMB which might expand the applications of constrained 
peptides. 
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6.4 Expanding the roles of bicyclic peptides 
Bicyclic peptides have currently been used individually for therapeutics – they are in theory 
easily adaptable to uses in diagnostics or as molecular tools such as imaging reagents due to 
their specificity of binding. However there are many possible applications outside of these 
uses. The use of chemical cyclisation allows an on-switch event for binding. For example 
the expression of a bicyclic peptide sequence on the terminus of its own binding partner may 
then allow controllable protein polymerisation via addition of the cyclisation reagent. An 
interesting avenue may be the use of bicylic peptides to form interfaces in heterogenous 
supramolecular protein structures for example in artificial capsids or nanotubes. This would 
allow tunable structure formation and avoid the need for complex interface engineering. It 
may also be interesting to create conjugates of different bicyclic peptides linked by a flexible 
linker - a double bicyclic peptide could be used as a polymerisation reagent acting as the 
glue between two protein interfaces.  
 
Figure 75: Potential supramolecular structures which could use bicyclic peptides as a controllable 
on-switch. A. Expression of the peptide sequence as a terminal extension would then allow the 
cyclisation reaction to control the polymerisation event. B. The combination of multiple binding sites 
with specific bicyclic peptides acting as interface junctions could template supramolecular structures. 
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6.5 Effective display of peptide libraries for chemical modification 
The key step which was unsuccessful in this work was the creation of a library display 
platform. Successful expression of the g3p-peptide conjugate may deliver an effective 
display platform such as that used by Heinis and co-workers. It is optimistic to assume that 
the chemical modification to form dehydroalanine and cyclise with 
tris(mercaptomethyl)benzene would not alter the phage viability but this cannot be ruled out 
and merits further investigation. Likewise the use of a g8p fusion does not guarantee that 
chemical modification does not affect the WT g3p protein. 
It is plausible that this two-step chemical modification strategy is more suited to a less 
complex display platform. Phage contain many substituent parts and the display process 
relies on successful reinfection of E. coli. If it can be demonstrated that the chemical 
modification does not modify nucleic acid bases it is likely that a shift to mRNA display 
would be advantageous. mRNA display allows purification of expressed components and 
their RNA partners and post-screening only an in vitro amplification is required to generate 
the new library. In addition the translation machinery is tunable to incorporate artificial 
amino acids more easily than when phage is used. 
Alternatively a solid-phase synthesis based approach could be used to create a synthetic 
library in the same manner as Pei and co-workers used to identify 14.
62
 Although in theory 
diversity is limited by the synthetic resources – specifically the handling of the resin (Pei and 
co-workers estimated of a theoretical library of 10
13
 they synthesised around 10
7
 sequences). 
With advances in synthetic technologies, microscale synthesis and screening methods the 
library size may be increased. In addition second and third iteration libraries can be built 
which improve upon initial hits in a focussed screening approach. 
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Chapter 7: Experimental Details 
 
7.1 Reagents and Equipment 
Unless otherwise stated, all reagents were purchased from Sigma Aldrich, Alfa Aesar, or 
Fisher Scientific and were used without further purification.  Human plasma kallikrein was 
purchased from Molecular Innovations (HPKA-MIN), Z-Phe-Arg-AMC was purchased from 
Cambridge Bioscience.  
NMR data were collected using a Bruker Avance 500, Bruker DRX500, or Bruker DPX300 
and analysed using MestReNova software. IR spectra were recorded using a Bruker 
Platinum-ATR. High resolution mass spectrometry was carried out on a Bruker maXis 
Impact or on a Bruker Daltonics micrOTOF using electrospray ionisation. Isotopic 
distributions in routine mass spectra were as expected.  Liquid Chromatography Mass 
Spectrometry (LCMS) was performed on an Agilent 1200 series LC system comprising a 
Bruker HCT Ultra ion trap mass spectrometer and a Phenomenex Luna C18 50 × 2 mm 
column (5 µm particle size) using a gradient of 5–90% MeCN over 1.8 min. ES-MS data 
were obtained using a Bruker MaXis Impact Mass Spectrometer. HPLC analysis was 
performed on an Agilent 1290 infinity LC using an Ascentis® Express Peptide ES-C18 
column (10 cm × 2. 1 mm, 2.7 µM particle size).  Mixtures of solvents, such as those used in 
column chromatography, are v/v and all column chromatography was carried out using 
Geduran Si 60 silica gel. Unless otherwise stated all non-aqueous reactions were performed 
under an atmosphere of nitrogen. 
 
7.2 Chemical synthesis 
 
2,5-dibromoadipamide (27) 
103
 
 
2,5-dibromoadipamide was synthesised following a literature procedure.
103
 Adipic acid 
(12.5 g, 85.6 mmol) was dissolved in SOCl2 (37.5 mL), heated to 80 °C under reflux open to 
the air for 90 min then cooled to rt. Carbon tetrachloride (50 mL) was added followed by 
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NBS (34 g, 191 mmol) (NBS freshly recrystallized from H2O and dried). With vigorous 
stirring HBr (aq) (48 %, 5 drops) were added and the reaction heated to 80 °C. The reaction 
turned from red to black over the course of 2.5 h at which point it was cooled to rt and then 
to 0 °C. The precipitated solid was removed by filtration and the flask washed with ether 
(50 mL). The filtrate was concentrated in vacuo to give the crude acid chloride as a dark red 
viscous liquid. Ammonium hydroxide solution (25%, 140 mL) was cooled to 0 °C and the 
crude acid chloride was added dropwise, turning the solution blue. The reaction was stirred 
for 1 h at 0 °C before the blue solid was isolated by filtration. The solid was suspended in 
MeOH–H2O (1:1, 100 mL) and heated to 60 °C for 30 min. Filtration and washing with 
methanol (100 mL) gave the product 27 (11.36 g, 44%), a mixture of diastereomers, as a 
grey solid. Characterisation was in line with the literature.
103
 H (500 MHz, DMSO-d6): 7.70 
(2H, s, NH2), 7.32 (2H, s, NH2), 4.37-4.32 (2H, m, BrCH), 2.10-1.79 (4H, m, CH2-CH2); m/z 
(ES): Found M+Na
+
 322.900256, expected for [C6H10O2N2
79
Br2
+
 Na] 322.900122. 
 
1,3,5-tris(mercaptomethyl)benzene (39) 
 
1,3,5-tris(bromomethyl)benzene (205 mg, 0.575 mmol) and thiourea (230 mg, 3 mmol) were 
combined and THF (5 mL) added before stirring at 75 °C for 4 h. After cooling to rt, 
potassium hydroxide solution (0.68 M, 5 mL) was added and the reaction stirred at 105 °C 
for 17 h. After cooling to rt the reaction mixture was concentrated under reduced pressure 
before addition of ethyl acetate (20 mL). The mixture was extracted with sodium hydroxide 
solution (0.1 M, 2 × 20 mL), aqueous layers were combined and acidified (pH 1) with 
hydrochloric acid (1M) before extraction with ethyl acetate (2 × 30 mL). Organic fractions 
were combined, dried (MgSO4), filtered and concentrated under reduced pressure. The 
product was further purified by column chromatography (1:1 ethyl acetate:hexane) to yield 
39 (72 mg, 0.33 mmol, 58%) as a colourless oil. H (300 MHz, DMSO-d6): 7.18 (3H, s, 
benzene CH), 3.70 (6H, d, J 7.0, benzyl CH2), 2.84 (3H, t, J 7.0, SH); C (75 MHz, 
d6-DMSO): 142.2 (benzene Cq), 126.8 (benzene CH), 28.0 (benzyl CH2); νmax/cm
-1
 (film) 
2549 (SH); m/z (ES negative): Found [M−H] 215.002092, expected for [C9H11S3] 
215.002837. 
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1,1'-[1,2-phenylenebis(2-bromo-1-oxo-2,1-ethanediyl)]bispiperidine (52) 
 
A solution of the acid chloride intermediate 56 (approx. 5.15 mmol) in CH2Cl2 (20 mL) and 
CCl4 (3 mL) was cooled to 0 °C before the dropwise addition of piperidine (3.2 mL, 31.4 
mmol) over 15 min. After stirring for 45 min total the reaction was concentrated under 
reduced pressure, dry-loaded using Celite and purified by silica column chromatography 
(ethyl acetate:hexane gradient, 1:4 to 1:1) to yield 52. Upon drying under vacuum the 
product degraded. 
Dimethyl α1,α2-dibromo-1,2-phenylenediacetate (53) 
 
A solution of the acid chloride intermediate 56 (approx. 5.15 mmol) in CH2Cl2 (15 mL) and 
CCl4 (3 mL) was cooled to 0 °C before the dropwise addition of methanol (5 mL) in CH2Cl2 
(20 mL) over 15 min. After stirring for 30 min total the reaction was concentrated under 
reduced pressure, dry-loaded using Celite and purified by silica column chromatography 
(ethyl acetate:hexane gradient, 1:9 to 1:3) to yield 53 (1.858 g, 4.89 mmol, 95% over 3 
steps) as a 1:1 mixture of diastereomers. H (300 MHz, CDCl3): 7.66 (2H, m, C4-H/H'), 7.41 
(1H, d, J 5.8, C3-H'), 7.40 (1H, d, J 5.8 C3-H), 5.80 (2H, s, CHBr), 3.83 (6H, s, methyl); C 
(75 MHz, CDCl3): 168.2 (2 × CO), 134.2 (C1/2), 130.7 (C4/5), 129.9 (C3/6), 53.8 (Me), 
53.7 (Me), 43.4 (CBr), 43.1 (CBr); 
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α1,α2-dibromo-1,2-phenylenediacetyl chloride (56) 
 
1,2-phenylenediacetic acid (1.00 g, 5.15 mmol) and thionyl chloride (2.30 mL, 31.15 mmol) 
were combined and heated to 80 °C for 1 h. After cooling to rt, carbon tetrachloride (3 mL), 
N-bromosuccinimide (2.8 g, 15.7 mmol, recrystallized from H2O) and HBr (3 drops) were 
added and the reaction heated to 80 °C for 2 hours. After cooling to rt, a further portion of 
N-bromosuccinimide (500 mg, 2.8 mmol) was added and the reaction heated to 80 °C for 30 
min. The reaction mixture was cooled to 0 °C and stirred for 30 min to ensure complete 
precipitation of succinimide by-products. The reaction mixture was filtered and washed with 
CH2Cl2 (15 mL) to yield a solution of the intermediate 56. The reactions were monitored by 
adding samples to methanol and observing the methyl esters by LCMS. 
 
Methyl 2,5-dibromovalerate (63) 
 
δ-Valerolactone (2.59 g, 25.9 mmol), bromine (1.99 mL, 38.9 mmol) and phosphorus 
tribromide (47 µL, 0.5 mmol) were combined and the reaction heated at 110 °C for 2.5 h. 
The reaction was then cooled to 0 °C before the addition of methanol (5.23 mL, 130 mmol) 
and p-toluenesulfonic acid monohydrate (47 mg, 0.25 mmol). The reaction was heated to 
80 °C for 3 h before cooling and removal of excess methanol under reduced pressure. 
CH2Cl2 (50 mL) was added and the lower organic layer obtained, washed sequentially with 
water (10 mL), NaOH (10%, 10 mL), and water (10 mL). Organics were dried (MgSO4) and 
concentrated under reduced pressure. The product was further purified by column 
chromatography (1:4 EtOAc:hexane) to yield 63 (5.457 g, 77%) as a colourless oil. H 
(300 MHz, CDCl3): 4.27 (1H, dd, J 8.0, 6.0, C2-H), 3.80 (3H, s, methyl), 3.43 (2H, t, J 6.3, 
C5-H2), 2.39-1.88 (4H, m, C3-H2, C4-H2); δC (75 MHz, CDCl3): 169.9 (C1), 53.0 (MeO), 
44.5 (C2), 33.3, 32.0 (C5), 30.1; νmax/cm-1 (film) 1736 (C=O);  The product proved difficult 
to obtain M.S. data for – either by accurate mass ESI-MS or the LCMS system.  
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3,6,9,12,15,18-hexaoxahenicosa-20-ynol (92) 
 
Hexaethyleneglycol (25.0 g, 88.5 mmol) was added to anhydrous THF (400 mL) and the 
solution cooled to 0 °C. Sodium hydride (60% in mineral oil, 3.57 g, 89.3 mmol) was added 
in 10 portions over 1 h. Propargyl bromide (80% in toluene, 10.0 mL, 111.7 mmol) was 
added dropwise over 45 min. The reaction was allowed to warm to rt and was stirred for 18 
h. The reaction was quenched with brine (50 mL) and solvent removed in vacuo. The 
reaction mixture was extracted with CH2Cl2 (3 × 100 mL), combined organic fractions were 
washed with brine (50 mL), dried (MgSO4) and concentrated in vacuo to yield a yellow oil. 
The crude product was purified by two-stage column chromatography (1. MeOH–CH2Cl2, 
2:98; 2. MeOH–CH2Cl2, 5:95) to give propargyl-PEG 92 (13.28 g, 47%) as a yellow oil. δH 
(300 MHz, CDCl3): 4.21 (2H, d, J 2.4, C19-H2), 3.58-3.75 (22H, m, C1-C17 H2), 2.70 (1H, 
t, J 6.3, OH), 2.44 (1H, t, J 2.4, C21-H); δC (75 MHz, CDCl3): 79.7 (C20), 74.5 (C21), 72.6 
(PEG CH2), 70.7-70.2 (multiple PEG CH2), 69.1 (PEG CH2), 61.7 (C1), 58.4 (C19); 
νmax/cm
-1
 (film): 3354 (alkyne C-H), 3241 (OH), 2112 (alkyne C≡C), 1087 (C-O); m/z (ES): 
Found M+NH4
+
 338.217975, expected for [C15H28O7 + NH4] 338.217329. 
 
21-bromo-4,7,10,13,16,19-hexaoxahenicosyne (93) 
 
92 (200 mg, 0.53 mmol) was dissolved in CH2Cl2 (2 mL) and cooled to 0 °C. Carbon 
tetrabromide (444 mg, 1.33 mmol) was added followed by a solution of triphenylphosphine 
(348 mg, 1.33 mmol) in CH2Cl2 (2 mL). The reaction was stirred at rt for 18 h. The solution 
was concentrated in vacuo and the residue triturated in ice-cold pentane (2 × 20 mL). The 
soluble fractions were combined, concentrated in vacuo and the crude purified by column 
chromatography (MeOH–CH2Cl2 gradient, 0:1 to 5:95). The bromide 93 was isolated as a 
yellow oil (68% pure w/w, 158 mg, 53% yield). δH (500 MHz, CDCl3): 4.21 (2H, d, J 2.5, 
propargyl-CH2), 3.81 (2H, t, J 6.5, C20-H2), 3.72-3.65 (20H, m, 10 x PEG CH2), 3.48 (2H, t, 
J 6.5, C21-H2); δC (75 MHz, CDCl3): 79.7 (propargyl C), 74.5 (propargyl CH), 71.2 (PEG 
CH2), 70.8-70.5 (PEG CH2), 70.4 (PEG CH2), 69.1 (CH2-OH), 58.4 (propargyl CH2), 30.3 
(C21-Br); νmax/cm
-1
 (CCl4 solution): 3270 (alkyne C-H), 2130 (alkyne C≡C), 1090 (C-O); 
m/z (ES): Found M+NH4
+
 400.133562, expected for [C15H27O6
79
Br + NH4] 400.132926. 
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Attempted alkylation of pentaerythritol with 93 to form 95, forming instead by-
product 4,7,10,13,16,19-hexaoxahenicos-1-en-21-yne 96 
 
Pentaerythritol (28.6 mg, 0.21 mmol) was dissolved in DMF (1 mL) and NaH (10.4 mg, 
0.26 mmol) added and the reaction stirred for 10 minutes. 93 (100 mg, 0.26 mmol) was 
dissolved in DMF (1 mL) and added dropwise. No sign of 95 was observed by LCMS 
however the major peak corresponded to 96 (m/z 302 and 325 – H+ and Na+ adducts 
respectively). Reaction was stirred for 18 h before the addition of water (20 mL). The 
reaction mixture was extracted with CH2Cl2 (2 × 40 mL) and organics combined and 
concentrated under reduced pressure. COSY NMR of the crude extracted material indicated 
the presence of alkene protons supporting formation of 96. 
3,6,9,12,15,18-hexaoxahenicosa-20-ynoic acid (97) 
 
Chromium(VI)oxide (0.625 g, 6.25 mmol) was added to conc. H2SO4 (1.2 mL) in a glass 
vial and the mixture transferred to a flask containing water (4 mL). Reaction was cooled to 
0 °C and a solution of 92 (1.0 g, 3.125 mmol) in acetone (10 mL) was added dropwise. The 
reaction was stirred open to air for 3 h at 0 °C. The reaction mixture was concentrated in 
vacuo and extracted with CH2Cl2 (3 × 100 mL). Organic fractions were combined and 
washed with H2O (30 mL). Organics were concentrated to 100 mL before extraction with 
NaOH (2 × 50 mL). Hydroxide layers were combined and washed with CH2Cl2 (10 mL), 
acidified with HCl (aq) (3M, to pH 1) and extracted with CH2Cl2 (5 × 50 mL). Organic 
fractions were combined, dried (MgSO4) and concentrated under reduced pressure to give 
the acid 97 (373 mg, 36%) as a yellow oil. δH (300 MHz, CDCl3): 4.20 (2H, d, J 2.4, C19-
H2), 4.16 (2H, s, C2-H2), 3.72-3.65 (20H, m, C4-C17 H2), 2.44 (1H, t, J 2.4, C21-H); δC (75 
MHz, CDCl3): 172.3 (C1), 79.6 (C20), 74.6 (C21), 71.1 (PEG CH2), 70.6-70.3 (multiple 
PEG CH2), 69.1 (C2), 69.0 (PEG CH2), 58.3 (C19); νmax/cm
-1
 (film): 3466 (OH), 3247 
(alkyne C-H), 2116 (alkyne C≡C), 1087 (C-O); m/z (ES): Found M+NH4
+
 352.197665, 
expected for [C15H26O8 + NH4] 352.196593.  
 
N-[tris(hydroxymethyl)methyl]-3,6,9,12,15,18-hexaoxahenicosa-20-ynamide (98) 
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97 (200 mg, 0.6 mmol) was added to a flask followed by water (5 mL), Tris base (218 mg, 
1.8 mmol) and EDC.HCl (230 mg, 1.2 mmol). The reaction was stirred open to air for 16 h. 
DMAP (218 mg, 1.8 mmol) was added and the pH adjusted to pH 8 using HCl (aq) (1M). 
Further EDC.HCl (230 mg, 1.2 mmol) was added and the reaction was stirred for 1 h at rt 
followed by heating at 60 °C for 2 h. After cooling, the reaction was extracted with CH2Cl2 
(3 × 50 mL). The aqueous fraction was diluted with sat. NaHCO3 (aq) (30 mL) and  
continuously extracted over 16 h using CH2Cl2 as the organic phase (200 mL). The organic 
phase was concentrated in vacuo and the crude product purified by column chromatography 
(MeOH–CH2Cl2, 1:9). The alcohol 98 (45 mg, 17%) was obtained as a colourless gum. 
δH (500 MHz, CDCl3): 7.65 (1H, bs, NH), 4.54 (2H, t, J 6.3, OH), 4.21 (2H, d, J 2.4, 
C19-H2), 4.02 (2H, s, C2-H2), 3.74-3.63 (26H, m, CH2OH + C4-C17 CH2), 2.47 (1H, t, J 
2.4, C21-H); δC (125 MHz, CDCl3): 171.3 (C1), 79.6 (C20), 74.7, 70.7-70.1, 69.0, 63.1, 
61.7, 58.4; νmax/cm
-1
 (CCl4 solution): 3410 (OH) 1670 (amide C=O), 1550 (N-H bend), 1100 
(C-O); m/z (ES): Found M+H
+
 438.233891, expected for [C19H35O10N + H] 438.233373. 
 
2,2-bis(bromomethyl)-3-bromopropanol (99) 
144
  
 
Pentaerythritol (12.8 g, 94 mmol) was dissolved in acetic acid (10 mL) and HBr (aq) (48%, 
50 mL) added. The reaction was heated to 120 °C for 16 h. After cooling, further HBr (aq) 
(48%, 50 mL) and sulfuric acid (conc., 23 mL) was added and the reaction heated to 120 °C 
for 16 h. The reaction was cooled and extracted with CH2Cl2 (3 × 100 mL). The product was 
isolated by column chromatography (EtOAc:hexane gradient 1:9 to 2:8) as an off-white 
solid (9.35 g, 31%). 2,2-bis(bromomethyl)-3-bromopropanyl acetate impurity (approx. 27%) 
was observed by NMR. Characterisation was in accordance with the literature.
144
 δH (300 
MHz, CDCl3): 3.75 (2H, s, CH2OH), 3.54 (6H, s, CH2Br); δC (75 MHz, CDCl3): 62.3 
(CH2OH), 44.1 (propyl C2), 34.4 (CH2Br). 
 
1-benzoxy-2,2,2-tris(hydroxymethyl)ethane (101) 
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Pentaerythritol (1.0 g, 7.34 mmol) was added to anhydrous DMF (5 mL) and cooled to 0 °C. 
Sodium hydride (60% in mineral oil, 320 mg, 8.0 mmol) was added and the reaction stirred 
for 30 min. Benzyl bromide (960 μL, 8.1 mmol) was added and the reaction was stirred for 4 
h. at rt before being kept at –20 °C overnight. The reaction was quenched with brine (15 mL) 
and extracted with CH2Cl2 (3 × 50 mL). The combined organic fractions were washed with 
brine (20 mL), dried (MgSO4) and concentrated in vacuo. The crude was purified by column 
chromatography (MeOH–CH2Cl2, 1:9) to yield alcohol 101 (291 mg, 18%) as an off-white 
gum. δH (300 MHz, D3COD): 7.37-7.23 (5H, m, phenyl H), 4.52 (2H, s, benzyl CH2), 3.64 
(6H, s, CH2OH), 3.52 (2H, s, ethane C1-H2); δC (75 MHz, D3COD): 140.0 (Ph C1), 129.4 
(Ph), 128.6 (Ph), 128.6 (Ph), 74.6 (Benzyl CH2), 71.1 (ethane C1), 63.4 (hydroxymethyl 
CH2), 46.9 (ethane C2); νmax/cm
-1
 (film): 3260 (OH), 1479 (Ar C=C), 1403 (Ar C=C), 1015 
(C-O); m/z (ES): Found M+Na
+
 249.109717, expected for [C12H18O4 + Na] 249.109730. 
 
2,2,2-tris(acetylsulfanylmethyl)-1-benzoxyethane (102) 
 
Triphenylphosphine (1.04 g, 3.98 mmol) was added to anhydrous THF (10 mL) followed by 
DIAD (805 mg, 3.98 mmol) to give a yellow solution. A solution of 101 (200 mg, 0.88 
mmol) and thioacetic acid (284 μL, 3.98 mmol) in anhydrous THF (10 mL) was added 
dropwise, giving a green solution. The reaction was stirred overnight at rt before quenching 
with brine (30mL) and extracting with CH2Cl2 (2 × 75 mL). Combined organic fractions 
were washed with brine (20 mL), dried (MgSO4) and concentrated in vacuo. The crude 
mixture was purified by column chromatography (EtOAc–hexane gradient, 0:1 to 1:4) to 
give a mixture of triphenylphosphine and 102. Trituration in pentane (2 × 30 mL) yielded 
product 102 (145 mg, 44%) as a yellow oil. δH (300 MHz, CDCl3): 7.39-7.25 (5H, m, phenyl 
H), 4.45 (2H, s, benzyl CH2), 3.29 (2H, s, ethane C1-H2), 3.09 (6H, s, CH2S), 2.33 (9H, s, 
SCH3); δC (75 MHz, CDCl3): 194.9 (acetyl CO), 128.3 (Ph), 127.6 (Ph), 127.6 (Ph), 73.4 
(benzyl CH2), 73.0 (ethane C1), 33.5 (CH2S), 30.5 (acetyl CH3) (quaternary carbons too 
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weak to assign); νmax/cm
-1
 (solid): 1689 (C=O), 1093 (C-O); m/z (ES): Found M+NH4
+
 
418.118998, expected for [C18H24O4S3 + NH4] 418.117498. 
 
Tris(acetylthiomethyl)nitromethane (107) 
 
Tris(hydroxymethyl)nitromethane (500 mg, 3.31 mmol) and triphenylphosphine (3.9 g, 
14.9 mmol) were combined followed by addition of THF (10 mL) and the reaction cooled to 
0 °C. DIAD (3.1 mL, 14.9 mmol) and thioacetic acid (1.06 mL, 14.9 mmol) were added 
upon which point the reaction turned yellow-orange and cloudy. The reaction was allowed to 
warm to rt and stirred for 16 h – the reaction turned orange and clear. Saturated 
NaHCO3 (aq) (20 mL) was added and the reaction mixture extracted with CH2Cl2 
(2 × 50 mL). Organics were combined and washed with saturated NH4Cl (aq) (25 mL), dried 
(MgSO4), filtered and concentrated under reduced pressure. Purification by two stage 
column chromatography (1. EtOAc–hexane gradient 3:17 to 3:10, 2. EtOAc–hexane gradient 
1:19 to 3:17) yielded 107 as a yellow solid (585 mg, 54%) δH (300 MHz, CDCl3): 3.60 (6H, 
s, CH2), 2.36 (9H, s, SAc CH3); δC (75 MHz, CDCl3): 193.0 (CO), 92.6 (NO2C), 33.3 (CH2), 
30.3 (SAc CH3); m/z (ES): Found M+NH4
+
 343.045814, expected for [C10H15NO5S3 + NH4] 
343.045061. 
 
Tris(chloromethyl)amine (109)
125
 
 
Hexamethylene tetramine (2.8 g, 20 mmol) was crushed using a mortar and pestle before 
addition of PCl5 (12.56 g, 60 mmol). A drying tube (CaCl2) was fitted and the reaction 
heated to 100 °C for 3.5 h whereupon the reaction mixure turned to a red/brown liquid. The 
product 109 was crystallised from CH2Cl2 at rt as light brown crystals (1.4 g, 43%) 
Characterisation was in accordance with the literature.
125
 δH (300 MHz, CDCl3): 5.14 (6H, s, 
NCH2Cl); δC (75 MHz, CDCl3): 65.4 (NCH2Cl). 
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1,3,5-tris(5-methylsulfonyl-1,3,4-oxadiazol-2-yl)benzene (110) 
 
120 (100 mg, 0.24 mmol), sodium periodate (459 mg, 2.14 mmol), and ruthenium chloride 
trihydrate (0.6 mg, 2.4 µmol) were combined. Carbon tetrachloride (2 mL), acetonitrile (2 
mL) and water (4 mL) were added and the reaction stirred open to air for 16 h. CH2Cl2 (20 
mL) was added and the precipitate collected by filtration. The reaction mixture had brine (10 
mL) added and further precipitate was collected. The precipitate was washed in acetonitrile 
(3 × 10 mL) and product obtained by removal of acetonitrile under reduced pressure to yield 
110 as a white solid (81 mg, 65%). δH (300 MHz, DMSO-d6): 8.93 (3H, s, benzene CH), 
3.79 (9H, s, SO2CH3); δC (75 MHz, DMSO-d6): 163.9 (oxadiazole C5), 162.7 (oxadiazole 
C2), 129.2 (benzene C2), 125.2 (benzene C1), 43.0 (SO2CH3); νmax/cm
-1
 1341 (S=O), 1151 
(S=O)  m/z (ES): Found [2M+NH4
+
] 1049.998070, expected for [C30H28N13O18S6] 
1049.99940. 
HPLC of 110 
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Tris(tert-butylthiomethyl)amine (112) 
 
109 (150 mg, 0.924 mmol) was dissolved in CH2Cl2 (2 mL) and cooled to 0 ° C before 
addition of tert-butyl thiol (360 µL, 3.22 mmol). The reaction was stirred for one hour 
before addition of H2O (5 mL) and extraction with CH2Cl2 (2 × 10 mL). Organics were 
combined, dried (MgSO4) and filtered before solvent was removed in vacuo to yield 112 
(167 mg, 56%). δH (300 MHz, CDCl3): 4.10 (6H, s, NCH2S), 1.35 (27H, s, tBu CH3); δC (75 
MHz, CDCl3): 52.6 (NCH2S), 42.6 (tBu Cq), 31.5 (tBu CH3); m/z (ES): Found M+Na
+
 
346.167575, expected for [C15H33NS3 + Na] 346.166734. 
 
1,3,5-benzenetricarboxylic acid trihydrazide trihydrate (118)
145
 
 
To a flask containing triethyl 1,3,5-benzenetricarboxylate (22.15 g, 75.3 mmol) was added 
methanol (400 mL) and hydrazine hydrate (64%, 86 mL, 1.13 mol) and the mixture stirred 
for 18 h at rt The precipitate was filtered, washed with methanol (2 x 100 mL) and dried 
under vacuum. The product was ground to a fine powder and further dried under vacuum to 
yield the product 118 as a white solid (20.5 g, 89%) Spectral characterisation was in 
accordance with literature.  δH (300 MHz, DMSO-d6): 9.83 (3H, bs, NH), 8.32 (3H, s, CH), 
4.55 (6H, bs, NH2); δC (75 MHz, DMSO-d6): 164.9 (CO), 133.8, 128.0; νmax/cm
-1
 3281, 
3187, 3053 (NH2 and H2O), 1621 (CO), 1502; m/z (ES): Found [2M+H
+
] 505.200763, 
expected for [C18H25N12O6] 505.201453. 
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1,3,5-tris(5-mercapto-1,3,4-oxadiazol-2-yl)benzene (119) 
 
118 (15.0 g, 49.0 mmol) and potassium hydroxide (15.0 g, 267.9 mmol) were combined and 
ethanol (300 mL) added. Carbon disulphide (16.9 mL, 267.9 mmol) was added in 5 mL 
portions followed by stirring at 110 °C for 64 h. After cooling to rt, the reaction mixture was 
concentrated under reduced pressure. Water (200 mL) was added and the solution filtered to 
remove unreacted starting material (2.6 g, 17%). The filtrate was acidified to pH 3 with HCl 
(aq) (1M) upon which a white slurry formed. The solid was obtained by filtration and dried 
under vacuum to yield 119 as a yellow solid (6.97 g, 38%). An unknown impurity was 
observable by NMR. δH (300 MHz, d6-DMSO): 8.25 (3H, s, benzene CH); δC  (75 MHz, d6-
DMSO): 177.8 (oxadiazole C2), 158.4 (oxadiazole C5), 133.3 (benzene C1), 125.0 (benzene 
C2); νmax/cm
-1
 2737 (SH); m/z (ES negative): Found [M−H] 376.960039, expected for 
[C12H5N6O3S3] 376.959075. 
 
1,3,5-tris(5-methylthio-1,3,4-oxadiazol-2-yl)benzene (120) 
 
119 (470 mg, 1.24 mmol) and DMSO (10 mL) were combined and heated to 50 °C for 20 
min to dissolve 119 before cooling to rt. Triethylamine (605 µL, 4.34 mmol) and methyl 
iodide (255 µL, 4.1 mmol) were added and the reaction stirred for 30 min. The product was 
obtained by precipitation at 0 °C. The solid was obtained by filtration and triturated in 
CH2Cl2, impurities were removed by filtration and the CH2Cl2 removed under reduced 
pressure to yield 120 as a yellow solid (267 mg, 51%). δH (300 MHz, CDCl3): 8.74 (3H, s, 
benzene C2-H), 2.83 (9H, s, SCH3); δC (75 MHz, CDCl3): 166.5 (oxadiazole C2), 163.8 
(oxadiazole C5), 126.6 (benzene C2), 125.9 (benzene C4), 14.7 (SCH3); νmax/cm
-1
 1462, 
1180; m/z (ES): Found [2M+H
+
] 841.033187, expected for [C30H25N12O6S6] 841.033879. 
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Methyl 3,5-bis(hydrazinocarbonyl)benzoate (123) 
 
To trimethyl 1,3,5-benzenetricarboxylate (1.01 g, 4.00 mmol) was added methanol (50 mL) 
and hydrazine hydrate (66%, 2.9 mL, 40 mmol) and the reaction stirred for 16 h. The 
precipitate was collected by filtration, upon which more precipitation from the filtrate 
occurred – this batch was also collected by filtration. Batches were combined and dried to 
give 123 (883 mg, 83%) This material was taken into the next step of the synthesis without 
further purification. δH (300 MHz, d6-DMSO): 10.03 (2H, bs, NH), 8.49 (3H, s, benzene 
C2-H and C4-H), 4.58 (4H, bs, NH2), 3.92 (3H, s, methyl). 
 
Ethyl 3,5-bis(2-mercapto-1,3,4-oxadiazol-5-yl)benzoate (124) 
 
123 (900 mg, 3.6 mmol) and potassium hydroxide (900 mg, 16.1 mmol) were combined and 
EtOH (100 mL) added. Carbon disulfide (966 µL, 16.1 mmol) was added dropwise before 
the mixture was heated to 110 °C for 22 h. The reaction was cooled and solvent removed in 
vacuo before addition of H2O (100 mL) and acidification (pH 1) with HCl (1 M). The white 
precipitate was obtained by filtration, redissolved in ethyl acetate (50 mL), dried (MgSO4), 
filtered and solvent removed in vacuo to yield a mixture of 124 and an unidentified impurity 
(770 mg total). Purification of a 400 mg sample of this mixture by mass-directed HPLC 
yielded 124 (90 mg, 7%). δH (300 MHz, d6-DMSO): 8.47 (2H, d, J 1.5, benzene C2-H), 8.40 
(1H, t, J 1.5, benzene C4-H), 4.43 (2H, q, J 7.1, ethyl CH2), 1.39 (3H, t, J 7.1, ethyl CH3); 
δC (75 MHz, d6-DMSO): 163.7 (COO), 158.7 (oxadiazole C2), 158.7 (oxadiazole C5), 132.1 
(benzene C1), 128.7 (benzene C2), 126.8 (benzene C4), 124.5 (benzene C3), 61.9 (ethyl 
C1), 14.0 (ethyl C2); m/z (ES): Found M+H
+
 351.021929, expected for [C13H10N4O4S2 + H] 
351.021623. 
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Ethyl 3,5-bis(5-methylthio-1,3,4-oxadiazol-2-yl)benzoate (125) 
 
124 (90 mg, 0.26 mmol) was dissolved in THF (1 mL) and methyl iodide (35 µL, 0.57 
mmol) added followed by triethylamine (79 µL, 0.57 mmol). The reaction was stirred for 2 h 
before quenching with H2O (2 mL) and extraction with ethyl acetate (2 × 10 mL). Organics 
were combined, dried (MgSO4), filtered and solvent removed under reduced pressure to give 
product 125 (99 mg, 99%). δH (300 MHz, DMSO-d6): 8.62 (1H, t, J 1.3, benzene CH), 8.58 
(2H, d, J 1.3, benzene CH), 4.44 (2H, q, J 7.1, ethyl CH2), 2.82 (6H, s, methyl CH3), 1.40 
(3H, t, J 7.1, ethyl CH3); δC (75 MHz, DMSO-d6): 14.1 (ethyl CH3), 14.4 (methyl CH3), 61.9 
(ethyl CH2), 125.0 (benzene C3/5), 127.4 (benzene C4), 128.9 (benzene C2/6), 132.2 
(benzene C1), 163.5 (oxadiazole C2), 163.8 (benzoic COO), 165.8 (oxadiazole C5). 
 
Ethyl 3,5-bis(2-mesyl-1,3,4-oxadiazol-5-yl)benzoate (126) 
 
To 125 (56 mg, 0.15 mmol) was added (NH4)6Mo7O24(H2O)4 (198 mg, 0.16 mmol) followed 
by ethanol (10 mL). The reaction was cooled to 0 °C before addition of hydrogen peroxide 
(30%, 245 µL, 2.4 mmol). The reaction was then heated to 60 °C for 90 min. The reaction 
was cooled followed by addition of sodium thiosulfate solution (10%, 10 mL). The mixture 
was extracted with ethyl acetate (2 × 30 mL), organics were combined, dried (MgSO4) and 
solvent removed in vacuo. Purification by mass directed HPLC gave 126 (10 mg, 23%) as a 
white solid. 126 degraded to the related oxadiazol-2-one before full characterisation was 
obtained. δH (300 MHz, DMSO-d6): 8.90 (1H, t, J 1.6, benzene C4), 8.80 (2H, d, J 1.6, 
benzene C2), 4.48 (1H, q, J 7.1, Et CH2), 1.42 (2H, t, J 7.1, Et CH3); m/z (ES): Found 
M+NH4
+
 460.059448, expected for [C15H14N4O8S2 + NH4] 460.059131. 
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Extraction of Noxafil solution yielding posaconazole (130) 
 
Noxafil® suspension (40 mg/mL, 5 mL) was diluted with water (50 mL) and extracted with 
EtOAc (3 × 50 mL). Organics were combined and washed with brine (20 mL) followed by 
sat. NaHCO3 (aq) (30 mL). Solvent was removed under reduced pressure to yield 130 
(130 mg, 65%). 
tert-butyl N-(2-aminoethyl)carbamate (133) 
 
Ethylene diamine (6.0 mL, 90 mmol) was added to a flask containing anhydrous CH2Cl2 (50 
mL). A solution of Boc-anhydride (3.27 g, 15 mmol) in CH2Cl2 (53 mL) was added 
dropwise with vigorous stirring over 3 h. The reaction was stirred for 16 h at rt before 
addition of Na2CO3 (aq) (20%, 40 mL) and extraction with CH2Cl2 (3 × 50 mL). The 
combined organic fractions were dried (MgSO4) and concentrated in vacuo to give product 
133 (1.76 g, 73%) as a white solid. δH (500 MHz, CDCl3): 4.85 (1H, bs, NH), 3.20-3.15 (2H, 
bm, C2-H2), 2.80 (2H, t, J 5.8, C1-H2), 1.45 (9H, s, Boc CH3), 1.22 (2H, bs, NH2); δC (125 
MHz, CDCl3): 156.2 (Boc NC(O)O), 79.1 (Boc OC(Me)3), 43.4 (CH2), 41.9 (CH2), 28.4 
(Boc CH3); νmax/cm
-1
 (solid): 3357 (NH), 1683 (C=O); m/z (ES): Found M+H
+
 161.128271, 
expected for [C7H16N2O2 + H] 161.128454. 
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N-[(2-tert-butoxycarbonylamino)ethyl]-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl]pentanamide (134) 
 
Biotin (2 g, 8.19 mmol), EDC.HCl (1.88 g, 9.82 mmol), 133 (1.31 g, 8.19 mmol), HOBt 
(1.33 g, 9.82 mmol) and DIPEA (3.56 mL, 20.5 mmol) were added to anhydrous DMF (30 
mL). The reaction was heated to 55 °C for 16 h. Brine (30 mL) was added and the reaction 
mixture extracted with CH2Cl2 (3 × 50 mL). The combined organic fractions were dried 
(MgSO4) and concentrated in vacuo. The product was purified by two-stage column 
chromatography (1. MeOH–CH2Cl2, 1:9; 2. MeOH–CH2Cl2, 1:9). Product elution was 
monitored by NMR during the second column procedure. The amide 134 (1.29 g, 41%) was 
isolated as a white solid. δH (300 MHz, D3COD): 4.51 (1H, dd, J 7.9, 4.8, Biotin C6a-H), 
4.32 (1H, dd, J 7.9, 4.5, Biotin C3a-H), 3.29-3.11 (5H, m, Biotin C4-H, 2 × CH2), 2.95 (1H, 
dd, J 12.8, 5.0, Biotin C6-H), 2.72 (1H, d, J 12.8, Biotin C6-H'), 2.22 (2H, t, J 7.1, CH2), 
1.82-1.54 (4H, m, 2 × CH2), 1.52-1.41 (11H, m, CH2, Boc CH3); δC (75 MHz, D3COD): 
176.4 (amide C, Boc C(O)O), 166.1 (Biotin C2), 80.2 (Boc OC(Me)3), 63.4 (Biotin C3a), 
61.6 (Biotin C6a), 57.0 (Biotin C4), 41.0 (Biotin C6), 40.6 (CH2), 36.9 (CH2), 29.8 (CH2), 
29.5 (CH2), 28.8 (Boc CH3), 26.9 (CH2); m/z (ES): Found M+Na
+
 409.1868, expected for 
[C17H30O4N4S + Na] 409.1880. 
 
N-[(2-amino)ethyl]-5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl]pentanamide (135) 
 
49 (840 mg, 2.17 mmol) was added to CH2Cl2 (10 mL) and TFA (3 mL). The reaction was 
stirred for 90 min. Concentration in vacuo yielded 135 as a TFA salt (1.28 g, >100%). δH 
(500 MHz, D3COD): 4.53 (1H, dd, J 7.9, 4.8, Biotin C6a-H), 4.33 (1H, dd, J 7.9, 4.8, Biotin 
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C3a-H), 3.47 (2H, dt, J 6.0, 5.3, ethyl C1-H2), 3.27-3.21 (1H, m, Biotin C4-H), 3.07 (2H, t, J 
6.0, ethyl C2-H2), 2.96 (1H, dd, J 12.8, 4.9, Biotin C6-H), 2.74 (1H, d, J 12.8, Biotin C6-H'), 
2.29 (2H, t, J 7.6, Biotin C4'-H2), 1.82-1.61 (4H, m, Biotin CH2), 1.52-1.45 (2H, m, Biotin 
CH2); δC (75 MHz, D3COD): 177.4 (amide C), 166.1 (Biotin C2), 63.4 (Biotin C3a), 61.7 
(Biotin C6a), 57.0 (Biotin C4), 41.0 (Biotin C6), 41.0 (CH2), 38.2 (CH2), 36.5 (CH2), 29.8 
(CH2), 29.5 (CH2), 26.5 (CH2); νmax/cm
-1
 (solid): 3000-3500 (NH), 1671 (C=O), 1648 
(C=O); m/z (ES): Found M+Na
+
 309.1344, expected for [C12H22N4O2S + Na]  309.1356. 
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(2S,3S)-3-{4-[4-(4-{4-[(3R, 5R)-5-(2,4-difluoro-phenyl)-5-([1,2,4]triazol-
1-ylmethyl)tetrahydrofuran-3-ylmethoxy]phenyl}piperazin-1-yl)phenyl]-5-oxo-4,5-
dihydro-[1,2,4]triazol-1-yl}pent-2-yl  6-{5-[(3aS,4S,6aR)-2-oxo-hexahydro-1H-
thieno[3,4-d]imidazol-4-yl]pentanoylamino}hexanoate (137) 
 
 
N-biotinyl-6-aminohexanoic acid 131 (40 mg, 0.112 mmol), posaconazole 130 (93 mg, 
0.134 mg), EDC.HCl (21 mg, 0.112 mmol) and DMAP (16 mg, 0.134 mmol) were added to 
anhydrous DMF (1 mL). The reaction was heated to 50 °C for 18 h before quenching with 
brine (10 mL) and extracting with CH2Cl2. Combined organic fractions were dried (MgSO4) 
and concentrated in vacuo. The crude was purified by two-stage column chromatography (1. 
MeOH–DCM, 1:9; 2. MeOH–DCM gradient, 0:1 to 2:98). The biotinylated drug 137 
(21 mg, 18%) was obtained as a white powder. δH (500 MHz, CDCl3): 8.12 (1H, s, 
oxotriazole C3-H), 7.80 (1H, s, triazole H), 7.69 (1H, s, triazole H), 7.43 (2H, d, J 8.5, N-Ar-
N C2-H), 7.40-7.35 (1H, m, difluorophenyl C-H), 7.03 (2H, d, J 8.5, N-Ar-N C3-H), 6.93 
(2H, d, J 9.0, N-Ar-O C2-H), 6.89-6.80 (2H, m, difluorophenyl C-H), 6.77 (2H, d, J 9.0, N-
Ar-O C3-H), 6.11 (1H, s, amide NH), 6.04 (1H, s, biotin N3-H), 5.28-5.17 (2H, m, biotin 
N1-H, pentyl C2-H), 4.65 (1H, d, J 14.2, triazolylmethyl CH2), 4.55-4.45 (2H, m, 
triazolylmethyl CH2, biotin C6a-H), 4.32-4.27 (1H, m, biotin C3a-H), 4.24-4.15 (1H, m, 
pentyl C3-H), 4.12 (1H, t, J 8.0, tetrahydrofuran C2-H), 3.78 (1H, dd, J 8.0, 6.8, 
tetrahydrofuran C2-H), 3.72-3.67 (1H, m, tetrahydrofuranylmethoxy CH2), 3.67-3.58 (3H, 
m, tetrahydrofuranylmethoxy CH2), 3.40-3.33 (4H, m, piperazine C2-H2), 3.25-3.20 (4H, m, 
piperazine C3-H2), 3.20-3.07 (3H, m, hexanoic acid C6-H2, biotin C4-H), 2.89 (1H, dd, J 
12.7, 5.0, biotin C6-H), 2.72 (1H, dd, J 12.7, biotin C6-H’), 2.66-2.51 (2H, m, 
tetrahydrofuran C3-H, tetrahydrofuran C4-H), 2.24 (2H, t, J 7.3, hexanoic acid C2-H2), 2.17 
(2H, t, J 7.3, biotin C4’-H2), 2.08 (1H, dd, J 12.5, 8.4, tetrahydrofuran C4-H’), 1.97-1.85 
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(1H, m, pentyl C4-H), 1.84-1.59 (3H, m, pentyl C4’-H, biotin C1’-H2), 1.58-1.48 (2H, m, 
hexanoic acid C3-H2), 1.47-1.38 (4H, m, hexanoic acid C5-H2, biotin C3’-H2), 1.35-1.21 
(7H, m, pentyl C1-H3, hexanoic acid C4-H2, biotin C2’-H2), 0.89 (3H, t, J 7.1, pentyl C5-
H3),  δC (75 MHz, CDCl3): 173.1, 172.8, 163.5 (biotin C2), 153.1 (triazole), 151.1, 150.6, 
134.4 (triazole), 123.4 (N-Ar-N C2), 118.6 (N-Ar-O C2), 116.6 (N-Ar-N C3), 115.2 (N-Ar-
O C3), 84.1, 71.0, 70.8, 70.6, 69.0, 61.8, 60.4, 60.2, 56.0, 55.5, 50.7, 49.2, 40.5, 39.1, 38.9, 
35.9, 34.3, 29.0, 28.1, 28.0, 26.3, 25.6, 24.5, 22.4, 17.4, 10.5; δF (282 MHz, CDCl3): -109.0 
(1F, d, J 7.5), -110.5 (1F, d, J 7.5); m/z (ES): Found M+H
+
 1040.499815, expected for 
[C53H67F2N11O7S + H] 1040.498647. 
(2S,3S)-3-{4-[4-(4-{4-[(3R, 5R)-5-(2,4-difluoro-phenyl)-5-([1,2,4]triazol-1-
ylmethyl)tetrahydrofuran-3-ylmethoxy]phenyl}piperazin-1-yl)phenyl]-5-oxo-4,5-
dihydro-[1,2,4]triazol-1-yl}pent-2-yl 14-Azido-3,6,9,12-tetraoxatetradecanoate (140) 
 
Posaconazole (200 mg, 0.285 mmol), 14-Azido-3,6,9,12-tetraoxatetradecanoic acid (0.5M in 
TBME, 856 µL, 0.428 mmol), EDC (82 mg, 0.428 mmol), DMAP (52 mg, 0.428 mmol) and 
DMF (3 mL) were combined and heated to 50 °C for 16 h. After cooling the reaction was 
purified by mass-directed HPLC. Product-containing fractions were combined and 
acetonitrile removed under reduced pressure. Water was then removed by lyophilisation to 
yield 140 (109.6 mg, 0.114 mmol, 40%) as an orange solid. δH (300 MHz, CDCl3): 8.11 (1H, 
s, oxotriazole C3-H), 7.80 (1H, s, triazole H), 7.63 (1H, s, triazole H), 7.44-7.36 (3H, m, N-
Ar-N C2-H, difluorophenyl C-H), 7.02 (2H, d, J 9.0, N-Ar-N C3-H), 6.93 (2H, d, J 8.9, N-
Ar-O C2-H), 6.88-6.80 (2H, m, difluorophenyl C-H), 6.78 (2H, d, J 9.0, N-Ar-O C3-H), 
5.34-5.28 (1H, m, pentyl C2-H), 4.65 (1H, d, J 14.4, triazolylmethyl CH2), 4.52 (1H, d, J 
14.4, triazolylmethyl CH2), 4.23-4.18 (1H, m, pentyl C3-H), 4.12 (1H, t, J 8.0, 
tetrahydrofuran C2-H), 3.78 (1H, dd, J 8.7, 6.8, tetrahydrofuran C2-H), 3.73-3.60 (16H, m, 
tetrahydrofuranylmethoxy CH2, 7 x PEG CH2), 3.39-3.34 (6H, m, piperazine C2-H2, PEG 
C14-H2), 3.25-3.21 (4H, m, piperazine C3-H2), 2.64-2.51 (2H, m, tetrahydrofuran C3-H, 
tetrahydrofuran C4-H), 2.08 (1H, dd, J 12.9, 8.4, tetrahydrofuran C4-H'), 1.97-1.88 (1H, m, 
pentyl C4-H), 1.83-1.74 (1H, m, pentyl C4'-H), 1.33 (3H, m, pentyl C1-H3), 0.89 (3H, t, J 
7.1, pentyl C5-H3);  νmax/cm
-1
 (solid): 2102 (N3),1710,  1690 (C=O), 1509; m/z (ES): Found 
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M+H
+
 960.456668, expected for [C47H59F2N11O9 + H] 960.453805. HPLC retention time: 
2.965 min. 
HPLC trace of 140 
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N-fluoresceinyl-N’-2-propyn-1-ylthiourea (142) 146 
 
Fluorescein isothiocyanate (50 mg, 0.128 mmol) was dissolved in DMSO (1 mL) and 
propargyl amine (12.3 µL, 0.192 mmol) added, with an instant colour change to red. After 
ten minutes the reaction mixture was purified by mass directed HPLC. Product-containing 
fractions were combined and acetonitrile removed under reduced pressure. Water was then 
removed by lyophilisation to yield 142 (17 mg, 0.038 mmol, 30%) as an orange solid. 
Characterisation was in accordance with literature.
146
 m/z (ES): Found M+Na
+
 467.067886, 
expected for [C24H16N2O5S + Na] 467.067213. HPLC retention time 1.889 (73%) 
HPLC of 142 
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(2S,3S)-3-{4-[4-(4-{4-[(3R, 5R)-5-(2,4-difluoro-phenyl)-5-([1,2,4]triazol-1-
ylmethyl)tetrahydrofuran-3-ylmethoxy]phenyl}piperazin-1-yl)phenyl]-5-oxo-4,5-
dihydro-[1,2,4]triazol-1-yl}pent-2-yl 14-
(4-[[(fluoresceinylamino)carbonyl]aminomethyl]-[1,2,3]triazinyl-3,6,9,12-
tetraoxatetradecanoate (143) 
 
130 (5 mg, 0.005 mmol), 142 (4.45 mg, 0.010 mmol), copper (II) sulfate (2.5 mg, 0.010 
mmol), sodium ascorbate (5 mg, 0.025 mmol) and DMSO (500 µL) were combined and 
stirred for 6 h at rt. Half of the reaction mixture was then purified by mass directed HPLC. 
Product-containing fractions were combined and acetonitrile removed under reduced 
pressure. Water was then removed by lyophilisation to yield 143 (2.8 mg, 0.002 mmol, 80%) 
as an orange solid. m/z (ES): Found [M+H
+
] 1388.554642, expected for [C71H76F2N13O15] 
1388.55464. HPLC retention time 2.835 min 
HPLC of 143 
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7.3 Peptides 
7.3.1 General Procedures 
 
General Procedure 1: Solid Phase Peptide Synthesis 
Peptides were synthesised using Rink amide or pre-loaded glycine chlorotrityl resin 
depending on C-terminal functionality. During all incubations the tubes were placed on a 
rotator. Couplings were performed using Fmoc-protected amino acids (5 eq.), HCTU (5 eq.) 
and DIPEA (5 eq.) with 1 h incubation time at rt The resin was washed with DMF (3 × 3 
mL, 2 min incubation), with 10% piperidine in DMF (5 × 3 mL, 2 min incubation), DMF (5 
× 3 mL, 2 min incubation). After the final coupling reaction the resin was washed with DMF 
(3 × 3 mL, 2 min incubation), DCM (3 × 3 mL, 2 min incubation) and MeOH (3 × 3 mL, 2 
min incubation). The peptide was cleaved and deprotected using a cleavage cocktail 
(TFA:TIS:EDT:H2O, 95:1:2.5:2.5, total volume = 3 mL) with incubation for 1 h. The 
cleavage mixture was eluted into ice-cold ether (40 mL) and the precipitate collected by 
centrifugation (4000 r.p.m., 5 min). The precipitate was resuspended and washed with ice-
cold ether (5 × 15 mL). After drying overnight the peptide was dissolved in water and 
lyophilised to yield final product. 
 
General Procedure 2: Conversion of cysteine to dehydroalanine in peptides using 27 
The peptide was dissolved in water (0.4 mL) and TCEP (0.5 eq.) added. A solution of 
2,5-dibromoadipamide  27 (10 eq.) in DMF (0.1 mL) was added before the entire solution 
was transferred to a vial containing K2CO3 (5 eq.). The vial was incubated in a 37 °C 
shaking incubator at 140 rpm. Reaction was monitored by LCMS. 
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7.3.2 Linear Peptides 
 
H-ACSDRFRNCPADEALCG-NH2 (36) 
Synthesised using general procedure 1 m/z (ES): Found M+2H
+
 913.890594, expected for 
[C72H117N25O25S3] 913.890180. 
H-AXSDRFRNXPADEALXG-NH2 (X=Dha) (38) 
Crude peptide H-ACSDRFRNCPADEALCG-NH2 36 (10 mg, 5.5 µmol) was incubated with 
TCEP (0.7 mg) in H2O (4.4 mL) for 45 min before addition of methyl 2,5-dibromovalerate 
(90 mg, 328 µmol) in DMSO (4.4 mL) and K2CO3 (113 mg, 821 µmol). The reaction was 
incubated at 37 °C for 3 h before purification by mass-directed HPLC (5-50% MeCN:H2O 
gradient + 0.1% formic acid). Product-containing fractions were combined, concentrated 
under reduced pressure before removal of water by lyophilisation to yield pure product 38 as 
a white flocculent solid (3.5 mg, 37%). m/z (ES): Found M+2H
+
 862.908689, expected for 
[C72H111O25N25] 862.908599. 
H-ACSDRFRNCPADEALCG-NH2 (8 stereoisomers) (individual isomers of 
36/precursors of 37+81-87) 
Synthesised using general procedure 1 by Patrick Foley and used crude. 
H-AYCDG-OH (41)  
Synthesised using general procedure 1 and used without further purification. m/z (ES): 
Found M+H
+
 528.175738, expected for [C21H29O9N5S + H] 528.175875. HPLC: 1.56 min 
(5-95% Ascentis Peptide Gradient). 
H-AYXDG-OH (X=Dha) (42) 
General procedure 2 from 41, observed by LCMS – not isolated. 
H-GCSDYVCGTHACA-OH (45) 
Synthesised using general procedure 1 and used crude. Observed M+2H
+
 by LCMS 643.7 
H-GXSDYVXGTHAXA-OH (46) 
General procedure 2 from 45, observed by LCMS – not isolated 
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H-ALCYG-OH (70) 
Synthesised using general procedure 1 and used without further purification. 
H-LTFCEYWAQLCSAA-OH (74) 
Purchased from Thermo Scientific (>80% purity) 
Ac-AC(tBS)GAW(Boc)AGAC(Trt)G-OH (150) 
Synthesised using general procedure 1 omitting cleavage steps (0.055 mmol scale) on pre-
loaded Gly chlorotrityl resin. Acetylation was carried out through addition of acetic 
anhydride (26 µL, 0.275 mmol) and DIPEA (102 µL, 0.275 mmol) and incubation on the 
rotator for 1 h. Acetylation was followed by washes with DMF (3 × 2 mL), DCM (3 × 2 
mL), and MeOH (3 × 2 mL) as in procedure 1. 
Deprotection of tBS protecting group on peptide 150 to form 151 
To a sample of peptide 150 (approx. 0.055 mmol) was added β-mercaptoethanol (38.8 µL, 
0.55 mmol) and DMF (2 mL) and the tube incubated on a rotator for 18 h with samples 
taken after 1 h, 4 h and 18 h. Samples for LCMS were taken by drainage of the liquid phase, 
washing the resin with DMF (2 × 2 mL) and adding a small amount of resin to a sample of 
100 µL TFA or hexafluoroisopropanol. Further deprotection attempts were made on the 
same peptide sample as follows: 1. PBu3 (15 µL, 0.061 mmol), H2O (20 µL) and DMF (2 
mL), rt 1 h. 2. PBu3 (150 µL, 0.61 mmol), H2O (150 µL), DCM (300 µL) and DMF 
(300 µL), rt 18 h. 3. DTT (85 mg, 0.55 mmol), NEt3 (200 µL), DMF (750 µL), H2O (250 
µL), rt 16 h. 4. DTT (850 mg, 5.5 mmol) K2CO3 (760 mg, 5.5 mmol), DMF (500 µL) and 
H2O (500 µL), 37 °C, 2 h. Each deprotection attempt had samples taken for LCMS as above. 
 
7.3.3 Cyclised Peptides 
 
Peptide Cyclisation with tris(bromomethyl)benzene (TBMB) to generate cyclised 
peptides 37/81-87 
Cyclisation reaction was carried out by Patrick Foley using the protocol in Heinis et al.
14
 
Crude peptides (1.83 mg, 1 µmol) were dissolved in 70% (v/v) ammonium bicarbonate (20 
mmol, 0.3 mL, pH 8) 30% acetonitrile (0.3 mL) with TBMB (0.36 mg, 1 µmol) added and 
agitated for an hour. The cyclised peptides were then purified using mass directed HPLC (5-
95% MeCN + 0.1 % formic acid, 8 min) to give: PK15 (0.58 mg, 0.29 µmol, 29%); LLD 
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(0.19 mg, 0.10 µmol, 10%); LDL (0.32 mg, 0.16 µmol, 16%); LDD (0.46 mg, 0.24 µmol, 
24%); DDD ( 0.50 g, 0.257 µmol, 26%); DLL (0.50 g, 0.257 µmol, 26%); DLD (0.3 mg, 
0.155 µmol, 16%); DDL (0.5 mg, 0.257 µmol, 26%). 
Peptide Cyclisation with tris(mercaptomethyl)benzene (TMMB) to make peptide 
mixture 40 
Peptide 38 (2 mg, 1.15 µmol) was combined with 1,3,5-tris(mercaptomethyl)benzene 39 
(0.3 mg, 1.39 µmol) and K2CO3 (1.6 mg, 11.59 µmol) in 1:1 H2O:DMF (1 mL). The reaction 
was incubated at 37 °C for 3 h before purification by mass-directed HPLC. Product-
containing fractions were combined, concentrated under reduced pressure before removal of 
water by lyophilisation to yield pure product 40 as a white solid (1.1 mg, 43%) A quarter of 
the reaction mixture was kept crude for testing in the kallikrein inhibition assay. m/z (ES): 
Found M+2H
+
 970.910013, expected for [C81H123O25N25S3] 970.913655. 
PK15 cyclisation with 110 (Synthesis of 121) 
Peptide 36 (2.0 mg, 1.1 µmol) was combined with TCEP (0.12 mg, 0.5 µmol) and K2CO3 
(0.45 mg, 3.3 µmol) in water (500 µL) before addition of a solution of 110 (0.56 mg, 1.1 
µmol) in DMF (500 µL). Complete reaction was observed after 5 minutes. HPLC 
purification yielded 121 (1.4 mg, 67%) as a white solid.  
 
Peptide 74 cyclised with Barbas core 126 (Synthesis of 128) 
Peptide 74 (1 mg, 0.6 µmol) was incubated with 126 (0.4 mg, 0.9 µmol) and K2CO3 (0.1 mg, 
0.7 µmol) in DMF (0.5 mL) for 2 h at 37 °C. The reaction was purified by mass directed 
HPLC to yield 128 (0.2 mg, 20%)  
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7.4 Assays 
7.4.1 LCMS assay to optimise conditions of dehydroalanine formation using 27 and 63 
Peptide (1.2 mg, 747 nmol) was pretreated with TCEP (0.09 mg, 373.5 nmol, 0.5 eq.) in 
water (300 µL), after half an hour at 37 °C this solution was used as the peptide stock 
solution. In a 96-well plate (polypropylene, Greiner Bio-one 651201), reactions were set up 
with the following conditions: peptide 6 0.623 mM, base (K2CO3 or NH4HCO3, 62.3 mM), 
dibromo compound (3 or 4, ranging from 1.2 mM to 62.3 mM), 1:1 water:organic 
(DMF/DMSO/MeCN) total volume 20 µL. After incubation at 37 °C for 3 hours, the 
reactions were examined using LCMS with blank runs as spacers between samples. Ions 
corresponding to the product 7 and stapled by-products 8/9 were extracted using Bruker ESI 
Compass data analysis software and the extracted ion peaks integrated. The ratio of these 
MS peak integrals of 7 to 8/9 was plotted to estimate levels of both product and stapled by-
product. 
7.4.2 Kallikrein Inhibition Assay 
The inhibitory activity (IC50) of each bicyclic peptide was determined by measuring the 
residual activity of HPK upon incubation for 30 min at room temperature with 
concentrations of bicyclic peptide ranging from 10 µM to 0.05 nM. The activity of HPK (2 × 
10
-4 
µM) was measured using fluorogenic substrate Z-Phe-Arg-AMC (0.1 mM) in Tris (10 
mM, pH 7.4) supplemented with NaCl (150 mM), MgCl2 (10 mM), CaCl2 (1 mM), BSA 
(0.1%, w/v), Triton X-100 (0.01%, v/v) and DMSO (5%, v/v). Excitation at 355 nm, 
emission 460 nm. Measurements were taken every 30 seconds. A linear fit of the data points 
from 1.5 min to 30 min gave the rate of substrate cleavage. Standard errors were calculated 
from the rates across triplicate wells. Rates were plotted against inhibitor concentration and 
a logistic fit used to determine the IC50 using equation [1]: 
[1] 𝑦 =  𝐴2 +  (𝐴1 − 𝐴2)/(1 +  (𝑥/𝑥0)^𝑝) 
7.4.3 Fluorescence anisotropy assay 
Adhirons were expressed by Thomas Taylor in the BSTG at Leeds. Adhirons were 
concentrated in Amicon 3K spin filters at 4000 r.p.m. Appropriate dilution series (A4C: 556 
µM to 0.5 µM) were set up in triplicate before addition of probe 143 (2 µM DMSO stock, 
5 µL) Total volume 100 µL, 5% DMSO, 100 nM probe. Fluorescence Anisotropy 
measurements were taken in 96-well plate format using an Envision 2103 Multilabel Reader. 
G-factor was calculated by the average of the readings on a blank probe sample where 
G=S/P 
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Anisotropy (r) of individual wells was then calculated using equation [2] 
[2]   𝑟 =
(𝑆−𝐺∗𝑃)
(𝑆+2𝐺∗𝑃)
 
The total fluorescence (S+2G*P) was plotted vs Adhiron concentration to confirm there was 
no observable quenching. 
The anisotropy values for the triplicate wells were averaged and standard errors calculated. 
These values were used to produce a plot of anisotropy vs Adhiron concentration. This plot 
was fitted with a logistic method (fixed power of 1) and this used to convert the anisotropy 
values to fraction bound. A hyperbolic fit of fraction bound vs Adhiron concentration gave 
the Kd value. 
 
  
135 
 
7.5 Macrocyclic Sampling Modelling Protocol 
2D representations of PK15 stereoisomers were created using ChemDraw with appropriate 
stereochemistry at all stereocentres. These were then converted to a random 3D structure 
using PipelinePilot. This 3D structure was loaded into MacroModel (Schrodinger Inc.), 
hydrogens were automatically added via an initial energy minimisation and the macrocycle 
sampling script used with the following settings: 
Force field OPLS_2005 
Energy window for saving structures 10 kcal/mol 
Eliminate conformers within RMSD 0.75 Å 
Simulation cycles 5000 
LLMOD search steps 5000 
 
The modelling procedure undertook 0.5 ps simulation at 1000 K followed by 0.5 ps at 300 K 
and then energy minimisation using Macromodel’s large scale low-mode search (LLMOD). 
The twenty lowest energy conformation molecular structures were exported and the pdb files 
edited using Notepad++ to allow visualisation in pymol. Structures were overlayed in pymol 
using the align command. 
The UK18 pdb structure was extracted from the pdb file 3QN7 and loaded into MacroModel 
and the same modelling protocol as above undertaken. 
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7.6 Molecular Biology 
7.6.1 Buffers, Media and Reagents 
Table 11: Media, buffers and reagents used in this work 
 Recipe/Supplier 
Media (per litre where applicable) 
LB 25 g LB broth mix 
LB-agar 15 g agar, 25 g LB 
2TY 10 g yeast extract, 16 g tryptone, 5 g NaCl 
Buffers  
TE Buffer 10 mM Tris, 1mM EDTA, pH 8.0 
PEG-NaCl solution 20% (w/v) PEG 8000, 2.5 M NaCl 
PBS-T 
137 mM NaCl, 10 mM phosphate, 2.7 mM KCl, 0.1% 
Tween-20, pH 7.4 
TBMB Reaction Buffer 20 mM NH4HCO3, 5 mM EDTA, pH 8.0 
TCEP Buffer TBMB Reaction buffer + 1 mM TCEP 
10× blocking buffer Sigma Cat. No. B6429 
2× blocking buffer 10× Buffer diluted in PBS-T 
Reagents  
TMB 
SeramunBlau® fast TMB/substrate solution) (Seramun, 
Cat. No. S-001-TMB) 
Anti-Fd-Bacteriophage-HRP (Seramun Diagnostica GmbH, Cat. No. A-020-1-HRP) 
 
7.6.2 General procedures 
General Procedure 1: Transformation of E. coli with plasmid DNA 
Cells and plasmid were mixed together in 1.5 mL Eppendorf tubes and incubated on ice for 
5 minutes. Samples were then immersed in a 42 °C water bath for 45 seconds before 
immediate cooling on ice for 5 minutes. LB (0.5 mL) was added to each sample and the 
samples incubated at 37 °C for 45-60 minutes. A 20 µL sample was plated on LB-agar 
containing the relevant antibiotic. The remaining transformation sample was centrifuged at 
2000 g for 2 minutes and the cell pellet resuspended in 100 µL before plating on LB-agar. 
Spreading was achieved via the use of sterilised glass shot. 
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7.6.3 1
st
 Generation Construct 
The construct (dsba)PK15-g3p* (pUC57) was purchased from genscript. XL10 E. Coli (15 
µL) were mixed with plasmid (1.5 µL) before transformation via general procedure 1. 
Colonies were minicultured in LB-Amp (5 mL) overnight at 37 °C. DNA was obtained via 
miniprep following the standard instructions for the Qiagen miniprep kit. 
PCR reactions 
PCR to install different leader sequences 
PCR reactions were set up using primer indicated in Table 12 (0.5 µL), reverse primer 
RP-PK15-g3p*(NheI) (0.5 µL), Pwo DNA polymerase (0.2 µL), Pfu buffer (5 µL), DNTPs 
mix (0.4 µL), template (dsba)PK15-g3p*(puc57) (0.2 µL), DMSO (2.5 µL) and water (40.7 
µL). PCR reactions were run under the conditions listed in Table 12. Reactions were 
examined and purified via gel electrophoresis using agarose gel (1.6%), bands excised by 
scalpel using ethidium bromide and UV illumination and DNA purified following the 
standard procedure in the Qiagen Gel extraction kit. 
Table 12: PCR conditions for the first PCR step in first generation plasmid construction 
Product Primer Conditions Anneal Temp (°C) 
OmpA-PK15-g3p* OmpA-PK15 b 54.4 
MalE-PK15-g3p* MalE-PK15 a 53.6 
STII-PK15-g3p* STII-PK15 b 60.3 
PhoA-PK15-g3p* PhoA-PK15 a 53.6 
M13KE-PK15-g3p* M13KE-PK15 a 53.6 
[a] 5% DMSO, 30 cycles: 30 s denaturation (95 °C), 60 s anneal, 210 s extension (72 °C) 
[b] 5% DMSO, 35 cycles: 30 s denaturation (95 °C), 60 s anneal,120 s extension (72 °C) 
 
PCR to install RBS site 
PCR reactions were set up using primer indicated in Table 13 (0.5 µL), reverse primer 
RP-PK15-g3p*(NheI) (0.5 µL), Pwo DNA polymerase (0.2 µL), Pfu buffer (5 µL), DNTPs 
mix (0.4 µL), template (product of PCRs above – listed in Table 13) (1 µL), DMSO (2.5 µL) 
and water (39.9 µL). PCR reactions were run under the conditions listed in Table 13. 
Reactions were examined via gel electrophoresis using agarose gel (1.6 %) and the 
remainder of the reaction purified via PCR clean-up: following the standard procedure in the 
Qiagen Gel extraction kit omitting the gel-running steps. Concentrations were measured 
using Nanodrop UV absorption readings at 260 nm. 
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Table 13: PCR conditions for the 2
nd
 PCR step to reinsert a ribosome binding site 
Product Primer Template Conditions 
R-MalE-PK15-g3p* RBS-MalE MalE-PK15-g3p* a 
R-PhoA-PK15-g3p* RBS-PhoA PhoA-PK15-g3p* a 
R-M13KE-PK15-g3p* RBS-M13KE M13KE-PK15-g3p* a 
[a] 5% DMSO, 35 cycles: 30 s denaturation (95 °C), 60 s anneal (53.4 °C),120 s extension 
(72 °C) 
 
Cloning into pBSTG1 
pBSTG1 [HindIII and EcoRI digested] 
pBSTG1 vector (15 µL, 1.5 µg) was digested using restriction enzymes EcoRI HF (1 µL) 
and HindIII HF (1 µL) in NEB restriction digest buffer 4 (5 µL)  and water (28 µL). The 
digestion mixture was incubated at 37 °C for 2.5 hours.  
(dbsa)PK15-g3p*[HindIII and EcoRI digested] 
(dbsa)PK15-g3p*(pUC57) vector (5.35 µL, 1.5 µg) was digested using restriction enzymes 
EcoRI HF (1 µL) and HindIII HF (1 µL) in NEB restriction digest buffer 4 (5 µL)  and water 
(37.65 µL). The digestion mixture was incubated at 37 °C for 2.5 hours. 
(dsba)PK15-g3p*(pBSTG1) 
Both pBSTG1(HindIII+EcoRI) and (dsba)PK15-g3p*(pUC57)(HindIII+EcoRI) were 
purified by gel electrophoresis. Ligation of the two components was set up (insert 17.5 µL, 
vector 4 µL, T4 10× buffer 2.5 µL, T4 ligase 1 µL) at rt for 10 min. Ligation mix (2.5 µL) 
was used to transform XL10 E. coli following general procedure 1. Isolated vector 
(dsba)PK15-g3p*(pBSTG1) was confirmed by Sanger sequencing (GATC Biotech). 
g3p*(pBSTG1) [HindIII and NheI digested] 
(dbsa)PK15-g3p*(pBSTG1) vector (4.28 µL, 1.5 µg) was digested using restriction enzymes 
NheI HF (1 µL) and HindIII HF (1 µL) in NEB restriction digest CutSmart buffer (5 µL)  
and water (38.21 µL). The digestion mixture was incubated at 37 °C for 1 hour. Phosphatase 
and ZnCl2 were then added followed by incubation at 37 °C for 45 min. 
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(MalE/PhoA/M13KE)PK15-g3p*(pBSTG1) 
PCR products R-MalE-PK15-g3p* (0.5 µg) was digested with NheI HF (1 µL) and HindIII 
HF (1 µL) in SmartCut buffer (5 µL) and water (26.3 µL) at 37 °C for 1 hour. The same 
conditions were used with R-PhoA-PK15-g3p* and R-M13KE-PK15-g3p*. Digested 
products were purified via PCR clean-up. Ligation of digested genes (13.3 ng) and 
g3p*(pBSTG1) (20 ng) was undertaken using T4 ligase (1 µL) in T4 buffer (10×, 2 µL) and 
water (total reaction volume 20 µL). Reaction proceeded at rt for 10 min. Ligation mix (1 
µL) was used to transform XL10 E. coli (10 µL) following general procedure 1. Isolated 
vectors (MalE/PhoA/M13KE)PK15-g3p*(pBSTG1) were confirmed by Sanger sequencing 
(GATC). 
 
Phage Production 
ER E. coli cells were transformed with one of the leader sequence variants 
(dsba/MalE/PhoA/M13KE)PK15-g3p*(pBSTG1) following general procedure 1 and 
colonies grown on LB-Agar-Amp. Minicultures were grown in 2TY-Amp (5 mL) overnight. 
Minicultures were used to seed 2TY-Amp cultures (50 mL) at OD600 = 0.1. Cultures were 
incubated at 37 °C and 170 rpm until OD600 = 0.5 at which point IPTG (0.5 M, 100 µL) was 
added. Cultures were incubated at 37 °C and 170 rpm for 90 minutes. Each culture was then 
split in two and either Hyperphage (0.47 mL, MOI=20) or Helperphage (1 ul, MOI = 15) 
were added. Cultures were incubated at 37 °C and 90 rpm for 1 hour before addition of 
Kanamycin (24 µL). Cultures were then incubated at 25 °C and 170 rpm overnight. 
Phage cultures had bacteria removed by centrifugation (3000 rpm, 10 min). Supernatant (25 
mL) was decanted into a PEG solution (25% PEG, 2.5 M NaCl, 6.25 mL) and stored at 4 °C 
for 2 hours. Phage pellet was obtained by centrifugation (4600 rpm, 10 min). The pellet was 
resuspended in TE buffer (4 mL) and passed through a 0.45 µM filter. 
Concentration of phage was assessed using formula [2] 
 [2] 
(𝐴269−𝐴320)×6×10
16
6400
 
Absorptions were measured on a 1 in 10 dilution. 
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Test of phage infectivity 
E. coli ER2738 were cultured to OD600 = 0.5 and split into batches (9 × 3 mL). Batches were 
infected with phage in an array of 4 leader sequences × 2 secondary phage types 
(MOI=100). Cultures were incubated at 37 °C and 90 rpm for 30 minutes. A dilution series 
(1 µL, 1 in 100 and 1 in 10000) of each culture was plated on LB-Agar-Amp and incubated 
at 37 °C overnight. 
Modification of phage with TBMB 
1 litre 2TY cultures of ER2738 cells transformed with either dsba-PK15-g3p*(pBSTG1) or 
PhoA-PK15-g3p*(pBSTG1) were grown at 37 °C and 190 rpm. At OD600 = 0.7 M13 Helper 
phage (40 µL) was added. Cultures were incubated at 37 °C and 90 rpm for 30 min before 
addition of Kan (1 mL). Cultures were then incubated at 25 °C and 170 rpm overnight. 
Bacteria were pelleted by centrifugation 4000 g for 15 min. Supernatant was decanted into 
PEG-NaCl solution (125 mL) and stored at 4 °C for 1 hour followed by ice incubation for 30 
min. Precipitated phage was pelleted by centrifugation at 4000 g for 30 min. The pellet was 
resuspended in 20 mL of TCEP buffer (Table 11) and incubated at 37 °C for 1 h. The phage 
solution was concentrated to 1 mL and washed with reaction buffer (2 × 10 mL) before 
addition to reaction buffer (32 mL) and followed by addition of TBMB solution (50 µM, 8 
mL). Reaction was incubated at 30 °C for 1 hour. PEG-NaCl solution (10 mL) was added 
and phage precipitated overnight at 4 °C. Phage pellet was obtained by centrifugation at 
4000 g for 30 min. Pellet was resuspended in TE buffer (dsba 1 mL, PhoA 2 mL) and cell 
debris removed by centrifugation (10000 g, 10 min). Concentration was estimated using 
equation 1. 
Kallikrein-binding phage ELISA 
2× Blocking buffer was added to streptavidin coated 96-well plate and incubated at 37 °C 
overnight. The plate was washed 1× in PBS-T before addition of biotinylated human plasma 
kallikrein (1 in 500 in 2× blocking buffer, 50 µL) to each well before incubation at rt for 1 h. 
To control wells 50 µL of 2× blocking buffer was added in place of kallikrein. The plate was 
washed 1× in PBS-T before addition of phage stock (approx. 10
15
 phage/mL, 60 µL) to the 
1
st
 column, and TE buffer (40 µL) to columns 2-12. A 3-fold dilution series of phage was 
created by 20 µL transfer and mixing from column 1 toward 12. 10× Blocking buffer (10 
µL) was added to each well and the plate incubated at rt for 1 h. The plate was washed 1× in 
PBS-T before addition of anti-phage HRP (1 in 1000 in 2× blocking buffer, 50 µL) to each 
well and incubation at rt for 1 h. The plate was washed 10× in PBS-T before addition of 50 
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µL TMB solution. The developed blue colour was measured by the A620 using a plate-
reader. 
7.6.4 2
nd
 Generation Phage 
Dsba-PK15-g3p(C-term truncation)  
The second generation dsba-PK15-g3p(C) gene was digested from puc57 into pBSTG1 
using NheI and NdeI. pUC57 vector (27.4 µL, 10 µg) was combined with NheI-HF (1 µL), 
NdeI (1 µL), SmartCut buffer (5 µL) and water (15.6 µL) and incubated at 37 °C for 1 hour. 
The digestion was monitored and purified by gel electrophoresis (1% agarose). Gel band 
containing digested insert was excised and purified following the Qiagen gel extraction 
protocol. 
Recipient pBSTG1 plasmid was digested with NheI and NdeI. pBSTG1 plasmid (2 µg, 20 
µL) was incubated with NheI-HF (1 µL) and NdeI (1 µL), Smart Cut buffer (5 µL), and 
water (16 µL) for 45 min at 37 °C. Antarctic phosphatase (2 µL) and ZnCl2 (5 µL) were 
added and the reaction incubated at 37 °C for 45 min. Reaction was monitored and purified 
by gel electrophoresis (1% agarose). Gel bands were excised and DNA obtained via Qiagen 
gel extraction protocol. 
Digested pBSTG1 vector (20 ng, 0.64 µL) and PK15 gene (15 ng, 0.55 µL) were combined 
with T4 10× buffer (1 µL), water (7.3 µL) and T4 DNA Ligase (0.5 µL). The reaction was 
incubated for 10 min at rt. 1.5 µL of ligation mix was used to transform XL10 E. coli 
following general procedure 1. Isolated vector (dsba)PK15-g3p(Ctrunc)(pBSTG1) was 
confirmed by Sanger sequencing (GATC). 
 
Phage Production 
ER2738 cells were transformed with (dsba)PK15-g3p(Ctrunc)(pBSTG1) plasmid following 
general procedure 1 with bacteria plated on LB-Amp agar. Minicultures (2TY, 5 mL) were 
grown overnight at 37 °C and used to seed 8 mL cultures (2TY, OD600 = 0.2) which were 
incubated at 37 °C and 230 rpm for 2 hours. M13K07 helper phage (0.32 µL) was added to 
each culture and the cultures incubated at 37 °C, 90 rpm for 30 min. Kanamycin (25 mg/mL, 
16 µL) was added and the cultures incubated at 25 °C and 170 rpm overnight. Phage-
infected cultures were centrifuged at 3500 g for 10 min before decanting the supernatant into 
PEG-NaCl solution (2 mL) – phage were precipitated at 4 °C overnight and pelleted by 
centrifugation at 4800  g for 30 min. The pellet was resuspended in TE buffer (320 µL) and 
centrifuged at 16000 g for 30 min to remove cell debris. 
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Anti-myc ELISA 
Anti-myc antibody (Abcam AB9106) (50 µL, 1 in 100, 1 in 1000 and 1 in 10000 dilution in 
TE buffer) was added to Nunc-Immuno
™ 
MaxiSorp
TM
 strips (Thermo Scientific, Cat. No. 
469949) and incubated overnight at 4 °C. Nunc strips were washed 3× in PBS-T before 
addition of 10× blocking buffer (250 µL) and incubation at 37 °C for 3.5 hours. Strips were 
washed 1× in PBS-T before addition of phage (2-fold dilution series starting from 10
12
 phage 
per mL, 50 µL per well) and incubation at rt. for 1 hour on a shaking platform. Strips were 
washed 1× in PBS-T before addition of anti-phage HRP (50 µL, 1 in 1000) and incubation at 
rt. for 1 hour on shaking platform. Strips were washed 10× with PBS-T before addition of 50 
µL TMB solution. No signal was observed. 
TEV cleavage 
Phage samples were spin-concentrated in an Amicon 30 kDa centrifugal spin filter (4000 g) 
to 50 µL and incubated with TEV-protease (5 mol%) for 2 hours at rt. The reaction was 
spin-filtered and the flow-through analysed by high resolution MS but no signal was 
observed. 
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Appendix 1 – DNA Sequences 
Gene Sequences 
(dsba)PK15-g3p* (Genscript gene ordered) 
AAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATAATGAAAAAGATTTGG
TTGGCTCTGGCTGGTCTGGTTCTGGCGTTTTCTGCGTCTGCAGGTGGCTGCTCTG
ACCGTTTTCGCAACTGCCCGGCCGATGAAGCATTATGTGGCGGGTCTGGAGCGG
CAGAAACAGTTGAATCCTCACTCGCCAAACCGCATATCGAAGGTAGCTTTACGA
ACGTATGGAAAGATGACAAAACCTTAGACTGGTACGCCAACTATGAAGGCATTC
TGTGGAAGGCCACCGGCGTGGTTGTCATCACGGGTGACGAGACGCAAGTTTATG
CAACGTGGGTCCCTATCGGGCTAGCGATTCCCGAGAACGAAGGTGGCGGCAGC
GAAGGTGGTGGGAGTGAAGGCGGGGGTAGCGAAGGTGGGGGCACGAAACCGC
CGGAATATGGTGATACTCCTATCCCGGGCTATATTTACATTAACCCGCTGGACG
GCACGTACCCCCCGGGTACCGAACAGAACCCGGCAAATCCGAATCCATCCTTAG
AAGAAAGCCATCCATTAAACACGTTTATGTTCCAGAATAATCGTTTCCGCAATC
GTCAGGGCGCACTCACCGTCTATACGGGTACTGTGACACAGGGCACTGACCCGG
TAAAAACCTATTATCAGTATACCCCGGTTTCTTCTAAAGCGATGTATGACGCCTA
TTGGAATGGTAAATTCCGTGACGTCGCATTCCACTCTGGCTTCAACGAAGACCC
GCTGGTGGCGGAGTATCAAGGCCAATCGTCCTACCTGCCGCAGCCGCCCGTCAA
TGCGGGTGGTGGGAGCGGTGGTGGGTCCGGTGGAGGGTCTGAGGGGGGGGGCA
GCGAAGGGGGTGGAAGTGAGGGGGGCGGAAGCGAAGGGGGTGGCTCTGGTGG
GGGCAGCGGGTCCGGGGACTTCGACTACGAAAAAATGGCGAATGCGAATAAAG
GTGCAATGACCGAAAATGCAGATGAAAACGCACTGCAATCTGACGCCAAAGGC
AAGCTGGACTCAGTTGCTACGGATTACGGCGCCGCCATCGATGGGTTTATCGGC
GATGTGTCTGGCCTCGCGAATGGTAACGGAGCAACTGGCGATTTTGCTGGCTCG
AACTCCCAGATGGCGCAAGTGGGAGATGGTGATAACTCTCCTTTGATGAATAAC
TTCCGGCAATATCTGCCCTCCCTGCCTCAGTCAGTTGAATGTCGCCCGTACGTGT
TCGGTGCCGGTAAACCGTATGAATTTTCCATTGATTGCGACAAAATCAATCTGTT
CCGGGGCGTATTCGCTTTCCTGTTATATGTGGCTACCTTCATGTATGTTTTTTCCA
CGTTTGCGAACATCCTGCGCAACAAGGAGTCATAATAAGAATTC 
2
nd
 generation construct (NheI)-PK15-g3p(trunc)(NdeI) 
GCTAGCGGTTGTTCGGATCGTTTCCGTAATTGTCCTGCGGATGAAGCTCTGTGTG
GAGGTAGTGGCGAACAGAAACTGATTTCTGAAGAAGACCTGGAAAATCTTTATT
TTCAAGGTGCGGCAGGTAACGGTGGTGGTAACGGTAACTCTGGTGGTGGTTCTG
GTACCGGCGGCTCCGGTTCCGGTGATTTTGATTATGAAAAAATGGCAAACGCTA
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ATAAGGGGGCTATGACCGAAAATGCCGATGAAAACGCGCTACAGTCTGACGCT
AAAGGCAAACTTGATTCTGTCGCTACTGATTACGGTGCTGCTATCGATGGTTTCA
TTGGTGACGTTTCCGGCCTTGCTAATGGTAATGGTGCTACTGGTGATTTTGCTGG
CTCTAATTCCCAAATGGCTCAAGTCGGTGACGGTGATAATTCACCTTTAATGAAT
AATTTCCGTCAATATTTACCTTCTTTGCCTCAGTCGGTTGAATGTCGCCCTTATGT
CTTTGGCGCTGGTAAACCATATG 
 
Primers used in PCR reactions 
 
Leader Sequence Oligos 
STII-PK15 
GAAAAAAAATATCGCCTTTCTCCTCGCGTCAATGTTCGTATTCTCAATTGCTACG
AACGCATATGCGGGTGGCTGCTCTGACC 
OmpA-PK15 
GAAGAAAACCGCAATTGCAATCGCTGTCGCCTTGGCCGGGTTCGCAACCGTTGC
ACAAGCGGGTGGCTGCTCTGACC 
PhoA-PK15 
GAAGCAGAGCACAATCGCCCTTGCTTTGCTTCCCCTGCTGTTTACCCCAGTTACC
AAGGCGGGTGGCTGCTCTGACC 
MalE-PK15 
GAAAATCAAAACCGGTGCCCGTATTCTGGCCCTGAGTGCACTCACAACGATGAT
GTTTAGTGCTAGCGCCTTGGCGGGTGGCTGCTCTGACC 
M13KE-PK15 
GAAAAAACTGTTGTTCGCCATTCCCTTGGTGGTCCCTTTTTATAGCCACAGCGGT
GGCTGCTCTGACC 
Overlap Region: GGTGGCTGCTCTGACC (Same for all 5) Tm 55.9 
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RBS Oligos 
RBS-PelB 
GCAATGAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATAATGAAGTAT
CTCCTGCCTACTG 
Overlap Region:  GAAGTATCTCCTGCCTACTG   Tm 58.4 
RBS-StII 
GCAATGAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATAATGAAAAAA
AATATCGCCTTTCTCC 
Overlap Region: GAAAAAAAATATCGCCTTTCTCC  Tm 57.6 
RBS-OmpA 
GCAATGAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATAATGAAGAAA
ACCGCAATTGCAATC 
Overlap Region: GAAGAAAACCGCAATTGCAATC  Tm 58.4 
RBS-PhoA 
GCAATGAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATAATGAAGCAG
AGCACAATCGCC 
Overlap Region: GAAGCAGAGCACAATCGCC  Tm 59.5 
RBS-MalE 
GCAATGAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATAATGAAAATC
AAAACCGGTGCCC 
Overlap Region: GAAAATCAAAACCGGTGCCC  Tm 58.4 
RBS-M13KE 
GCAATGAAGCTTGCATGCAAATTCTATTTCAAGGAGACAGTCATAATGAAAAAA
CTGTTGTTCGCCATTC 
Overlap Region: GAAAAAACTGTTGTTCGCCATTC Tm 59.2 
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Reverse Primer 
RP-PK15-g3p*(NheI) Reverse Primer NheI site in PK15-g3p* 
CGG GAA TCG CTA GCC CG    Tm 59.8 
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